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CHAPTER 1
General Introduction and 
Aims of the Thesis
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1·1
EVOLUTION OF NEUROMODULATION FOR 
LUTD (PAST, PRESENT, FUTURE)
Chronic lower urinary tract dysfunction (LUTD) is a common disorder that has 
a significant impact on quality of life. The term ‘dysfunction’ refers to an ab-
normality in the physiology of the lower urinary tract, including the detrusor 
muscle, urinary sphincter, bladder neck and associated nervous system. Accord-
ing to the type of dysfunction, different clinical symptoms can arise. Overactive 
bladder syndrome (OAB) is the most common disorder, and is defined as the 
presence of urinary urgency, usually accompanied by frequency and can occur 
with or without urinary incontinence. In contrast, LUTD can also result in the 
inability to evacuate urine. Hypocontractility of the detrusor muscle or hyper-
tonicity of the urinary sphincter can cause chronic (non-obstructive) urinary 
retention. 
Initial management consists of behavioural therapy. This includes bladder 
training, bladder control strategies, pelvic floor muscle training and fluid man-
agement. Behavioural therapy can target bladder function by modifying void-
ing habits with bladder training and delayed voiding, or target the bladder out-
let with pelvic floor muscle strengthening or relaxation techniques, depending 
on the type of disorder. Patients with detrusor hypocontractility are usually 
managed with clean intermittent self catheterization.
Second line treatment for OAB consists of oral drug therapy. The use of anti-
muscarinic medications has been thoroughly studied and is considered safe and 
effective in the treatment of OAB with or without urinary incontinence. There 
are multiple antimuscarinics available and all have similar efficacies, but differ 
in their side-effect profiles. In general, antimuscarinics are frequently discon-
tinued due to bothersome side-effects. A review of the literature demonstrated 
that 43–83% of women abandon antimuscarinic therapy within 1 month, and 
less than 35% of women continue their medication after the first year.1 Recently, 
the US Food and Drug Administration (FDA) approved the use of beta-3 agonist 
mirabegron as a new drug for OAB. The long-term effectiveness and tolerability 
of this drug still needs to be evaluated. 
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A considerable amount of patients do not respond to first or second-line 
treatment due to insufficient response or intolerability. Treatment of these pa-
tients has long been a therapeutic challenge since there were no valid options 
except intrusive surgery, such as bladder augmentation or urinary diversion. 
Hence there was a need for less invasive procedures. Instead of focusing on the 
bladder and urethral muscle as a target for treatment, methods were investigat-
ed to modulate the neural pathways of micturition. Experiments with differ-
ent ways of electrical stimulation led to the development of neuromodulation 
therapies that are nowadays implemented in the standard care of patients with 
LUT disorders. In the last two decades, various minimally-invasive treatments 
have become available, which have closed the gap between conservative and 
invasive treatment. In the early 90’s, sacral neuromodulation (SNM) was intro-
duced as a treatment for patients with OAB. In this treatment, an electrical sig-
nal is applied to the sacral nerve roots S1-3 with an implantable electrode. This 
treatment proved to be beneficial for patients with overactive bladder as well 
as chronic urinary retention. At the same time, percutaneous and transcuta-
neous techniques were developed for the same purpose. Furthermore, chemical 
methods of neuromodulation have also arisen, in particular intravesical injec-
tions with botulinum toxin-A. Nowadays, these neuromodulatory techniques 
have achieved a prominent role in the treatment of patients with LUTD. Figure 
1 illustrates their current position in the clinical treatment of OAB (EAU guide-
lines 2012).2
This thesis focuses on the evolution of neuromodulation in the treatment of 
LUTD, evaluating advancements in technique, patient selection and expanding 
indications.
1
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FIGURE 1
Treatment algorithm for women with urinary incontinence
SURGICAL TREATMENT
IN WOMEN
Stress
predominant
Urgency
predominant
Stress
incontinence
Oer fascial sling or
colposuspension if MUS
unavailiable
Oer MUS
Consider peri-urethral injections
for temporary relief of symptoms
Oer Bolulinum toxin A or the
opportunity for SNS
Discuss bladder augmentation or
urinary diversion
Re-evaluate patient and consider
second-line surgery - re-enter
algorithm at appropriate stage
Urgency
incontinence
Mixed
incontinence
Failure
Failed conservative or drug therapy
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1·2
WHAT IS NEUROMODULATION?
Neuromodulation is the physiologic principle that activity in one neural path-
way modulates the pre-existing activity in another through synaptic interac-
tion. During the micturition process, different neural pathways are involved to 
ensure correct interaction between muscle contraction and relaxation. Micturi-
tion includes two phases: urinary storage and elimination. During the storage 
phase, the bladder works as a reservoir and the urethra remains closed avoiding 
any urine leakage, while in the elimination phase, the bladder works as a pump 
that expels urine at the same time as the urethra opens, allowing a free conduct 
for urine flow. A good coordination of the antagonistic functions of the bladder 
and urethra demand a complex interaction between the peripheral and central 
nervous system. The main goal of neuromodulation is to restore the normal 
micturition reflexes that are involved in lower urinary tract (LUT) function-
ing. The neural control of the LUT involves three sets of peripheral nerves: the 
autonomic (parasympathetic, sympathetic) and the somatic nerves. Although 
dependent on autonomic reflexes, vesical and urethral functions are controlled 
by higher cortical centers to ensure the voluntary control of micturition. This 
feature differentiates these organs from other viscera innervated by the auto-
nomic nervous system. The pelvic nerve is the main (parasympathetic) nerve 
responsible for bladder contraction in the elimination phase and it uses the 
neurotransmitter acetylcholine in its synapses. The hypogastric (sympathetic) 
nerve is originated in the thoracolumbar spinal cord nucleus (T10–L2), which is 
responsible for conducting the impulses resulting in urethral smooth muscle 
contraction in the storage phase. An inhibitory stimulus is sent to the detrusor 
smooth muscle and excitatory stimulus to the urethra. The somatic control is 
mediated by the pudendal nerve and the efferent motorneurons originate in 
the somatic nucleus in the sacral spinal cord (S2–S4), commonly referred to as 
Onuf’s nucleus. Pudendal nerve stimuli cause (voluntary) contraction of the ex-
ternal urethral sphincter and pelvic muscles in the urinary storage phase.
Although the pathophysiology of LUT dysfunction is not well understood, 
1
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multiple changes on different levels (e.g. detrusor, urethra, neural innervation) 
are involved. Continence is maintained by a synergic accommodation of the 
smooth muscle of the bladder wall to increasing volumes of urine without a 
change in detrusor pressure and closure of the bladder outlet. An involuntary 
contraction of the detrusor (as seen in detrusor overactivity) can lead to leakage 
of urine. Alternatively, insufficient contraction of the detrusor (detrusor under-
activity) can lead to difficult elimination or urinary retention. It is hypothesized 
that by modulation of the disbalanced neural activity (either over- or underac-
tivity), normal micturition can be restored.
FIGURE 2
Neuronal innervation of the lower urinary tract
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-66.
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1·3
HOW DOES NEUROMODULATION WORK?
Electrical stimulation of an organ can be done in different ways. A nerve or mus-
cle can be stimulated directly or indirectly. In neurostimulation nerves or mus-
cles are directly stimulated by efferent neurons to achieve immediate responses 
(e.g. muscle contraction). In neuromodulation electrical stimuli are applied to 
alter present neurotransmission processes by afferent neurons. Initially it was 
hypothesized that stimulation of the S3 level amplified the continence reflex 
by stimulation of the pelvic nerve. A support for this theory was the contrac-
tion of perianal muscles during acute stimulation of the S3 roots.3 Fowler et al 
in contrast registered increased latencies with EMG of the anal sphincter on 
stimulation of the S3 root, compared to stimulation of the pudendal nerve, sug-
gesting that SNM acts through a polysynaptic reflex. No distinction between a 
spinal or a supraspinal reflex was found.4 Schurch confirmed the involvement of 
afferent pathways and spinal reflexes by latency measurements in patients with 
complete spinal cord injury.5 However, SNM did not improve voiding in these 
patients and it was suggested that supraspinal mechanisms are also involved. 
SNM might act merely on the processing of the sensory information from the 
bladder and has an influence on the pathological transmission of afferent in-
formation from the bladder through the C-fibers.6 Furthermore, recent f-MRI 
images indicate that afferent information in the periaqueductal grey and in the 
cingulate cortex can be normalized with SNM.7
OAB
In patients diagnosed with overactive bladder, SNM inhibits detrusor activity 
without affecting urethral resistance or the strength of detrusor contractions 
during voiding.8
Sievert et al showed that bilateral SNM in patients with a complete spinal 
cord injury initiated during the spinal shock phase could prevent the develop-
ment of detrusor overactivity.9 This could be an indication for a modulatory ef-
fect at the level of the spinal cord itself. Studies by Blok and by Dasgupta showed 
1
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activity of centers in the brain involved in micturition. SNM can potentially en-
hance or reduce the activity in these centers suggesting a central effect.8,10 Blok 
studied patients with chronic stimulation and compared them to patients with 
a new implanted system that was first activated (acute SNM) in a PET scanner. 
He showed that areas in the brain previously implicated in detrusor overactivi-
ty were influenced by SNM. During acute SNM, areas involved in sensorimotor 
learning were involved in change of activity.
Urinary Retention
Functional (non-obstructive) causes of urinary retention are a decreased or ab-
sent tonus of the detrusor muscle, or hypertonia of the sphincter. In patients 
with Fowler’syndrome, an abnormal electromyographic activity of the external 
urethral sphincter is seen in combination with polycystic ovaries.11 Dasgup-
ta compared healthy controls with Fowler’s syndrome patients. During PET 
scanning, activity was seen in the brain stem and limbic cortical regions in 
the healthy controls, whereas in the patients with Fowler’s syndrome, this ac-
tivity was absent with a full bladder. This activity could be restored by SNM. 
Functional MRI was also used to measure brain responses to a full bladder in 
patients with Fowler’s syndrome, and compared to a situation with an empty 
bladder. These authors concluded that an overactive urethra generates abnor-
mally strong inhibitory afferent signals, so effectively blocking bladder afferent 
activity at the sacral level and deactivating the periaqueductal grey and high-
er centres, with consequent loss of bladder sensation and ability to void. SNM 
has been postulated to suppress the guarding reflex, and as a consequence, de-
creased urethral sphincter tone facilitates voiding.7
The exact working mechanism of SNM in treating LUTD is complex and still 
not fully understood. It probably involves different modes of action and acts on 
various levels of the nervous system, including sacral, spinal, supraspinal and 
cortical areas of the brain. 
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1·4
DEVELOPMENT OF NEUROMODULATION
In 1878 Saxtorph reported (transurethral) intravesical stimulation in patients 
with hypocontractile bladder and urinary retention.12 In 1958 Katona’s group 
started transurethral electrical stimulation, a technique derived from Sax-
torph. Their hypothesis was that stimulation of intramural bladder receptors 
in patients with incomplete central or peripheral nerve lesions may reactivate 
these receptors. In 1975 they published results of 420 patients treated with this 
therapy. Of these patients, 314 achieved micturition control.13
McGuire performed direct bladder stimulation in dogs in 1954. Boyce et al 
found that two or more bipolar wire electrodes produced a more uniform re-
sponse than a single lead and stimulated a group of 3 paraplegic men directly in 
the bladder musculature. One of these male subjects had a successful response 
and another had partial success.14 New electrodes and techniques were devel-
oped over the years, but results remained disappointing. In 1978 Jonas reported 
on eleven patients, of whom only one was successfully treated with this thera-
py.15 Other groups studied stimulation of pelvic nerves, but pelvic nerves were 
thought not to tolerate stimulation for long periods of time.16
During the 1960’s various implantable pelvic floor stimulators were devel-
oped. There was a high incidence in technical failure and electrode dislocation.17 
At the same time experiments started with spinal cord stimulation in animal 
models. Nashold et al reported the first results in humans in 1972.18 Jonas and 
Tanagho showed that muscle response of the bladder during stimulation in pa-
tients with spinal cord transection rose and dropped more slowly than that of 
the urethral sphincter. After the stimulus there was a short time when bladder 
pressure exceeded sphincteric pressure, and thus repetitive stimuli resulted in 
complete bladder evacuation.19
Later, Brindley developed an electrode for long term stimulation and in 1978 
the first patients were implanted with this prosthesis for direct sacral nerve 
stimulation.20 Tanagho and Schmidt demonstrated that stimulation of the 
sacral root S3 modulates detrusor and sphincter action and could be used in 
1
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daily practice in patients with lower urinary tract dysfunction.21 This technique 
was further improved and in 1997 the FDA in the United States approved SNM 
for therapeutic use in urgency urinary incontinence.
21
1·5
NEUROMODULATION TECHNIQUES
Sacral Neuromodulation (SNM)
In order to achieve SNM a sacral root is stimulated with a quadripolar lead po-
sitioned in the sacral foramen (in general S3). The lead is connected to an im-
plantable pulse generator which is located in a subcutaneous pocket, mostly in 
the buttock area. Since 1999, a percutaneous nerve evaluation (PNE) has been 
used to monitor the effect of SNM prior to implantation. During the PNE, a wire 
electrode is placed in a sacral foramen and connected to an external stimulator. 
The test duration is limited to 3-7 days due to the high risk of lead migration. 
Improvement of symptoms is monitored during the test with voiding diaries. 
An improvement of at least 50% compared to baseline is defined as success. Af-
ter a successful test period a permanent IPG can be implanted. Later, the two-
stage procedure was introduced by Janknegt et al. Patients who experienced an 
initial good effect of PNE (but loss of this effect after one or two days) were 
tested again with a definitive lead implanted and connected to an external 
stimulator (first stage). If this showed a positive effect, a definitive device was 
implanted at a second stage.22
In 2002 a self-anchoring lead was introduced by Spinelli et al, which allowed 
a percutaneous placement of the lead, the so-called Tined Lead Procedure (TLP). 
Originally, the permanent lead was implanted under direct vision using an open 
surgical procedure with a midline incision over the sacrum. Advantages of the 
percutaneous lead placement are a shorter operation time and less invasiveness 
of the procedure. Furthermore, the lead can be introduced under local anesthe-
sia so that sensory responses can be evaluated during the procedure.23 After the 
implantation of the tined lead, a test phase can be performed for a prolonged pe-
riod of time (up to 4 weeks) in the same way as the original two-stage procedure.
 
TENS
Transcutaneous electrical nerve stimulation (TENS) applies a small electrical 
current to the skin that can usually be felt and stimulates sensory nerves. TENS 
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is often used in patients with chronic pain syndromes. In urology it was first 
reported to have had positive results in patients with interstitial cystitis. It re-
lieved not only pain, but patients also reported less frequency.24 A disadvantage 
of TENS is the time-consuming effect. TENS is applied for 30 minutes a day for 
60 days. Almost all published studies report only short term results.
Vaginal stimulation
As mentioned earlier, different ways of electrical stimulation have been test-
ed and used over the past few decades. Uncontrolled studies using vaginal and 
also rectal electrical stimulation reported success rates of up to 80%.25 Many 
variables such as duration of therapy and electrical parameters differ. Spruijt 
et al. concluded after a randomized feasibility study to treat incontinent elder-
ly women, that vaginal stimulation of the pelvic floor has a high physical and 
emotional cost for the individual. The effectiveness is low and it is not reason-
able to advise elderly women with urinary incontinence to undertake this treat-
ment procedure. Their study was terminated because of the negative outcome.26 
Compared to SNM, this therapy is time-consuming, less effective and physically 
and emotionally more invasive.
PTNS
Percutaneous tibial nerve stimulation (PTNS) is a peripheral neuromodulation 
technique. The nervus tibialis posterior is stimulated above the median malle-
olus of the tibia. PTNS uses an acupuncture point that originates from Chinese 
medicine. The possible working mechanism is neuromodulation at the spinal 
level.27 PTNS requires repeated sessions of stimulation. In patients with OAB for 
example, 8 weekly sessions are performed. PTNS is used in patients with OAB, 
urinary incontinence, fecal incontinence and in patients with chronic pelvic 
pain. A review by Biemans et al reported an improvement in incontinence ep-
isodes, frequency and urgency of 60-80% in patients with OAB. Furthermore, 
they concluded that only minimal evidence is provided for the efficacy of PTNS 
in fecal incontinence and chronic pelvic pain. The CONFIDeNT trail (dou-
ble-blind, multicentre, pragmatic, parallel-group, randomised controlled trial) 
studied 227 patients, 115 patients treated with PTNS, 112 patients treated with a 
sham therapy. They concluded PTNS given for 12 weeks does not confer signifi-
cant clinical benefit over sham electrical stimulation in the treatment of adults 
with faecal incontinence.28
PTNS is considered a safe intervention.29 A recent review that compared 
PTNS to SNM reported good results for both in OAB patients. SNM is the only 
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treatment that has shown efficacy in UR. Regarding cost-effectiveness, after a 
period of 2 years SNM began to show improved effectiveness and favorable cost 
value compared to PTNS. This study concluded that PTNS is an office-based 
procedure that provides a carryover clinical effect. SNM on the contrary offers 
constant stimulation without the burden of weekly or monthly visits.30
Pudendal Nerve Stimulation
The pudendal nerve is one of the major nerves that innervates the pelvic floor, 
the external and urethral sphincters and the pelvic organs. In 1990 Schmidt 
et al reported on two patients with myelomeningocele implanted with chron-
ic pudendal stimulation (PS).31 Patients not responding to SNM were the main 
reason for Spinelli et al to study a less invasive procedure to stimulate the pu-
dendal nerve.32 Most patients tested can be helped with SNM (60-70%), those 
who do not respond to SNM seem to be good candidates for a test stimulation 
with PS. Peters et al. retrospectively studied a group of patients having a tined 
lead placed at the pudendal nerve via the ischial-rectal approach. The majority 
of 84 patients had interstitial cystitis/painful bladder syndrome, or overactive 
bladder. Pudendal response occurred in 60/84 (71.4%). Almost all (93.2%) who 
had previously failed sacral neuromodulation responded to pudendal stimula-
tion. Outcomes were evaluated in 55 continuing on PS (median follow up 24.1 
months). Over time, significant improvements in frequency (P < 0.0001), void-
ed volume (P < 0.0001), incontinence (P < 0.0001), and urgency (P = 0.0019) oc-
curred. ICSI-PI scores significantly improved over 12 months (P < 0.0001). Survey 
responses indicated that most still had a device (35/40; 87.5%) continuously in 
use (24/29; 82.8%), and overall bladder, pelvic pain, incontinence, urgency, and 
frequency symptoms had improved. They concluded that PS is a reasonable al-
ternative in complex patients refractory to other therapies including sacral neu-
romodulation.33
1
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1·6
CLINICAL APPLICATIONS
The lower urinary tract, anorectal channel and pelvic floor are closely related, 
both anatomically and functionally. Dysfunction of the lower urinary tract and 
dysfunction of the bowel are problems that can have a major impact on the 
quality of life. Patients may complain about multiple symptoms: urgency and 
frequency, urgency urinary incontinence, urinary retention, genito-urinary 
pain syndromes and also fecal incontinence and constipation.
OAB
Various forms of neuromodulation have proven to be effective in the treatment 
of OAB. In a worldwide clinical study, Van Voskuilen et al described SNM suc-
cess rates of 58% in leaking episodes, to a 68% success rate in patients with 
heavy leaking episodes five years after implantation. At a 1 year follow-up, the 
average number of voids had decreased from 19.3 ± 7 to 13 ± 7.9. This reduction 
was maintained through to the long-term follow-up after 5 years.34
A systematic review by Siddiqui reported efficacy results of 67 to 84% based 
on 5 clinical studies. They concluded that SNM results in significantly less pad 
use and fewer incontinent episodes per day in women with refractory OAB. Al-
most half of the subjects reported no daily incontinence episodes after treat-
ment with SNM, and results were maintained up to 5 years after implantation.35
Very recently the results of a prospective, randomized, multicenter study 
evaluating SNM compared to standard medical therapy (SMT) were published. 
In total, 147 subjects were randomized (70 to SNM and 77 to SMT). The prima-
ry intent to treat analysis showed OAB therapeutic success was significantly 
greater in the SNM group (61%) than the SMT group (42%; P = 0.02). In the as 
treated analysis, OAB therapeutic success was 76% for SNM and 49% for SMT 
(P = 0.002).36 
A paper by Guo et al. reported on the results of TENS in post-stroke patients 
with urinary incontinence. Patients in the treatment group were treated daily 
for 30 minutes for a period of 60 days. TENS improved incontinence symptoms 
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and enhanced quality of life compared to the control group.37 
A review by Gaziev et al found an overall percentage of patients classified as 
successfully treated for OAB symptoms with PTNS of 54.5-79.5%. The definition 
of success differs among studies from the use of urodynamic data to clinical 
parameters and quality of life measures.38
As mentioned earlier, Spinelli et al performed pudendal stimulation in pa-
tients that did not respond to SNM. A perineal approach in 6 patients and a 
posterior approach in 9 was studied. All were neurogenic patients. The average 
number of incontinent episodes decreased from 7 to 2.6 episodes, eight patients 
became continent. Four out of seven patients with associated constipation at 
baseline reported normalization of bowel evacuation.32
Urinary Retention
Most patients with functional urinary retention perform clean intermittent 
catheterization (CIC) for bladder emptying. SNM can restore micturition in pa-
tients with non-obstructive urinary retention. An average decrease in the num-
ber of catheterizations in the group treated with SNM was seen from 5.3 ± 2.8 at 
baseline to 1.9 ± 2.8, with a clinical efficacy of 58% five years after implantation.34 
Results from a 10-year experiment in this group treated with SNM showed 
a success rate of 72% (43 out of 60 patients voided spontaneously after implan-
tation) and 50% of patients no longer needed to use CIC. Women with a normal 
urethral sphincter electromyogram had worse outcomes than women with an 
abnormal test (43% vs 76%).39 
PTNS is also proposed as a treatment option for these patients. Vandoninck 
et al published one of the few studies with results for this group. The primary 
outcome measure was a reduction of the total catheterized volume per 24 hours. 
Using a reduction of >50%, the percentage of responders was 41%.40
Bowel Dysfunction
Fecal incontinence (FI) is a common symptom that can have a devastating im-
pact on the quality of life. Reported prevalence ranges from 7-15% in community 
dwelling men and women.41 Because healthcare providers do not often screen 
for these symptoms and patients do not voluntarily report them, the real prob-
lem is probably underreported. Constipation presumably has less impact on the 
quality of daily life; however it represents a significant burden and is often as-
sociated with FI or urinary problems. A recent survey among Brazilian women 
with pelvic floor dysfunction reported a prevalence of 67% for constipation in 
a group of women with defecation disorders. Of the women with UI 23% had 
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associated FI.42 Both of these conditions can be treated with SNM. A review by 
Thin et al reported success rates of 63% (short term) to 54% (long term) for the 
treatment of fecal incontinence.43 Thomas et al presented a review on the use 
of SNM in patients with constipation. Test stimulation was successful in 42-100 
per cent of patients. In those who proceeded to permanent SNM, up to 87 per 
cent showed an improvement in symptoms at a median follow-up of 28 months. 
The success of stimulation varied depending on the outcome measure being 
used.44 
In patients with fecal incontinence PS was also tested. A pilot study showed 
>50% short-term improvement in 50% (5/10) of the tested patients. These pa-
tients were implanted and at a median follow-up time of 24 months, three of the 
patients had maintained these results.45 
Edenfield et al recently published a review on the effect of PTNS in patients 
with fecal incontinence. They found 13 case series and 4 randomized controlled 
trials. In total, 745 subjects were studied, and of those, 90% were women and 
10% were men. Studies involved PTNS in 57% (428/745) of the subjects, trans-
cutaneous electrical nerve stimulation in 30% (223/745), and sham technique 
in 13% (94/745). Therapy frequency, maintenance therapy, and follow-up time 
varied across the studies. Eleven studies assessed FI episodes and bowel move-
ment deferment time; all but 1 showed statistical improvement after therapy. 
They concluded that multiple low-quality studies show improvement in FI after 
PTNS.46 These promising results could not be confirmed in the CONFIDeNT 
trial, a double-blind, multicentre, pragmatic, parallel-group, randomized con-
trolled trial. They had to conclude that PTNS given for a period of 12 weeks did 
not confer significant clinical benefit over sham electrical stimulation in the 
treatment of adults with fecal incontinence.28
Chronic Pelvic Pain
Urological pain syndromes like interstitial cystitis and chronic pelvic pain syn-
drome or non-bacterial prostatitis can be treated with medication, analgetics, 
physiotherapy and sometimes dietary manipulation. If these therapies are not 
effective, other (invasive) therapies including SNM can be considered.47
Marcelissen et al evaluated the role of SNM in the treatment of chronic pel-
vic pain and identified 12 papers on this subject. Of these papers, 10 mainly ad-
dressed the efficacy of SNM in patients with interstitial cystitis/bladder pain. 
The percentage of patients who responded to test stimulation was reported to 
be between 51% and 77%. Of the 10 articles, 7 reported on treatment outcome 
after implantation. The duration of follow-up ranged between 5 and 87 months. 
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The mean reduction in pain scores was reported to be between 40% and 72%48. 
Although these results seem promising, the evidence of SNM in the treatment 
of pelvic pain is still limited due to the lack of high-quality trials and long-term 
follow-up. 
The efficacy of PTNS in the treatment of chronic pelvic pain was evaluat-
ed in one study. A total of 89 patients with therapy-resistant pelvic pain were 
randomized to receive either PTNS (n=45) or sham treatment (n=44). An objec-
tive response was observed with the VAS and NIH-CPSI scores after 12 weeks of 
PTNS in 18 (40%) and 30 (66.6%) of the patients. The mean NIH-CPSI scores did 
not differ significantly in the sham treatment group.49
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OUTLINE OF THIS THESIS
This thesis focuses on the evolution of SNM and further differentiation of this 
technique. 
Chapter 1 contains the introduction, in which the working mechanism, tech-
niques and clinical applications of neuromodulation are discussed. 
Chapter 2 presents an overview of the clinical results published on SNM, in-
cluding aspects of patient selection, efficacy and adverse events of this treat-
ment. 
Chapter 3 presents the long-term results of a transversal cohort study on 149 
SNM implants performed in our center between 1990 and 2003. In this group 
of 149 patients, 20 patients had a neurological cause for their urological com-
plaints. In 129 patients re-operations were performed, but no severe adverse 
events were seen. 
Chapter 4 reports on our experience with 49 tined lead implants. This new 
technique changed the treatment algorithm and results. With a mean follow-up 
of 15.5 months, 90.3% of the patients maintained more than 50% improvement 
in at least one of the relevant voiding diary parameters. One of the reasons for 
re-intervention is IPG battery depletion. With the introduction of the Interstim 
II with a smaller battery capacity, we studied the feasibility of on-demand SNM 
use in patients with OAB syndrome (Chapter 5). 
Due to the upcoming use of intravesical botulin toxin for OAB syndrome, 
many of our patients were treated with this therapy before a test stimulation 
with SNM was planned. Chapter 6 explores whether SNM is still effective in this 
patient group. 
Numerous reports have been published on the results of SNM on purely uri-
nary or fecal incontinence. However, results of patients with double inconti-
nence are rarely published. We performed a study on patients with double in-
continence (fecal and urinary) treated with SNM. The results and predictive 
factors are described in Chapter 7.
Chapters 8 and 9 conclude this thesis with a discussion and an overview on 
the topics of this thesis, and also present future perspectives of the SNM tech-
nique.
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ABSTRACT
Patients with symptoms of overactive bladder syndrome or non-obstructive 
urinary retention, refractory to conservative therapy, can nowadays be treated 
minimally invasively with sacral nerve stimulation (SNS). The use of electric 
currents to treat urological pathology has a long history but SNS therapy only 
received FDA approval in 1997. The mechanisms of action are still not known 
so there are different theories explaining the modulation effect. Recent studies 
have shown a central modulation effect. Predictive factors which can help to 
identify the perfect candidates are not known. Over the years the technique of 
SNS has become less invasive and because of two stage implantation test results 
have proven to be more reliable. The clinical results for this therapy have proven 
to be safe and effective and with the technical improvements over the years the 
re-operation and complication rates have decreased significantly. The clinical 
results have led to expanding indications because of positive effects in other 
symptoms. In the field of urology this has resulted in the use of SNS therapy for 
interstitial cystitis, neurogenic lower urinary dysfunction, and pediatric void-
ing dysfunction. In the field of gastro-intestinal pathology, SNS therapy is used 
to treat faecal incontinence and constipation. 
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INTRODUCTION
Chronic types of lower urinary tract dysfunction, including urgency inconti-
nence (UI) and urgency-frequency (UF) and non-obstructive urinary retention 
(UR), still present a therapeutic challenge. Most patients are initially treated 
with conservative therapies including bladder retraining, pelvic floor exercises 
and biofeedback. In the majority of patients this standard regimen is supported 
with pharmacological therapy (anticholinergics). However, approximately 40% 
either do not achieve an acceptable level of therapeutic benefit or remain com-
pletely refractory to treatment. Alternative surgical procedures such as bladder 
transsection, transvesical phenol injection of the pelvic plexus, augmentation 
cystoplasty and even urinary diversion have been advocated for these chronic 
conditions. However these procedures have variable efficacy and have been as-
sociated with significant morbidity and risk. Therefore research into the use of 
electrical currents for the treatment of lower urinary tract dysfunction has been 
initiated. 
In 1878, Saxtorph reported intravesical electrostimulation in patients with 
an acontractile bladder and complete urinary retention.1 He inserted a special 
catheter with a metal electrode transurethrally. Later both Ascoli2 and Katona3 
applied electrostimulation in patients with chronic neurogenic retention and 
neurogenic overactivity. In the field of urology electrical currents were and are 
used particularly in the bladder, the pelvic floor muscles and the sacral roots.4-6 
Electrostimulation of the sacral nerves was developed to empty the bladder and 
later post stimulus voiding was developed.7–10 Brindley developed an electrode 
for long-term stimulation of the spinal roots and the first patient was implant-
ed in 1972.11 The first paraplegic patients were implanted in 1978, using direct 
stimulation.12 A study by Nashold et al. reported on a successful implantation of 
a neural prosthesis in the sacral segment of the spinal cord.13 The implant was 
used to activate voiding in a patient with spinal cord injury. Jonas and Tanag-
ho10 tried to improve this prosthesis because this type of stimulation resulted 
not only in bladder contractions but also in urinary sphincter contractions as 
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well.9 Later Tanagho and Schmidt demonstrated that the stimulation of sacral 
root S3 generally modulates detrusor and sphincter action and could be used in 
clinical practice.17 
After two decades of experimentation with sacral root stimulation, finally 
in October of 1997, sacral neuromodulation for treatment of refractory UI was 
approved by the Food and Drug Administration in the United States. More than 
25,000 patients have undergone SNS since then. 
The stimulation of afferent nerve fibers by electrical currents modulates re-
flex pathways involved in the filling and evacuation phase of the micturition 
cycle through spinal circuits mediating somato-visceral interactions within 
the sacral spinal cord. SNS is proposed to activate or ‘reset’ the somatic affer-
ent inputs that play a pivotal role in the modulation of sensory processing and 
micturition reflex pathways in the spinal cord.18,19 As beneficial effects can be 
demonstrated at intensities of stimulation that do not activate movements of 
striated muscle, the afferent system is the most likely affected.20 Fowler et al. 
demonstrated that the anal sphincter reaction seen by acute testing is the result 
of an afferent mediated response.21
UR and dysfunctional voiding can be resolved by inhibition of the guarding 
reflexes. Detrusor overactivity can be suppressed by one or more pathways, that 
is, direct inhibition of bladder pre-ganglionic neurons, as well as inhibition of 
interneuronal transmission in the afferent limb of the micturition reflex.19 
Recent research with PET-studies indicates that at the level of the brain, the 
activity of centers in the paraventricular gray involved in activation or inhibi-
tion of the micturition reflex, can be enhanced or reduced by SNS. This results 
in up- or down-grading of lower urinary tract activity.22–24 Blok et al. reported on 
the acute and chronic effects of SNS on the brain in patients with urge-incon-
tinence. They registered differences between newly and chronically implanted 
patients in brain areas involved in sensory and motor learning. No differences 
were seen in regional cerebral blood flow (rCBF) in areas that are part of the 
micturition reflex. Changes in rCBF were seen in specific areas: areas known to 
be involved in micturition and areas involved in awareness and consciousness. 
Acute SNS modulates sensorimotor learning areas and these become less active 
during chronic SNS.25
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All patients with symptoms of voiding dysfunction and who cannot be helped 
by other measures should be considered for SNS. Patient selection begins with a 
careful history, physical examination, routine urine tests, and very important-
ly, voiding diaries. Voiding diaries are a valuable instrument for selection and 
have to be filled out carefully. Urodynamics are used to identify the patients 
with detrusor overactivity with or without urinary leakage or UR. Koldewijn et 
al.studied predictors of success in 100 test stimulation patients but could not 
identify any.26 Scheepens et al. studied data from 211 patients who underwent a 
test stimulation (percutaneous nerve evaluation [PNE]) to determine the clin-
ical parameters that can enhance the prediction of PNE success.27 They found 
that intervertebral disk prolapse (IPD) surgery, duration of complaints, neuro-
genic bladder dysfunction, and UI were significant predictive factors. IPD sur-
gery can compromise the sacral root function and can therefore cause UI and 
UR.28,29 In the study by Scheepens et al. patients who underwent IPD surgery 
had a 3.7 times higher chance of a positive test. Patients with UI responded 2.51 
times better to the PNE test. Duration of complaints for more than 7 months 
and neurogenic bladder dysfunction were both found to be negative predictors 
of success. However, a PNE remains necessary to evaluate a patient’s chance of 
permanent implant success objectively. 
Cohen et al. recently published a study on motor versus sensory response. 
They concluded that a good motor response during implantation was a predic-
tive factor (in 95% of successfully treated patients) for success while a sensory 
response was not. All these patients were implanted under local anesthesia but 
with intravenous sedation therefore the sensory perception of these patients 
may be unreliable.30 
Although not clearly reported before, it is known that a substantial portion 
of the patients selected for SNS therapy have a history of psychological dysfunc-
tion and/or sexual abuse. Weil et al. reported that special attention is needed for 
this group of patients.31 They noted that patients with a history of psychological 
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disorders, who had a good response during temporary test-stimulation, had a 
far greater chance of losing the primary effect after permanent implantation. 
Of these patients 82% showed a poor result after definitive implantation com-
pared to 28% of the patients without a history of psychological disorders. Be-
sides this lack of effect 25% of the re-operations were done in this group, most 
of them with no effect. Psychological testing or psychiatric evaluation in case of 
doubt was advised before implantation of a permanent system. 
A study by Everaert et al.showed similar findings.32 In this study the two-
stage procedure was compared with the single-stage procedure. In the two-
stage implant group there were no failures during the first stage while in the 
single-stage procedure three patients had an immediate failure. They suggested 
that these results might be strongly influenced by psychological factors. Mental 
disorders were not related to objective or subjective success but these cofactors 
surely interfere with symptomatology and therefore co-influence the results of 
therapy. 
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TECHNIQUE OF SACRAL NEUROMODULATION
SNS incorporates a temporary test stimulation procedure that allows patients 
and physicians to assess SNS over a trial period.33 This test stimulation, also 
known as a PNE test, is conducted as an outpatient procedure. It is preferably 
performed under local anesthetic and comprises two steps, acute testing and 
the home evaluation phase. The original technique was described by Schmidt 
et al.33 A test needle is inserted into the third sacral foramen to stimulate the 
sacral root. During 4–14 days patients are tested with a temporary lead. Lead 
migration is a known complication of this test, other complications are techni-
cal failures or pain.34 
Some patients who fail a PNE test are still good candidates for SNS therapy. 
For this reason a two-stage implant technique was developed.35 With this tech-
nique a permanent electrode is implanted and connected to an external stimu-
lator. Less lead migration and a longer test period made it possible to separate 
non-responders from technical failures. Using this two stage implant technique 
8 out of 10 patients who failed a PNE test had a good result with SNS therapy 
and were implanted with a permanent system. Also long-term results for pa-
tients implanted with this technique are promising.36 A less invasive technique 
in combination with a newly designed self-anchoring lead made it possible to 
test patients with this two-stage technique.37,38 This ‘tined lead’ has four sets of 
self anchoring tines and made a minimally invasive percutaneous placement 
possible. The procedure can be performed under local anesthesia, requiring no 
additional incision and no additional anchoring. Besides these advantages this 
method of implantation made it possible to test the sensitive responses during 
implantation resulting in a reduction of operating time. The ‘tined lead’ staged 
implant technique is widely used in Europe and the US.39 
The acute phase, whether a PNE or Tined Lead procedure is performed, is 
used to test the neural integrity, therefore sensory and motor responses should 
be obtained during this test. The motor responses are important to identify 
the correct sacral root. Typical S3 stimulation results in bellows movement of 
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the pelvic floor, plantar flexion of the great toe and paraesthesia in the rectum, 
perineum, scrotum, or vagina. Stimulation of the other sacral roots results in 
different motor responses: S2 stimulation results in clamp movement or twist-
ing and pinching of the anal sphincter and plantar flexion with lateral rotation 
of the entire foot; S4 stimulation results in bellows motion of the pelvic floor, no 
lower extremity activity and a sensation of pulling in the rectum.40 
It can be difficult to palpate the bony landmarks necessary to identify the 
right puncture place in obese patients. Fluoroscopy can then be used for S3 lo-
calization. More importantly, the use of lateral imaging helps to determine the 
depth required for implanting the S3 lead. The use of fluoroscopic localization 
of S3 allowed the introduction of a tined S3 lead and transformed the place-
ment of a lead from an open procedure to a completely percutaneous one.37,38 The 
widely adopted percutaneous use of a tined lead approach abandoned the need 
for fixation of the lead by methods such as bone anchors. 
If the patient’s symptoms improve by at least 50% then the patient is a can-
didate to undergo the stage II or permanent step in which the permanent im-
plantable pulse generator (IPG) is implanted in the soft tissue of the patient’s 
buttock. 
Relatively low amplitudes (0 – 3.0 V) are sufficient for stimulation of the 
somatic nerve fibers and to minimize the potential for nerve damage due to 
over-stimulation. Within the recommended stimulation parameters (210 msec, 
10 – 16 Hz) continuous stimulation is possible without pain sensation. 
43
2·5
UNILATERAL OR BILATERAL STIMULATION
Although temporary and chronic SNS can result in significant permanent clin-
ical improvement, some patients improve only partially or temporarily.41,42 For 
these patients several methods have been developed to improve the results.37–39 
The most widely accepted method to test a patient for SNS therapy is unilateral 
stimulation. In some clinics bilateral stimulation has been suggested as a meth-
od to obtain better results.43,44 The bilateral innervation of the bladder is the 
basis for this type of intervention.45,46 Animal studies were performed to find 
a scientific basis for the application of bilateral stimulation. Schultz-Lampel et 
al. suggest that bilateral SNS can be a more effective technique for voiding dys-
function.47 They conclude that bilateral stimulation may be more effective at 
lower stimulation intensities with positive side-effects such as longer stimula-
tor-battery life and less potential nerve damage. 
The only prospective randomized crossover trial to compare the unilateral 
approach with bilateral sacral nerve stimulation was performed by Scheepens 
et al.48 In this study 33 patients with chronic voiding dysfunction underwent 
unilateral as well as bilateral test stimulation to assess the possible advantages 
of bilateral stimulation. All patients were stimulated during at least 72 hr in a 
unilateral and a bilateral setting with a washout period of at least 48 hr between 
these two test periods. Standardized voiding records were used and urine was 
measured using standard measuring cups. They analyzed results of 12 patients 
with UI and 13 patients with non-obstructive UR. They did not find any signifi-
cant differences comparing the results of unilateral with bilateral stimulation. 
However, two patients from the retention group started voiding during bilater-
al stimulation, while during unilateral stimulation they were still in complete 
retention. The reason for this result could be that with bilateral stimulation 
sufficient sacral nerve afferents are stimulated to achieve a marked effect at the 
central level. 
In conclusion unilateral stimulation should be performed before bilateral 
sacral stimulation is considered. However, a bilateral test stimulation could 
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be indicated when a unilateral test fails.48,49 Further research with clinical fol-
low-up could identify suitable patients for bilateral sacral nerve stimulation. 
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CLINICAL RESULTS
In 1999 a prospective randomized study was published in which the results 
of SNS therapy for UI were evaluated.50 In total 76 patients were treated in a 
multi-center trial; 34 patients were implanted and received chronic stimulation 
for 6 months, after which they completed a therapy evaluation test (on vs. off), 
42 patients in a delay group were treated with standard medical therapy for 6 
months and were offered implantation after this period. After 6 months the 
number of daily incontinence episodes, the number of daily replaced diapers 
and the severity of incontinence was significantly reduced in the stimulation 
group. In the stimulation group 16 patients (47%) were completely dry and 10 pa-
tients (29%) showed a greater than 50% reduction in incontinence episodes. In 
the delay group (controls) the average incontinence episodes increased during 6 
months of conservative therapy from 2.6 3.5 heavy episodes a day at baseline to 
3.9 3.8 heavy episodes a day at 6 months. After 18 months the efficacy appeared 
to be sustained. During the therapy evaluation at 6 months the stimulation 
group returned to baseline symptoms when stimulation was stopped.51 
Hassouna et al. reported in 2000 on the treatment of UF symptoms with SNS 
therapy. In total 51 patients, a stimulation group of 25 patients and a control 
group of 26 patients, enrolled in this multicenter trial. All these patients had 
been tested with a PNE test and showed satisfactory responses. The stimulation 
group was implanted directly after this test and the control group was implant-
ed after a 6 month delay period. Statistically significant improvements were 
seen in the stimulation group for diary parameters such as: number of voids 
daily (16.9 ± 9.7 to 9.3 ± 5.1), volume per void (118 ± 74 to 226 ± 124 ml) and degree 
of urgency (rank 2.2 ± 0.6 to 1.6 ± 0.9). In the control group no significant chang-
es were seen. After 6 months the stimulation group underwent an evaluation 
test and urinary symptoms returned to baseline when stimulation was turned 
off. After reactivation of the stimulation sustained efficacy was seen at 12 and 
24 months. 
A report of the use of SNS in UR was published in 2001 by Jonas et al.52 177 
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patients with UR refractory to conservative therapy were enrolled in this multi-
center trial between 1993 and 1998. Thirty-seven patients were assigned to treat-
ment and 31 to the control group. At 6 months the stimulation group showed 
69% elimination of catheterization and an additional 14% with greater than 
50% reduction in catheter volume per catheterization. Temporary inactivation 
(3 days) of SNS therapy resulted in significant increase in residual volume. The 
effectiveness of SNS therapy was sustained for 18 months after implantation. 
The first medium term follow-up results of the above mentioned patient-se-
ries were published in 2000.34 Results were reported for 1.5 – 3 years of follow-up. 
Of 41 UI patients 59% showed a greater than 50% reduction in leaking episodes 
with 46% of these patients being completely dry after 3 years. After 2 years of 
follow-up 56% of the UF patients showed a greater than 50% reduction in voids 
per day. In the retention group 70% of 42 patients showed a greater than 50% 
reduction in catheter volume per catheterization. 
During the MDT-103 trial depression and health related quality of life 
(HRQOL) was assessed in 89 patients.53 Patients were divided to a direct im-
plant group or a delayed implant group. At baseline they noted detectable levels 
of depression in 73% of all patients. After 3 months patients in the implant-
ed group had a significant improvement in depression scores. These improved 
scores remained at the 6- and 12-month visits. The scores on the SF-36 question-
naire, a questionnaire to investigate pain, vitality, physical functioning, social 
functioning, and mental health, increased in the implant group for role-phys-
ical, pain, and social functioning. This study demonstrated the serious impact 
unresolved voiding dysfunction has on quality of life. SNS was associated with 
significant improvement in depression and HRQOL. 
Recently, the 5-year follow-up results of patients included in the trial in order 
to obtain FDA approval were analyzed. Of 163 patients enrolled, 152 have been 
implanted. Of the 163 patients, 103 (64%) had UI, 28 (17%) UF, and 31 (19%) UR. 
Voiding diaries were collected annually over 5 years. For UI patients, the mean 
number of leaking episodes per day declined from 9.6 ± 6.0 to 3.9 ± 4.0. For UF 
patients, mean voids per day decreased from 19.3 ± 7.0 to 14.8 ± 7.6. Mean volume 
voided per void increased from 92.3 ± 52.8 to 165.2 ± 147.7 ml. In the UR group the 
average number of catheterizations per day decreased from 5.3 ± 2.8 at baseline 
to 1.9 ± 2.8 at 5 years post implant. No life-threatening or irreversible adverse 
events occurred. Of 152 patients, 102 experienced 31 device-related and 240 ther-
apy-related adverse events. Among these therapy related events, the most fre-
quently reported event was new pain or undesirable change in stimulation (60 
times in 41 patients). Pain at the implant site or related to the implanted pulse 
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generator (IPG) was the second most reported event (40 times in 30 patients). 
However an important finding in this study is the high correlation between the 
1- and 5-year success rates. Of the implanted patients, 84% with UI, 71% with UF 
and 78% with UR continued to have a successful outcome at 5-year follow-up if 
successful at 1 year.54 
Different groups have published their long term results in recent years.55–57 
They all conclude that SNS therapy is safe and effective (Table 1). 
TABLE 1 
Results
Study # Patients Indication
> 50%  
improvement
Follow-up
Schmidt et al.50 34 UI 76% 6 months
Hassouna et al.51 21 UF 43% 2 years
Jonas et al.52 29 UR 83% 6 months
Siegel et al.34 41 UI 59% 3 years
29 UF 56% 2 years
42 UR 70% 18 months
Dasgupta et al.55 26 UR 77% 37 months
Voskuilen et al.57 149 UI/UF/UR 59.7% 46.2 months
aThe study by Voskuilen et al. measured good result or insufficient result. Therefore data on pa-
tients with > 50% improvement are not available. 
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COMPLICATIONS
Most of the studies mentioned in the clinical results section, reported on com-
plications during SNS. Siegel et al.34 summarized the complications in patients 
that were included in the original trials of SNS. The complications were by PNE 
related and implant related. Of the 914 test stimulation procedures done on the 
581 patients, 181 adverse events occurred in 166 of these procedures (18.2% of the 
914 procedures). The vast majority of complications were related to lead migra-
tion (108 events, 11.8% of procedures). Technical problems and pain represented 
2.6% and 2.1% of the adverse events. For the 219 patients who underwent implan-
tation of the permanent system, the following adverse events were seen during 
follow-up: pain at neurostimulator site (15.3%), new pain (9%), suspected lead 
migration (8.4%), transient electric shock (5.5%), pain at lead site (5.4%), adverse 
change in bowel function (3.0%) and some less frequent events like technical 
problems, device problems, change in menstrual cycle, and others. Surgical revi-
sions of the implanted neurostimulator or lead system were performed in 33.3% 
of cases (73 of 219 patients) to resolve an adverse event. Mostly this was done to 
relocate the stimulator because of pain or because of suspected lead migration. 
No serious adverse events, side effects or permanent injury were reported. 
Recently our long term follow-up results with complication rates were pub-
lished.57 Of 149 patients analyzed, 107 had overactive bladder symptoms and 
42 had urinary retention. Mean follow-up was 64.2 (SD=38.5) months. In the 
whole group 194 adverse events occurred. Six patients had infection in their 
implanted system and one was explanted for infection. Most events could be 
solved by giving advice or by reprogramming the stimulator. One hundred and 
twenty-nine reoperations were performed and 21 patients had their system ex-
planted. The most frequent surgical procedures performed were repositioning 
of the IPG, revision of the electrode because of suspected lead migration, and 
reoperation for parameter changes in patients implanted with the Itrell-I IPG 
(the first model used for SNS). Analysis of the data shows a striking difference 
in the incidence of reoperations, but small differences in subjective results in 
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the groups of patients implanted before or after 1996, suggesting that a proac-
tive approach towards adverse events is worthwhile. In our experience with the 
tined lead implantation we see a clear decrease in reoperation rate.58 Of 39 pa-
tients implanted with the tined lead Voskuilen van et al. described, there were 
seven severe adverse events in the medium term and three of these needed a re 
operation. Three patients could be treated with one or two reprogramming ses-
sions. Three patients had a reoperation to reposition the IPG after complaints 
of pain. These three patients had good results afterwards. One patient with an 
incomplete spinal cord lesion had no benefit of the implanted system. 
Of 161 patients implanted with the tined lead between July 2002 and Septem-
ber 2004. Hijaz et al.described the complications seen in their institute.59 They 
used three categories for complications: infections, mechanical problems, and 
response related dysfunction. In total they reported 17 explantations (10.5%). 
Eight explantations were done due to infection and seven due to loss of effect. 
In 26 (16.1%) patients they performed a revision after these patients presented 
with a decrease in clinical response. The reasons for revision were: mechani-
cal (lead) problems, IPG site discomfort, lead migration and infectious causes. 
These complication rates show a decrease over the years mainly due to techni-
cal and procedural improvements. Gaynor-Krupnick et al.60 as well as Hijaz and 
Vasavada61 presented an algorithm for evaluation and management of a mal-
functioning neuromodulation system. 
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EXPANDING INDICATIONS
With the widespread use, incidental improvements were published for other 
pathological conditions. Use of SNS for other off-label applications have been 
reported for treatment of interstitial cystitis, chronic pelvic pain, pediatric 
voiding dysfunction, and neurogenic lower urinary dysfunction seen in multi-
ple sclerosis. 
Long-term results for the use of SNS in neurogenic UI patients were present-
ed by Chartier-Kastler et al.62 The results for nine patients were shown with a 
mean follow-up of 43.6 months. All patients had significant clinical improve-
ment and 5 (56%) patients were completely dry. The number of leakages per day 
went from an initial 7.3 to 0.3 (at last follow-up). Frequency improved after im-
plantation from 16.1 to 8 voids per day and the mean volume per void increased 
from 115 to 249 ml. 
In 2000 the first papers were published with positive results for the use of 
SNS in interstitial cystitis.63,64 Comiter evaluated the effect of SNS therapy for 
interstitial cystitis in a prospective study in 2003.65 Seventeen out of 25 patients 
were implanted with a permanent system. After a mean follow-up of 14 months 
there were significant improvements in daytime frequency, and nocturia im-
proved from 17.1 to 8.7 and 4.5 to 1.1, respectively (P<0.01). Mean voided volume 
increased from 111 to 264 ml (P < 0.01). Average pain score decreased from 5.8 to 
1.6 points on a scale of 0–10 (P < 0.01). Interstitial Cystitis Symptom and Prob-
lem Index scores decreased from 16.5 to 6.8 and 14.5 to 5.4, respectively (P < 0.01). 
In 2001, Siegel et al.66 implanted 10 patients with chronic pelvic pain. These 
patients all had a history of at least 6 months of pelvic pain refractory to con-
ventional treatment without a primary complaint of voiding dysfunction. After 
9 months of follow-up 9 out of 10 patients had a decrease in most severe pain 
scores, and after a median follow-up of 19 months 6 out of 10 patients reported 
significant improvement in pain symptomatology. 
After the clinical implication of SNS therapy for voiding dysfunction, Matzel 
together with Schmidt and Tanagho started to investigate SNS therapy in bow-
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el dysfunction.67,68 In a prospective non-randomized multicenter study 37 pa-
tients underwent a test stimulation with SNS therapy for faecal incontinence.69 
Thirty-four patients were implanted with a permanent system. The effect on 
incontinence was assessed by daily bowel habit diaries and a disease specific 
quality of life questionnaire. The frequency of incontinent episodes per week 
decreased from 16.4 to 3.1 at 12 months and to 2.0 at 24 months for both urge 
and passive incontinence. The mean number of incontinence episodes per week, 
staining and pad use declined significantly too. Quality of life improved sig-
nificantly in ASCRS scales, although in the SF-36 scales only social functioning 
improved significantly. 
Jarrett et al. did a systematic review of SNS for faecal incontinence and con-
stipation.70 They reported total continence in 41–75% of the patients, 75–100% 
experienced improvement in the incontinence symptoms. The results for pa-
tients treated with SNS for constipation discussed in this review seem promis-
ing but only limited data is available at this time. 
The results of SNS therapy in children with neurogenic bladder dysfunction 
is described by Guys et al.71 In total 2 children with neurogenic bladder dysfunc-
tion, mainly due to spina bifida, enrolled in this prospective randomized con-
trolled trial. Twenty-one patients were treated conservatively while the other 21 
patients were treated with SNS therapy. After 12 months no significant improve-
ment in results were seen in the group treated with SNS. The authors stated that 
probably the intervention group was too small or the bladder dysfunction in 
these patients too severe. 
Pauls et al. recently reported a pilot study to determine if sacral neuromod-
ulation has an effect on the patient’s subsequent sexual function.72 Eleven pa-
tients with a permanent system implanted were questioned about their sexual 
function before and after implantation. With SNS therapy sexual frequency and 
Female Sexual Function Index (FSFI) increased significantly. No correlation was 
found between improvement in urinary symptoms and FSFI scores. 
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CONCLUSIONS
After years of experimental therapy, initiated by Tanagho and Schmidt, SNS is 
nowadays a widely used therapy. Although the mechanisms of action are still 
not fully understood, the therapy has been proven effective in the long term. 
Due to the less invasive technique and other technical improvements it is ex-
pected that complication rates will further decrease within the coming years. 
The expanding use of SNS therapy in fields other than urology will probably 
result in FDA approval for gastro-intestinal indications. 
Further research, possibly with the help of animal models, has to be per-
formed to understand in a more precise way the mechanism of SNS therapy. 
Other goals in research could be: patient selection (finding ways to identify the 
best candidates), the effect of SNS in combined (urological/gynaecological/gas-
tro-enterological) pathology and the effect of bilateral versus unilateral stimu-
lation. 
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ABSTRACT
Objective
To analyse the influence of technical improvements of Sacral Nerve Stimula-
tion (SNS) on the incidence of surgical interventions and subjective long-term 
results of SNS. 
Methods
Retrospective, transversal study analyzing records of implanted patients at our 
department of Urology.
Results
Of 149 patients analyzed, 107 had overactive bladder symptoms and 42 had uri-
nary retention. Mean follow-up was 64,2 (sd = 38,5) months. In the whole group 
194 adverse events occurred. 6 Patients had infection in their implanted system, 
one was explanted for infection. Most events could be solved by giving advice 
or by reprogramming the stimulator. 129 reoperations have been performed and 
21 patients had their system explanted. Analysis of the data shows a striking 
difference in the incidence of reoperations, but small differences in subjective 
results in the groups of patients implanted before or after 1996, suggesting that 
a proactive approach towards adverse events is worthwhile. 
Conclusions
SNS gives lasting benefit in patients with refractory symptoms of overactive 
bladder and non-obstructive urinary retention. The differences in outcomes 
and incidence of reoperation can be attributed to the learning curve and tech-
nical and surgical improvements in the application of SNS.
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INTRODUCTION
In 1994 neuromodulation by sacral nerve stimulation (SNS) became available 
as a new treatment option for patients with refractory urge incontinence, ur-
gency-frequency and nonobstructive urinary retention.1–4 The SNS procedure 
is non-mutilating compared to other surgical procedures. Therefore, it gained 
a place in the list of therapeutic options a physician can offer to patients with 
the above-mentioned symptoms. Sacral neuromodulation is placed between 
non-invasive therapies such as anticholinergics or pelvic floor training and sur-
gical procedures, such as bladder augmentation and urinary deviation. Initially 
patients were implanted according to the protocol of a multicenter study initi-
ated by the manufacturer of the implanted equipment in order to achieve FDA 
approval (MDT-103).5–8 From early application of SNS until now continuous re-
search is carried out to improve this therapy and to determine the exact mecha-
nism of action. This research has yielded some technical improvements in SNS. 
In the period covering our study the design of the Implantable Pulse Generator 
(IPG) has been changed two times, lead design has changed and there have been 
advancements in surgical techniques. In our experience these advancements 
have contributed to decreased complications rates as well as increased satis-
faction rates in our patients receiving SNS therapy.9–11 This study is set up to 
confirm this hypothesis. 
3
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METHODS
This is a transversal cohort study. The surgery logs of the department of Urolo-
gy of the University Hospital Maastricht covering the period between 1990 and 
December 2003 have been scrutinized for patients who received a new definitive 
neuromodulation system or had revision surgery. Patients were included if they 
had follow-up of longer than one year and if complete data were available. All 
patients were implanted according to the open procedure as proposed by Tana-
gho and Schmidt.12 Patients, implanted through the percutaneous tined lead 
procedure were excluded, as well as patients receiving bilateral stimulation.9 
All patients had shown successful on screening using the Percutaneous 
Nerve Evaluation (PNE) with a temporary lead or after a two-stage procedure.13 
12 patients had their definitive implant through a 2-stage procedure. 
The first series of patients were implanted with the Itrel-I IPG, which was the 
first model used for SNS. Parameter change was done in an open surgical proce-
dure. The Itrell-II was introduced in 1994 and allowed parameter modification 
by the physician using an external programmer. 
Patients, implanted with the Itrell-II could switch the IPG on and off and 
choose between two preprogrammed settings with a magnet. Since 1999 the In-
terstim IPG is used. This latest model is supplied with a patient remote control 
for switching the device on/off and for changing amplitude within a prepro-
grammed range. In our opinion this decreases outpatient visits as patients can 
handle amplitude related events by themselves. 
The first model of the implanted lead had separate fixation connectors, which 
had to be sutured onto the lead. In 1994 a new lead model was introduced with 
fixation connectors integrated into the lead. From 2000 the IPG was implanted 
gluteally instead of abdominally, as this placement gave less complications.10 
From the files of the implanted patients the following data were collected: 
type of complaints, date of implantation, date and result of neuromodulation of 
last check-up, number of adverse events and if adverse events had successfully 
been addressed, date of reoperations for adverse events. 
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Patient complaints were stratified on an ‘urge’ category and ‘retention’ cate-
gory. The urge category comprises patients suffering from urge incontinence or 
urgency-frequency with or without pelvic pain complaints. The retention cate-
gory consists of patients with non-obstructive retention, regardless of the cause 
of the complaints. 
The subjective results of the patients at their last visit were categorized as 
‘good’ or as ‘insufficient’. The criteria for success were complete and lasting dis-
appearance of symptoms or satisfactory symptoms for the patient. 
An insufficient result was noted when the patient was not satisfied, when 
symptoms recurred, in the case of an uncorrected adverse event or when the 
system was explanted. If at last follow-up visit the stimulation parameters of 
the IPG were changed, the chart of the patient was analyzed a second time 
during the revision period of this manuscript and the result was noted. This is 
based on the fact that patients are instructed to report back if symptoms do not 
improve. The patients are encouraged to contact the clinic when they suspect 
neuromodulation-related complaints. 
The number of adverse events the patient had in the period from implant 
until last follow-up was counted as well. An adverse event was noted when the 
patient had neuromodulation-related complaints, not solved by changing the 
stimulation amplitude. Necessary outpatient reprogramming sessions of the 
stimulator for loss of sensation were only recorded as an adverse event if loss of 
sensation was accompanied by loss of efficacy. Battery depletion of the IPG was 
recorded separately if the procedure was not combined with other neuromodu-
lation related surgery. 
The data of the patients were analyzed using SPSS 11.5 for Windows (SPSS 
inc., USA). 
Analysis of contributing factors to the results was done using bivariate cor-
relation analysis by Pearson’s Chi-square test. Further statistical analysis was 
performed using the Mann-Whitney test. 
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RESULTS
Between October 1990 and December 2002 190 patients were implanted. 15 pa-
tients were implanted less than a year ago, and therefore not analyzed. The data 
in the files of 26 patients was incomplete. In 17 of these files data on the implant 
was missing as these patients were implanted in another hospital and had re-
operations in our department. In the remaining 9 files other data on adverse 
events or reoperations were missing. A total of 149 patients met the inclusion 
criteria and were analyzed. The group consisted of 27 male (18,1%) and 122 female 
patients (81,9%). Among these patients 129 (86,6%) had an idiopathic cause of 
their symptoms and 20 (13,4%) patients had a neurologic cause of their urinary 
complaints. Table 1 shows the diagnosis and results of these patients. 
Indications for implant were overactive bladder symptoms in 107 (71.8%) and 
retention in 42 (28.2%) patients. Mean age at implantation was 46.7 (sd = 10.0) 
years, range between 21 and 72 years. 
Follow-up ranged between 12 and 154 months after implant, mean follow-up 
period was 64.2 (sd = 38.5) months. 
The mean follow-up for patients who were implanted for urgency symptoms 
was 69,8 months (sd = 41.6) and for patients with urinary retention 70.5 months 
(sd = 38.0). In the whole group 89 (59.7%) patients were scored having a good 
result, 44 (29.5%) patients had insufficient results and 16 patients (10.7%) had a 
reprogramming session at their last visit. 
During the revision process of this manuscript the follow-up of these 16 
patients after database closure showed that 11 (68.8%) had good results after a 
period of three to 6 months after their visit and 5 (31.3%) patients kept insuffi-
cient results after reprogramming. With these 16 patients included a total of 
100 patients (67.1%) had a good result and 49 (32.9%) had insufficient results. 68 
(63.6%) of the 107 patients with urgency had good results at the time of their 
last follow-up and 39 (36.4%) patients with urgency had insufficient results. In 
the retention group of 42 patients 32 (76.2%) patients had good results and 10 
patients (23.8%) had insufficient results. 
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TABLE 1
Diagnosis # patients Result  
good
Result  
insufficient
ALS 1 1 0
Cauda Equina syndrome 3 1 2
Peripheral polyneuropathy 2 2 0
Guillain Barre 1 1 0
IDP 5 3 2
SCI 1 1 0
Multiple Sclerosis 1 1 0
Paraplegia 1 0 1
Spina Bifida 1 1 0
Spondyolysis 1 1 0
Whiplash 2 1 1
Unknown neorologic 1 0 1
Total 20 (100%) 13 (65%) 7 (35%)
ALS: Amyotrophic Lateral Sclerosis, IDP: Intevertebral Disk Prolaps, SCI: Spinal Cord Injury.
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TABLE 2
Diagnosis #
Pain/undesirable change in stimulation 64
Undesirable change in voiding function/Loss of efficacy 42
Oain at IPG implant site 41
Afverse change in bowel function 15
Suspected lead migration 10
Suspected device problem (including lead breakage) 6
Infection 6
Technical problem 5
Suspected neuropraxia 2
Other 3
Total 194
The figures described in this table are numbers of adverse events. Some patients had more than 
one ad-verse event. Pain or undesirable stimulation was only recorded as an adverse event when 
changing the stimulator amplitude could not solve the problem. Suspected neuropraxia was seen 
in 2 patients who set their amplitudes very high and was in both patients successfully solved by 
switching the IPG off for 6 months. The events in the ‘Other’ category all were with one occur-
rence.
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In the group of 149 patients with a total of 9562 months of SNS experience 
194 adverse events occurred in 106 patients. There were no irreversible or severe 
adverse events. The most frequently occurring adverse events were changes in 
stimulation sensation, loss of efficacy and pain at the Implantable Pulse Gener-
ator (IPG) site (Table 2). 
Of all analyzed patients 48.3% had at least one reoperation due to an adverse 
event. A total of 129 reoperations were performed in the total patient group to 
address adverse events, averaging 0.87 reoperations per patient. 
The most frequent surgical procedures were repositioning of the IPG for 
pain, revision of the electrode because of suspected lead migration and reoper-
ation for parameter change in patients implanted with the Itrell-I IPG. The 129 
surgical procedures do not include replacement of the IPG for battery depletion. 
19 revisions for battery depletion took place in 18 patients. One patient who 
was implanted in 1992 has had two revisions for battery depletion. The mean 
life span of the replaced IPGs in these patients was 73,7 months with a range 
between 28 to 127 months. 
Chi-square correlation analysis between implantation date, the sex of the 
patient, type of complaints, follow-up duration, number of adverse events and 
whether adverse events had been resolved at last follow-up and the result at last 
follow-up was performed. 
The analysis showed a significant correlation between result and adverse 
events being resolved: 0.830 (p = 0.000). Also the surgery per year ratio and the 
final results were correlated: 0.397 (p = 0,000). 
However an inverse correlation was noted between result and the number 
of adverse events: 0.355 (p = 0.000). Patients without adverse events had the 
highest chance of a good result, but when patients had an adverse event, it was 
in most cases satisfactorily resolved. 
The Chi-square test did not show a significant difference between the results 
of patients with or without a neurologic cause for their complaints. Analysis of 
the data shows a clear decrease in the number of the adverse events and reoper-
ations during the study period. 
Fig. 1 shows the ratio of revisions and the ratio of adverse events in the pa-
tients implanted in each year divided by the number of implanted patients in 
that year (Table 3). 
In the patients implanted before 1995 the mean number of reoperations was 
1.56, while in the patients implanted after 1995 the mean decreased to 0.49 reop-
erations. This difference is statistically significant (p < 0.0001). 
The difference in the results between both groups changed as well: 60.7% of 
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the patients implanted before 1995 had a good result while 65.9% of the patients 
implanted after 1995 had a good result. This difference is not statistically sig-
nificant (Fig. 2). 
In 21 (14.1%) of the 149 patients the neuromodulation system had been re-
moved. The most common indication for explant was loss of efficacy (18 pa-
tients). The remaining three patients have been explanted for uncorrectable 
side effects, one of these patients had an explant due to infection. 
Of the explanted patients 15 (71.4%) had urge symptoms, while 6 patients 
(28.6%) suffered from retention. The mean follow-up was 53.6 months (sd = 40.7), 
while the follow-up ranged between 12 and 145 months. Statistical analysis in 
the 21 explanted patients shows a higher mean surgery/year ratio of 0.56 (sd = 
0.09) than in the non-explanted group with a ratio of 0.12 (sd = 0.2) (p < 0.005). 
In 14 patients (66.7%) the operation in which the IPG was explanted was their 
only reoperation, in the remaining explanted patients the number of surgical 
sessions before the explant ranged between 1 and 11 sessions. 
69
TABLE 3
The number of implants, adverse events, reoperations and the ratios of revisions/implants and 
adverse events/ implants for each year
Year # Implants # Revisions
# Adverse 
events
Revision  
ratio
Events  
ratio
1990 4 17 18 4,25 4,50
1991 14 19 24 1,36 1,71
1992 8 10 14 1,25 1,75
1993 9 5 10 0,56 1,11
1994 14 21 26 1,50 1,86
1995 12 10 14 0,83 1,17
1996 12 10 12 0,83 1,00
1997 10 11 16 1,10 1,60
1998 14 9 17 0,64 1,21
1999 16 5 21 0,31 1,31
2000 17 6 17 0,35 1,00
2001 14 0 5 0,00 0,36
2002 4 0 1 0,00 0,25
2003 1 0 0 0,00 0,00
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FIGURE 1
Revision/implant ratio over time. The ratio of revisions carried out in the patients implanted in 
each year divided by the number of the implants in each ear. Revisions for empty batteries are 
excluded.
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FIGURE 2
Number of surgical revisions/patient before and after 1995. The amount of patients with surgical 
revisions of their implanted neuromodulation system before/in 1995 and after 1995. 
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3·5
DISCUSSION
Sacral neuromodulation gives lasting and satisfactory relief in patients with 
refractory symptoms of overactive bladder and urinary retention.4,7,14–16 
Because the study setup is retrospective and voiding diaries were not always 
found in the file, the outcome of the patients was based on patient and physi-
cian satisfaction, instead of on voiding diary parameters. 
Usually patients are satisfied when they are without symptoms or have very 
few symptoms. These results, however, are not comparable to other studies be-
cause of the subjective measurement of the outcome. 
Some retrospective studies have been performed to identify predictive fac-
tors regarding the success of the Percutaneous Nerve Evaluation.17,18 
So far no research has been done about predictive factors for the success of 
the definitive implant. In this study logistic regression analysis between result 
and date of implantation, sex of the patient, the type of complaints, follow-up 
time, the number of adverse events and whether adverse events had been re-
solved at last follow-up has been carried out. However, none of these factors 
seemed to predict the outcome of neuromodulation. The therapy-dependent 
factors for a successful result that we identified were a low number of adverse 
events and surgical correction of an adverse event. There was no significant dif-
ference in the results between patients with complaints of neurogenic origin 
and idiopathic patients. The number of neurogenic patients (20 patients) was 
low in comparison with the non-neurogenic group (120 patients). Previous stud-
ies by Weil and by Everaert show that psychiatric factors play a role in the first-
year results of SNS.4,19 
Weil et al. described that patients with a previous history of psychiatric dis-
order are more prone to loose effect of their implanted neuromodulation sys-
tem, while Everaert et al. demonstrated a greater chance of different outcomes 
between the temporary test and definitive implant in patients diagnosed with 
psychiatric disease. To avoid bias by placebo effect in patients, we established 
the criterion of a minimum follow-up of one year. 
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The rate of surgery for adverse events seems high, compared to other studies. 
In the literature the percentage of patients needing a reoperation is around 33%, 
while in our study we found a reoperation rate of 48,3%.4,5,7 
This suggests a considerable learning curve in patient selection. Throughout 
the years we select patients more strictly. In the early years potential candidates 
underwent up to five PNE’s when there was doubt if the patient reacted. Now 
patients get maximal two PNE's before offering them a two-stage tined lead 
procedure or excluding them from neuromodulation. Furthermore improved 
temporary lead design made the PNE more reliable.20 Another reason for higher 
reoperation rates is that the used equipment was still under development in 
the early years of SNS. Fig. 1 shows that the greatest decrease in both adverse 
events and reoperations is between 1991 and 1992. An important reason for the 
decrease in adverse events and surgical interventions is the experience that is 
accumulated, particularly in the first years of the application of sacral neuro-
modulation. In 1994 both the Itrell-II and a new definitive electrode became 
available. Fig. 1 shows that in 1994 the adverse events ratio and the reopera-
tion ratio rises. This suggests a learning curve after the introduction of the new 
techniques. 
The years thereafter the ratios drop, showing the benefits of the new tech-
niques. The same phenomenon is seen in 1999 when the Interstim IPG is avail-
able and in 2000 when the buttock placement is introduced. Despite the drop 
in adverse events and reoperation rate a center that embarks on this therapy 
needs to schedule regular follow-up visits and can expect inbetween visits for 
troubleshooting patients. 
In 1997 Janknegt et al. tried to improve the testing procedure for neuromod-
ulation by testing through the 2-stage procedure.13 The long-term efficacy of the 
2-stage procedure has been determined by Scheepens et al.11 Recently the im-
plant through the 2-stage procedure has been compared with the single-stage 
procedure in a randomized trial and gives a higher chance of a good result.21 
Since 2002 a new procedure has been developed for lead implant.22 This 
procedure allows for minimal invasive lead placement under local anesthesia. 
The procedure takes place on outpatient basis and the tined lead can easily 
be removed. Therefore two-stage testing through the tined lead has become a 
valuable addition to the PNE. Experience shows that the rate of patients with 
positive screening results increases by using the tined lead.9 This is probably 
because the tined lead is less susceptible to lead migration and the tined lead 
allows for longer screening periods. 
Since mid-2002 about 50 patients were implanted with the tined lead proce-
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dure in our department. These patients are not included in this study. 
We suspect that use of patients’ sensory responses during the tined lead im-
plant to guide lead placement gives less chance of failure of the definitive SNS 
system. Furthermore we expect a decrease in adverse events due to minimal in-
vasive lead implant. These hypotheses have yet to be confirmed in a trial, which 
is currently ongoing in our clinic. 
In 2000 buttock placement of the IPG has been investigated.10 The buttock 
placement reduced average operating time from 2.5 to 1.5 hours because patient 
turning during surgery was not necessary and the flank incision was not per-
formed. More importantly, postoperative pain, postoperative infections and the 
need for reoperations for IPG position-related pain were reduced. Despite the 
lack of a randomized trial the buttock placement has quickly become the stan-
dard method of IPG implant. 
The occurrence of late failures remains still problematic in SNS. In this study 
18 out of 149 patients have been explanted due to loss of efficacy. 
This group had more reoperations than the patients that were not explanted. 
No other predictors were found. 
The cause of this phenomenon is still unknown, although we suspect that 
neuro-plasticity of the micturition center could play an important role. 
Currently a trial is ongoing, investigating the effect of bilateral stimulation 
in patients with therapy failure in our department. Still, more research is need-
ed in this particular group of patients. 
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CONCLUSION
Sacral neuromodulation produces prolonged subjective benefit in a group of 
patients with highly therapy resistant lower urinary tract symptoms. The de-
crease in the number of adverse events and reoperations over the study period 
suggests a considerable learning curve in selecting, implanting and follow-up 
of patients with neuromodulation. Other contributing factors are the develop-
ment and implementation of new surgical techniques and the new technical 
developments as the external patient programmer and new implant hardware. 
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ABSTRACT
Objective
To describe patient selection for sacral neuromodulation, also known as Inter-
stim therapy, and the results of tined-lead implantation in the medium term.
Patients and Methods
In all, 49 patients, 39 with refractory overactive bladder symptoms and 10 with 
urinary retention, were implanted with the tined lead under local anaesthesia. 
The mean (SD) test period was 12.4 (5.8) days. Patients were implanted when 
they had a ≥50% improvement in voiding diary variables during the test period. 
The mean follow-up for implanted patients was 15.5 (7.9) months. Changes in 
voiding variables were compared using a t-test.
Results
Ten patients had a one-stage and 39 a two-stage implant; of the latter group, 
31 (80%) had a positive response and eight (21%) did not. In all, 31 patients were 
included in the follow-up. At the last follow-up, 28 (90%) patients had a >50% 
improvement in diary variables and three (10%) did not. In 21 patients with ur-
gency symptoms the mean (SD) number of voids decreased from 11.7 (8.9)/day at 
baseline to 7.3 (3.4)/day (P=0.1); the voided volume increased from 160.2 (70.7) 
mL to 231.1 (119.5) mL (P=0.001); and the number of leakages decreased from 9.5 
(8.7) to 3.3 (2.2)/day (P=0.17). In the 10 patients with retention, the number of 
catheterizations decreased from 5.44 (1.6)/day with a volume of 297.6 (76.8) mL, 
to 1.2 (1.7)/day and 111.6 (158.1) mL; the mean number of voids increased from 3.7 
(3.8)/day with a volume of 123.3 (141.7) mL, to 4.2 (2.4)/day and 248.3 (146.0)mL. 
There were no significant differences in the variables in the patients with reten-
tion. Seven patients had an adverse event. There was one incomplete electrode 
migration that was treated conservatively.
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Conclusion
This new minimally invasive approach gives positive results in the medium 
term. Two-stage testing with the tined lead seems more reliable than the classic 
percutaneous nerve evaluation. The lead anchoring method seems sufficient for 
fixing the electrode in the medium term.
Keywords
electric nerve stimulation, LUTS, minimally invasive
4
84
4·2
INTRODUCTION
Since its introduction about a decade ago, sacral neuromodulation (SNM) is 
applied in patients with refractory urge incontinence, urgency-frequency and 
unobstructive urinary retention.1–5 Typically, potential candidates are tested 
with a temporary lead before the implantation of a definitive neuromodulation 
system is considered. Clinical experience with the test procedure for neuromod-
ulation showed that the temporary electrode is prone to migration during the 
subchronic test phase. Consequently, and due to the probability of bacterial 
infections in temporary electrodes that are implanted for a prolonged period, 
the duration of the subchronic test phase is limited to a maximum of ≈1 week. 
Moreover, there are some implanted patients who experience inconsistencies 
between the results of the test period and the results of the definitive implant. 
In 2003, Spinelli et al.6,7 introduced a new, minimally invasive technique for 
implanting a definitive electrode. Using this electrode, the duration of the sub-
chronic test phase can be prolonged, and if the test results are insufficient, the 
electrode can easily be removed. In this article we describe our clinical results 
with this procedure.
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PATIENTS AND METHODS
In all, 49 patients (nine men and 40 women, mean age 50.0 years, SD 13.2, range 
18–73) with symptoms of overactive bladder (OAB) or urinary retention refrac-
tory to conservative therapy, had the new electrode implanted. All patients had 
a percutaneous nerve evaluation (PNE) with the conventional temporary elec-
trode before the tined-lead implant. Under local anaesthesia, in a minimally 
invasive procedure, a lead (Model 3889, Medtronic, Minneapolis, MN, USA) was 
placed in the left or right S3 foramen.6 The lead is equipped with silicone tines 
that allow it to be fixed in the tissue above the sacrum. Local anaesthesia al-
lowed both patients’ sensory and motor responses to be used as a guide. The 
depth of the electrode was controlled by lateral fluoroscopy. 
The patients with a positive result from the classic PNE had a one-stage im-
plant. In these patients, the electrode was tunnelled to an incision made at the 
ipsilateral gluteal area and connected to an extension cable. This extension ca-
ble is connected to an implantable pulse generator (IPG, model 3023, Medtronic) 
inserted into a s.c. pocket in the gluteal area. The one-stage procedure took a 
mean of 40 min. The patients with inconclusive results of the classic PNE had a 
two-stage procedure. In these, the lead was tunnelled to a small ipsilateral glu-
teal incision. After connecting it to an extension cable, the lead was tunnelled 
to a contralateral exit point and connected to an external stimulator (model 
3625, Medtronic). The subchronic phase of the two-stage test took a mean (SD, 
range) of 12.4 (5.8, 5–31) days. During this phase, patients were asked to keep 
voiding diaries to record changes in their urinary symptoms. These data were 
compared to baseline voiding diaries. 
Patients with a ≥50% improvement in their relevant urinary symptoms were 
implanted with an IPG as a second stage. In these, the ipsilateral incision was 
re-opened and the extension cable was disconnected and removed. A short 
extension cable was connected to the lead and an IPG was implanted. When 
the subchronic phase was unsuccessful the lead and extension cable were dis-
connected and removed. The lead could easily be removed up to a month after 
4
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implantation by applying moderate traction. The first stage of the two-stage 
procedure took a mean of 30 min, while the second stage took 15 min. All proce-
dures were done under local anaesthesia on an outpatient basis. After implant-
ing the IPG, patients were followed at regular intervals of 6 weeks, 6 months, 
and yearly thereafter. 
Patients were told to contact the clinic when they had problems related to 
the implanted system. All patients were told to avoid stretching, bowing and 
bicycling for at least 6 weeks after implantation, after which they were encour-
aged to resume all activities that they did before the implant. Each patient with 
loss of efficacy during follow-up had a radiograph taken to check whether there 
was electrode migration. In June 2005, all implanted patients were asked to 
complete another set of voiding diaries; these were compared with the baseline 
diaries. The variables at baseline and at the last follow-up were compared using 
a t-test. 
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RESULTS
Of the 49 patients, 39 (80%) were implanted for OAB symptoms, and 10 (20%) 
had urinary retention. Ten patients had a positive classic PNE and were implant-
ed in a one-stage procedure. The other 39 patients had an inconclusive PNE, and 
were re-tested in a two-stage procedure. Reasons for the inconclusive results 
were: discrepancy in recorded 24-h output between the baseline and test period 
(13 patients), suspected 108 electrode migration (seven) and technical failure of 
the PNE (two). One patient with a technical failure had a different anatomy 
due to spina bifida; in another patient the external stimulator switched off by 
itself. The other 17 patients with an inconclusive PNE had subjective improve-
ment, while analysis of the voiding diary showed a <50% improvement. In the 
39 patients who had two-stage testing, 31 (80%) were eligible for the definitive 
implant and eight (21%) were not. 
Of all 49 patients, 41 had a definitive implant either in one stage or after two-
stage testing, and 31 of them were included in the further follow-up. Four of the 
10 patients who were not included had a follow-up of <6 weeks. A fifth patient 
with a follow-up of 18.3 months had loss of efficacy after a vaginal wall correc-
tion. A sixth patient died 8.9 months after implantation from causes unrelated 
to neuromodulation, and the seventh patient was explanted for to psychiatric 
reasons after 13.3 months of follow-up, but had had good results. This patient 
had hallucinations after the implant and blamed adverse life-events on having 
the nerve stimulation system. Three patients were lost to follow-up and did not 
respond to repeated requests to complete an additional diary. These 10 patients 
were excluded from the analysis. 
The mean (SD, range) follow-up of the 31 analysed patients was 15.5 (7.9, 3.2–
32.4) months. At the last follow-up, 28 (90%) of the patients still had a >50% 
improvement in at least one of the relevant voiding diary variables and three 
(10%) patients had a <50% improvement. In all implanted patients, the voided 
volume was increased from 153.0 (86.9) to 234.5 (122.5) mL at the last follow-up 
(P < 0.001). Table 1 shows the overall success rates in each patient category. 
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In the patients with urge incontinence or urgency-frequency the mean num-
ber of voids at baseline was 11.7 (8.9)/day. At last follow-up this decreased to 7.3 
(3.4)/day (P=0.1). The voided volume increased from 160.2 (70.7) to 231.1 (119.5) 
mL at the last follow-up (P=0.001). 
The patients who had urge incontinence had a mean of 9.5 (8.7) incontinent 
episodes/day at baseline; at the last follow-up this decreased to 3.3 (2.2)/day 
(P=0.17). In the 10 patients with retention, the mean number of catheterizations 
was 5.44 (1.6)/day and the catheterized volume was 297.6 (76.8) mL at baseline. 
At last the follow-up the mean number of catheterizations was 1.2 (1.7)/day and 
the catheterized volume was 111.6 (158.1) mL. Three of these 10 patients had com-
plete retention at baseline. At the last follow-up, two of these three patients had 
a normal voiding pattern. Six of the patients with retention no longer catheter-
ize, and the other four catheterize up to a maximum of twice a day. The mean 
number of voids at baseline was 3.7 (3.8)/day with a volume of 123.3 (141.7) mL. At 
the last follow-up the number of voids was 4.2 (2.4)/day with a volume of 248.3 
(146.0) mL. There were no significant differences in the variables in patients 
with retention, when analysed by a t-test. 
Of 31 patients, seven had a significant adverse event. Two patients had loss 
of efficacy after non-urological surgery; both patients had positive results after 
up to two re-programming sessions. Another patient with retention due to an 
incomplete spinal cord lesion still has no benefit from his system. Two patients 
complained of pain at the IPG implant site; one had a re-operation under local 
anaesthesia to reposition the IPG, and the other had a buttock implant of the 
IPG, while she was dependent on a wheelchair. In this patient the IPG was re-po-
sitioned from the gluteal region to the abdominal wall. Both patients are now 
free of pain and have positive results. 
A patient with positive results had an open revision because of troublesome 
leg stimulation. Investigation showed that the tined lead was placed too deep 
and stimulated the S2 nerve that runs below the level of the S3 root. 
During the follow-up there was one incomplete electrode migration. The 
patient presented at 5.3 months of follow-up with different sensations and de-
creased efficacy after a fall. A radiograph image of the sacrum showed that the 
electrode had migrated by 2–3 mm. The patient was successfully treated by 
re-programming the stimulator. 
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TABLE 1
The overall success rates for patients with urge urinary incontinence and patients with urinary 
retention.
Patients, # (%) Success Failure Total
OAB patients 19 (90) 2 (10) 21
Retention 9 1 10
Total 28 (90) 3 (10) 31
4
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DISCUSSION
Successful neuromodulation largely depends on the careful selection of candi-
dates. To date the only means of selecting patients likely to benefit was the clas-
sic PNE.8 However, the PNE has its limitations. The duration of the subchronic 
phase of the PNE is limited to a maximum of ≈1 week because of the chance of 
infection. Furthermore there is a chance of electrode migration. Edlund et al.8 
reported that eight of 20 patients had a loss of efficacy during the subchronic 
phase of the PNE; this was probably due to electrode migration, but not in all 
patients with an insufficient result, as electrode migration could be shown by a 
sacral radiograph. 
In 1997, the two-stage approach was introduced.9,10 Testing with a definitive 
electrode enabled longer testing periods and decreased the chance of a negative 
test due to electrode migration. Recently Everaert et al.11 proved in a randomized 
trial that testing with the two-stage procedure gave more positive subjective 
results and a greater improvement in diary variables. As the tined lead can be 
implanted using a minimally invasive procedure under local anaesthesia, and 
can easily be removed, testing through the two-stage procedure is easier and 
applied more often. 
The proportion of patients in the present study who had a positive two-stage 
procedure (80%) is higher than the published positive results with the classic 
PNE, of 30–62%.8,11–14 This comparison is not entirely fair, because some nonre-
sponders were filtered out by the classic PNE, but shows that ≈20% of the nega-
tive classic PNEs are false-negative, possibly because the testing period was too 
short to show clear results, or perhaps because of undetected electrode migra-
tion. In a recent study, Kessler et al.15 reported a significant difference between 
50% positive responders after 4–7 days vs 80% after ≥14 days. These results in-
dicate that the duration of the test period is important in selecting candidates 
for SNM. It would be interesting to compare the results of the PNE and the two-
stage tined lead in a randomized prospective trial. 
However, in our experience the PNE still has value for initial screening, as it 
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is a cost-effective way of establishing whether a patient is a suitable candidate 
for SNM. Until there are better predictors for the success of SNM, the only tool 
for patient selection is a temporary test procedure. The PNE keeps the threshold 
for testing potential candidates low, while filtering unsuitable candidates at an 
early stage of the assessment. Examples of unsuitable candidates are patients 
who cannot cope with the testing equipment or the diaries, or those who do not 
tolerate SNM. 
Indications for a two-stage tined lead procedure are a <50% symptom reduc-
tion during the PNE and/or technical difficulties of the PNE, including suspect-
ed lead migration. The patients with urgency had significant improvements at 
the last follow-up vs baseline. Although patients with retention improved, the 
variables did not change significantly, but the present group of patients with 
retention is small and most patients had no complete retention at baseline. The 
differences in number of voids and voided volume are relatively small, account-
ing for high P values. However, the number of catheterizations decreased to a 
mean of 1/day, and the need to catheterize is bothersome for patients. Of the 
implanted patients, 90% maintained a favourable result during the follow-up. 
This suggests that, in addition to better selection, placing the definitive lead 
implant under local anaesthesia gives a better chance of lasting positive results 
than the open implant. 
Minimally invasive lead placement is guided by both sensory and motor re-
sponses, rather than only motor responses in the open procedure. We suspect 
that the use of sensory responses in addition to motor responses provides better 
electrode placement and less chance of complications and therapy failure. This 
has yet to be confirmed in a study with more patients and a longer follow-up. 
One patient had an incomplete electrode migration after a fall. We took 
sacral radio-graphs in each patient who had loss of efficacy. Despite this rigor-
ous screening policy, there was one migration of 2–3 mm, that was treated con-
servatively. Kessler et al.described a patient with bilateral electrode migration, 
who was successfully treated by re-programming the modulator.16 
In the present study, two patients needed a re-operation due to pain at the 
implant site. One patient uses a wheelchair, and the IPG implanted in the glu-
teal area caused discomfort due to the pressure of the wheelchair on the region 
of the implanted IPG. After repositioning the IPG in the abdominal wall, the pa-
tient is free of complaints. Therefore abdominal placement of the IPG should be 
considered in wheelchair-bound patients. In the other patient with pain at the 
position of the IPG, we found during re-operation a subcutaneous nerve run-
ning through the pocket wall. After re-positioning the IPG away from the nerve 
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the patient was free of complaints. 
In conclusion, the new minimally invasive approach for SNM is easier to per-
form than the classic open method. It gives positive results in both the short- 
and medium-term. Two-stage testing with the tined lead appears to be a more 
reliable method than the classic PNE because of a prolonged testing period and 
perhaps because of the lower risk of electrode migration. Therefore testing with 
a tined lead is a useful alternative in patients with an inconclusive PNE result. 
As there was only one lead migration during the medium-term follow-up of up 
to 3 years, it is obvious that that the lead anchoring method is sufficient for fix-
ing the electrode. However, long-term follow-up data on the performance and 
possible migration of the tined lead are not yet available. 
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ABSTRACT
Introduction
Sacral neuromodulation (SNM) of the lower urinary tract has proven to be safe 
and effective in patients with complaints of OAB syndrome who are not re-
sponding to conservative therapy. After five years of treatment the implanted 
system is still effective in 56–71% of patients. The loss of effect could be caused 
by adaptation of the nerve system to prolonged stimulation of the sacral nerves.
Materials and Methods 
We set up a pilot intervention study. After a run-in period of 2 weeks patients 
were randomized into two groups: one group with on-demand neuromodulation 
(intervention group) and one group with continuous neuromodulation (control 
group). Patients in the intervention group were instructed to switch their INS 
off by default and to switch it on again when they felt recurrent symptoms, pa-
tients in the control group were asked to use their system as normally. 
Results
After 2 weeks 10 out of 16 subjects reported a comparable symptom score during 
on-demand use of their neuromodulation system. Patients appreciated the 
comfort of being self-determent in the need for therapy. 
Conclusions
Possible benefits for patients could be: more autonomy, longer battery life of 
the implanted INS, decreasing the chance of adaptation by the nervous system. 
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INTRODUCTION
Sacral neuromodulation (SNM) of the lower urinary tract has proven to be 
safe and effective in patients with complaints of OAB syndrome who are not 
responding to conservative therapy.1,2 SNM treatment is also used in patients 
with non-obstructive urinary retention and as an off-label treatment in patients 
with interstitial cystitis.3 After 5 years of treatment the implanted system is 
still effective in 56–71% of patients.4 The system consists of an implanted lead, 
stimulating the sacral nerves through one of the sacral foramina (preferably S3), 
connected to an implantable neurostimulator (INS). Typical battery life is 8–10 
years; depending on the parameters used for stimulation. The expected lifespan 
of the recently introduced ‘Inter-stim II’ lies around 3–5 years when used 24 hr/
day. 
Most of the patients with an implanted neuromodulation system for urinary 
complaints receive continuous neuromodulation 24 hr a day. However, they are 
instructed to turn the INS off at certain moments, for example, when driving a 
car or when working with heavy machinery. This is to prevent accidents caused 
by reactions to sudden changes in the electrical current. 
Until now evidence is lacking whether it is necessary to apply 24 hr of neu-
romodulation per day or if discontinuation of neuromodulation is possible for a 
short period of time. 
In early trials on SNM the effect of prolonged discontinuation of neuromod-
ulation for at least 72 hr showed return to baseline of voiding symptoms in all 
patients. This was reversible in most patients by turning the neuromodulator 
on again.1,5 
The working mechanism of SNM is not fully understood but seems to involve 
modulation of spinal cord reflexes and brain networks by peripheral afferents, 
rather than direct stimulation of the motor response of the detrusor muscle. 
SNM is proposed to activate or ‘reset’ somatic afferent inputs that play a pivotal 
role in the modulation of sensory processing and micturition reflex pathways in 
the spinal cord.6,7 Furthermore, there are indications that SNM influences brain 
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areas that are involved in detrusor hyperactivity, awareness of bladder filling, 
the urge to void and the timing of micturition.8,9 
With on-demand rather than continuous neuromodulation, the physiologi-
cal situation is more adequately approximated, since in the normal physiological 
situation there is no continuous tonic afferent information coming from affer-
ents to the dorsal sacral horn. Therefore, patients are expected to have a lower 
risk of developing side effects of SNM such as gastrointestinal complaints, pain, 
or menstrual cycle changes. 
Clinical experience as well as the literature on SNM has shown that a cer-
tain percentage of implanted patients stop having benefit from their implanted 
system after a few years, despite adequate neuromodulation. A suggested hy-
pothesis for this phenomenon is adaptation of the nerve system to prolonged 
stimulation of the sacral nerves.10 It could be expected that on-demand neuro-
modulation postpones or diminishes this effect. 
The objective of this prospective pilot study was to investigate whether the 
on-demand use of SNM is a feasible therapy regime, therewith mimicking the 
normal physiological situation as well as diminishing the need for frequent re-
placement of the INS.
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PATIENTS AND METHODS
This study was set up as a pilot intervention study. Patients who were treated 
with SNM for symptoms of urgency incontinence or urgency-frequency syn-
drome refractory to conservative therapy were included. Patients were consid-
ered eligible for the study when they had a functioning neuromodulation sys-
tem with unchanged stimulation settings for at least 6 months. All participants 
were implanted with a system that includes a patient programmer, which gives 
the possibility to deactivate the system (Medtronic Interstim model 3023 and 
Model 3031A patient programmer, Medtronic, Minneapolis, MN). Patients with 
relevant co-morbidity were excluded (e.g. urinary tract infection, non-function-
ing system, and malignancy of the urinary tract). 
For this study a hybrid design was followed, based on previous work by Po-
cock.11 Instead of a 50:50 allocation of patients, 25% of the participants were 
randomized to the control group, permitting 75% to be assigned to the new in-
tervention. We started with all patients and follow them for 2 weeks to establish 
a firm baseline (and the knowledge that with continous SNM there will be max-
imum ‘on’ time and very likely no change in symptoms). After 2 weeks patients 
were randomized to the on-demand group, while five stayed in the continuous 
(control) group. At the end of study, the data from the controls were compared 
to the baseline group and showed stability. This allowed us to combine all con-
trols and compare them to the on-demand group. This enabled us to perform a 
transversal comparison with a minimum of patients. The main criteria for such 
an approach (rather recent included patients, the same procedure, investigator, 
and identical outcome assessments) were all met in this trial. 
All included patients signed an informed consent and were asked to register 
a voiding diary for 2 weeks (baseline) and to fill out a Urologic Measurement 
Questionnaire (UMQ). This UMQ measures subjective urologic complaints in 
patients. This UMQ consists of seven questions on urologic complaints; a score 
of 1 (much worse) to 5 (much better) can be given to each of the questions (Ap-
pendix 1). The questionnaire is previously used in other studies regarding SNM 
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for the measurement of subjective complaints.12 This questionnaire was chosen 
because it has been used in our practice since the start of our neuromodulation 
database and appeared to be very useful in clinical practice and follow-up of 
individual patients. Although it is not a validated questionnaire, it gives a com-
parable scale of subjective complaints. We consider the data of interest to the 
clinician as they give an impression of the magnitude of change. 
The total study duration was 4 weeks and started with a run in period of 
2 weeks: in this period all subjects registered a voiding diary (baseline symp-
toms). At the end a urogical questionnaire had to be filled out. After the run-in 
period of 2 weeks all patients were randomized into two groups: one group with 
on-demand neuromodulation (intervention group) and one group with contin-
uous neuromodulation (control group). For the remaining 2 weeks, the patients 
in the intervention group were instructed to switch their INS off by default and 
to switch it on again when they felt recurrent symptoms. So when they experi-
enced more urgency symptoms or incontinence they turned their INS on. When 
symptoms had disappeared they could turn the INS off again. The patients in 
the control group were asked to use their system as normally: this means they 
were not allowed to change settings during the trial. 
At the end of this period, subjects were asked to fill out the UMQ again (Ap-
pendix 2). 
With a voiding diary urinary complaints as well as the on and off-hours were 
registered for both groups. The following voiding diary parameters were eval-
uated: number of voids/24 hr, voided volume/void, number of leakages/24 hr, 
number of pads/24 hr, and the degree of urgency. 
On-demand neuromodulation was considered successful when patients were 
able to switch the INS off for at least 4 hr/day, without worsening of urinary 
symptoms recorded with voiding diaries and UMQ. This cutoff point was set at 
4 hr because this was considered a time span that could give a relevant change 
in battery lifespan. 
Institutional review board approval was obtained for this study. All included 
patients signed an informed consent. Data analysis was performed using Statis-
tical Package for the Social Science version 12.0 (SPSS Inc., Chicago, IL).
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TABLE 1
Baseline symptoms for both groups with continuous neuromodulation
Pads/ 
day
Volume/ 
void
# Micturition/
day
# Leakages/ 
day
On-demand 0.9 131 ml 8.7 2.9
Control 1.1 202 ml 7.3 2.8
5
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RESULTS
In total 26 patients were included in this study. Five patients were excluded 
from analysis because they did not fill out the voiding diaries correctly. 
Complete voiding diaries were obtained of the remaining 21 patients, who 
were randomized into two groups. Five patients were randomized into the con-
trol group and 16 into the on-demand group. In the on-demand group there 
were 2 men and 14 women, in the control group only women. The mean age of 
these patients was 53.6 years. All patients had their neuromodulation system 
implanted between 1992 and 2004 for urgency incontinence. By the time they 
were participating in this study an Interstim model 3023 was implanted. In all 
patients the INS configuration was unchanged in the last half year and all sub-
jects were capable of using their patient programmers correctly. 
Baseline symptoms for both groups with continuous neuromodulation are 
shown in Table 1. There were no statistical differences in baseline parameters 
between the two groups. 
In the control group no differences were observed between the results of 
voiding diaries and UMQ during the first 2 weeks (baseline) and the second 2 
weeks of this study. In the intervention group 10 of 16 subjects reported a com-
parable symptom score (no worsening) during on-demand use of their neuro-
modulation system. They had a mean off-time of 12.4 hr a day. 
Table 2 shows the mean off-times in hours a day for the intervention group. 
Worsening was measured based on the results of the voiding diaries. 
Table 3 shows the different parameters for the subjects of the intervention 
group. 
After the intervention period all participating subjects filled out a UMQ. 
With this questionnaire subjective differences between both periods were mea-
sured with seven questions. (min–max score 7–35). A score below 17 was consid-
ered as a worsening in subjective measurements (Table 4).
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TABLE 2
Number of patients with off-hours/day during intervention
Modulator off (hrs) Worsening No worsening Total
4-14 0 2 2
14-24 6 8 14
Total 6 10 16
TABLE 3
Micturition parameters during intervention period (mean off-time per day in hours)
No. Pts.
Increase (not successful)
No. Pts.
No increase (succesful)
Voids/24 hr 4 (10 hr) 12 (18 hr)
Leakage episodes 6 (8,4 hr) 10 (12,4 hr)
Pad use 6 (8,4 hr) 10 (12,4 hr)
Severity of leakage 4 (10 hr) 12 (18 hr)
TABLE 4
Scores for subjective measurements (urologic measurement questionnaire)
Subjective change Control On-demand Total
Worsening (</=17) 0 8 8
No worsening (>17) 5 8 13
Total 5 16 21
5
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DISCUSSION
SNM is an approved treatment for different challenging urological condi-
tions.1–3 Unfortunately some patients tend to loose their initial effect over the 
years. Long-term multicenter results show an efficacy off 56–71% for the differ-
ent relevant parameters at 5 years.4 Possible explanations for failures during 
use of SNM include the potential placebo effect of test stimulation, insufficient 
test stimulation sensitivity before implantation, and inadequate patient selec-
tion. These explanations are supported by a good correlation between the 1- and 
5-year success rates. 
Adaptation of the nervous system, although never clearly studied, is another 
proposed mechanism for the loss of effect on the long-term for prolonged stim-
ulation of the sacral nerves. On-demand neuromodulation might be an ideal 
way of stimulation to prevent this phenomenon. 
The results in Table I show that 14 out of 16 patients in the intervention 
group had their INS turned off for at least 14 hr a day. 10 out of 16 patients could 
turn their INS off without worsening of complaints during this period, and 8 of 
these patients could do that for at least 14 hr. 
In this study, 62.5% of the patients in the intervention group showed no in-
crease in pad use and/or number of leakage episodes a day (Table 2). Looking to 
the number of voids in a day and the severity of leakage 75% of the intervention 
group had no increase in symptoms. This means that for an average group of 
patients treated with SNM for urgency incontinence almost 2/3 could be treated 
with on-demand neuromodulation. 
In the intervention group 50% of patients experienced worsening in sub-
jective symptoms. This result can be explained by the way our patients were 
instructed. They were told to the turn the INS on during the intervention peri-
od when they felt recurring symptoms. As expected the patients in the control 
group experienced no difference (Table 3). 
Another method of non-continuous neuromodulation is stimulation by cy-
cling mode. This is possible with all INS nowadays used for SNM therapy. With 
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this setting the INS turns itself on and off in a preprogrammed cycle. For ex-
ample the stimulation can be programmed on during 10 second then off for 5 
sec. Disadvantages of this method compared to on-demand neuromodulation 
is that a patient experiences this on/off event every time. Most patients in our 
practice reported discomfort during this cycling mode stimulation. A second 
disadvantage is that it is not the patient itself that determines the need for 
therapy. 
When patients were asked how they experienced on-demand neuromodula-
tion, many patients appreciated the comfort of being self-determent in the need 
for therapy. They felt less dependent on their neuromodulation system. Howev-
er, we did not directly measure the influence of this reported effect on quality of 
life. While an improvement in quality of life may be appreciated by some, those 
who are satisfied with continuous stimulation such that they no longer think 
about their prior voiding complaints, may view intermittent stimulation as an 
interruption and an impediment to their quality of life. 
The long-term effects of on-demand neuromodulation were not studied in 
this pilot. Therefore long-term studies are necessary to determine if on-demand 
neuromodulation can prevent adaptation of the nervous system.
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CONCLUSION
According to this pilot study, on-demand neuromodulation is a feasible therapy 
regime in the majority of patients with urgency incontinence successfully treat-
ed with SNM therapy. Possible benefits for patients could be: 
• More autonomy; it allows patient to confidently turn of their SNM system 
without losing efficacy. 
• Longer battery life of the implanted INS. 
• Decreasing the risk of adaptation by the nervous system. 
Nevertheless, larger, randomized controlled studies with longer follow-up are 
needed and should include quality of life measurements as well as a more de-
tailed data on battery life improvement.
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APPENDIX 1
Urologic Measurements Questionnaire
1. Do you think that voiding in general goes better? 
No, it’s much worse/no it’s worse/no difference/yes, some improvement/yes a 
lot better. 
2. Do you think that your flow has improved? 
No, it’s much worse/no it’s worse/no difference/yes, some improvement/yes a 
lot better.  
3. Does your bladder feel emptier? 
No, it feels much fuller/no, it feels a bit fuller/no difference/yes, it’s emptier/
yes, it’s much emptier.  
4. Do you think you are drier? 
No, much wetter/no, a bit wetter/ no difference/yes, a bit drier/yes, much drier. 
 
5. Have your urge-sensations changed? 
Clearly worsened/a bit worse/no difference/a bit less/clearly diminished. 
6. Has your voiding frequency changed?
No, I had to go more often/no, I had to go a bit more often/no difference/Yes, I 
had to go somewhat less often/yes, I clearly had to go less often.  
7. Do you have more control over your bladder?
No, it’s worse/No, it’s somewhat worse/no difference/yes, it’s better/yes, it’s 
much better. 
Score 1 (much worse)—5 (much better)
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APPENDIX 2
Course and Timing of the Study
VISIT 1:
· Start to register voiding diaries (#) for 2 weeks
· UMQ at 2 weeks
VISIT 2 (VISIT 1+2 WEEKS):
· Randomization
· Stop voiding diary #1
· Stop voiding diary #2
Control group,
N=16
VISIT 3 (VISIT 1+4 WEEKS):
· Stop voiding diary #2
· Urologic measurement questions
Control group,
N=5
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ABSTRACT
Purpose
We evaluated whether patients with overactive bladder and incontinence who 
discontinued intravesical botulinum toxin therapy can be successfully treated 
with sacral neuromodulation. 
Materials and methods 
All patients who were referred to our center after discontinuation of botuli-
num toxin-A between 2005 and 2010 were included in this observational study. 
All patients underwent test stimulation with sacral neuromodulation and were 
evaluated with voiding diaries. Success was defined as more than 50% improve-
ment in leakage episodes. Successful test stimulation was subsequently fol-
lowed by a definitive implant. Patient satisfaction with sacral neuromodulation 
therapy was evaluated 1 year after the definitive implant. 
Results 
A total of 20 patients were included in the study. Of these patients 17 (85%) 
had discontinued botulinum toxin-A because of lack of efficacy and 3 had been 
treated successfully with botulinum toxin-A but requested a more permanent 
solution. The mean interval between the botulinum toxin-A and the sacral 
neuromodulation test stimulation was 23 months. In 14 patients (70%) the test 
stimulation was successful and they received a definitive implant. Of the 14 pa-
tients 5 even showed a decrease of greater than 90% in leakage episodes. One 
year after implantation 11 patients (79%) were satisfied with the sacral neuro-
modulation treatment. 
Conclusions
Despite the small sample size, this study indicates that patients who are dissat-
isfied with or in whom botulinum toxin-A treatment fails can respond success-
fully to sacral neuromodulation. The success rate of the test stimulation was 
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comparable to that of patients who have never been treated with botulinum 
toxin-A. The 1-year satisfaction rate was comparable that of patients without a 
history of botulinum toxin-A treatment. 
6
118
6·2
INTRODUCTION
Overactive bladder is defined as lower urinary tract symptoms of urgency with 
or without urinary incontinence (OAB-wet and OAB-dry), usually with frequen-
cy and nocturia. It can be caused by detrusor overactivity of neurogenic or id-
iopathic origin. The prevalence is estimated up to 17% in the adult population 
and increases with age. First line conservative treatment consists of lifestyle 
modifications, pelvic floor physiotherapy and anticholinergic medications. 
These conservative treatments do not always lead to sufficient improvement of 
complaints and are often associated with considerable side effects resulting in 
limited compliance and treatment failure. Intravesical injections with botuli-
num toxin and sacral neuromodulation are minimally invasive and reversible 
second line treatment alternatives which have gained wide acceptance in the 
treatment of OAB.1 
BoNTA treatment has largely been investigated in patients with neurogenic 
detrusor activity for which there is now unanimously a high level of recommen-
dation and approval of the U.S. Food and Drug Administration (FDA). The use of 
BoNTA treatment in patients with idiopathic detrusor overactivity is currently 
studied. The FDA has recently approved the treatment for idiopathic detrusor 
overactivity and it has been adapted in the clinical practice guidelines and is 
performed on a large scale. Recent placebo controlled randomized control trials 
have shown BoNTA treatment to be effective for idiopathic detrusor overactiv-
ity, with success rates ranging from 40 to 80% depending on the dose used.1,2 
BoNTA treatment is regarded overall safe and well tolerated when inject-
ed in the bladder wall with current doses and techniques. The most common 
side effect of the treatment is the increase in PVR resulting in possible need for 
CISC and urinary tract infections. The need for CISC after BoNTA treatment 
has been reported in a range from 16% to 42%.3,4 Remarkably, up to 37% of the 
patients discontinue the treatment after the first 2 injections. This is mainly 
due to lack of efficacy, presence of adverse events such as post-void residual that 
needs clean intermittent catheterization or the desire for a more permanent 
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solution (without the need for repeated treatments).5 If BoNTA treatment fails 
or when patients are dissatisfied with the result, sacral neuromodulation is the 
only other minimal invasive alternative. In this study we determined whether 
patients who have been unsuccessfully treated with BoNTA treatment can be 
successfully treated with SNM.
6
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MATERIALS AND METHODS
In this single center observational study we included all patients with idio-
pathic OAB-wet that were referred between 2005 and 2010. All these patients 
had stopped BoNTA treatment due to dissatisfaction and had recurrent or per-
sistent symptoms. 
History taking and a 3-day voiding diary assessed the complaints of OAB. 
The voiding diary was used as baseline. Physical examination and urinalysis 
was used to rule out other conditions. Urodynamics were performed in all pa-
tients to confirm the diagnosis of detrusor overactivity and to exclude other 
diagnosis. 
All patients underwent SNM test stimulation with use of the PNE test. In all 
patients there was a minimum interval of 6 months between the last BoNTA 
injections and this SNM test stimulation, to prevent bias caused by botulinum 
toxin at SNM screening. This 1-week test stimulation was subsequently fol-
lowed by a 1 or 2-stage TLP. During the test stimulation period, a 3-day voiding 
diary was again filled out to evaluate the effect of SNM. The test stimulation 
was evaluated by comparing the data of the voiding diary filled out during the 
test stimulation to the baseline voiding diary. 
Primary outcome measure was improvement in leakage, defined as greater 
than 50% improvement in episodes of leakage and severity of leakage (subjective 
on a scale from 1 to 4). Improvement in frequency and/or urgency was stated 
as the secondary outcome, for which success was defined as greater than 50% 
improvement in frequency and urgency. In case of successful PNE, it was fol-
lowed by a 1-stage TLP with definitive placement of an implantable neurostim-
ulator (InterStim® I or InterStim II, Medtronic Inc). In case of an unsuccessful 
PNE test stimulation, a first stage TLP was performed. When the first stage was 
successful, the second stage of the TLP consisted of a definitive placement of 
an implantable pulse generator. If unsuccessful the first stage was surgically 
removed. Several pulse generator settings were used, preferably unipolar elec-
trode selection, frequency of 10 Hz, the pulse width 210 us and the amplitude 
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just above sensation threshold (preferably lower than 2.0 V). 
At routine annual control at the outpatient clinic the patients who received 
the definitive SNM implant were asked about their satisfaction. The patients 
who were not eligible for SNM underwent a telephone interview about the 
course of their treatment after SNM test stimulation failure. The data process-
ing of this study was performed with IBM SPSS® statistics, version 18.
6
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RESULTS
A total of 20 patients (16 female), mean age 56 years (range 37 to 82) were screened 
for SNM. Table 1 gives an overview of all patient data. 
Seventeen (85%) patients had stopped BoNTA treatment, because of lack of 
efficacy during the first or subsequent treatments. Three patients had experi-
enced successful BoNTA treatment, but were dissatisfied because of the tem-
porary relief and need of repeat injections and opted to be screened for treat-
ment with SNM. Four (20%) of the patients unsatisfied with BoNTA reported 
the need for performing CISC during BoNTA treatment, although they did not 
experience any effect on urgency urinary incontinence. Because of increased 
PVR (greater than 150 cc) 3 of the 4 were still performing CISC, at the time of 
SNM test stimulation. 
The number of injection sessions per patient ranged from 1 to 4 subsequent 
BoNTA treatments, dosages varying from 100 to 300 units onabotulinumtoxin 
A in up to 500 units abobotulinumtoxin A. The mean interval between the (last) 
BoNTA treatment and the SNM test stimulation was 23 months (minimum 7, 
maximum 53). Ten patients (50%) responded successfully to PNE and another 
4 (20%) in whom PNE failed experienced a secondary successful first stage TLP. 
The total success rate was 70% (14 of 20). Voiding diaries during test stimulation 
showed greater than 50% decrease of episodes (mean 75%) with a mean decrease 
in severity of leakage of 53% when comparing the diaries of the test stimulation 
to the baseline voiding diaries. Five (25%) patients even showed a decrease of 
greater than 90% in leakage episodes. The changes in frequency varied from an 
increase of 15% to a decrease of 62%. Of the 3 patients who still had to perform 
CISC before SNM test stimulation (table 1, patients 1, 9 and 17) 2 were voiding 
to completion during SNM test stimulation (patients 1 and 9). Table 2 shows an 
overview of the screening results. No difference is shown between success rates 
in patients who received repeated injections (patients 3, 5, 6, 9, 10 and 13) and 
those who only had a single injection.
All 14 patients underwent implantation of an internal pulse generator (In-
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terStim I or InterStim II). One year after implantation 11 of the 14 patients (79%) 
were subjectively satisfied with the SNM treatment. All 3 patients who were 
dissatisfied with SNM experienced a relapse of incontinence that could not be 
controlled by changing the parameter settings. 
In 5 patients the PNE and the secondary first stage TLP were unsuccessful. 
One patient refused a secondary first stage TLP after failure of the PNE. These 
6 patients who did not experience a sufficient effect during the PNE and TLP 1st 
stage test stimulation were questioned about their treatment course after this 
test failure and 4 did not receive any other treatment and are still experiencing 
symptoms of OAB. Two patients were lost to follow-up. 
TABLE 1
Supplementary table: overview patient data
Patient  
ID
Sex
Age  
(yrs)
No. of  
BoNTA
Efficacy  
BoNTA
Reason discontinuation 
BoNTA
1 Female 37 1 No effect No effect, PVR
2 Female 54 1 No effect No effect
3 Female 82 4 Dry Repeat treatment
4 Female 70 1 No effect No effect
5 Female 54 2 Dry Repeat treatment
6 Female 53 2 No effect No effect
7 Male 42 1 Dry Repeat treatment
8 Male 60 1 No effect No effect
9 Female 66 2 No effect PVR, persist incontinence
10 Male 78 2 No effect No effect
11 Female 44 1 No effect No effect
12 Female 47 1 No effect No effect
13 Male 67 1 No effect No effect
14 Female 55 1 No effect No effect
15 Female 49 1 No effect No effect, PVR
16 Female 66 3 Dry Repeat treatment, no effect
17 Female 68 1 No effect PVR, persist incontinence
18 Female 46 1 No effect No effect
19 Female 40 1 No effect No effect
20 Female 54 1 No effect No effect
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TABLE 2
Results of screening
Patient  
ID
Mos BoN-
TA-SNM
Test stimula-
tion result
Leakage im-
provement (%)
Frequency im-
provement (%)
1-yr  
satisfaction
Succesful test stimulation with definitive implant performed:
1 18 PNE succesful Greater than 50 Less than 50 Unsatisfied
2 25 PNE succesful Greater than 50 Less than 50 Satisfied
3 17 PNE succesful Greater than 50 Greater than 50 Satisfied
4 8 PNE succesful Greater than 50 Less than 50 Satisfied
5 41 PNE succesful Greater than 50 Greater than 50 Unsatisfied
6 11 PNE succesful Greater than 90 Greater than 50 Satisfied
7 21 PNE succesful Greater than 90 Less than 50 Satisfied
8 7 PNE succesful Greater than 90 Less than 50 Satisfied
9 17 PNE succesful Greater than 50 Less than 50 Satisfied
10 31
PNE unsuccesful, 
TLP 1st stage 
succesful
Greater than 50 Less than 50 Satisfied
11 18
PNE unsuccesful, 
TLP 1st stage 
succesful
Greater than 50 Less than 50 Satisfied
12 46
PNE unsuccesful, 
TLP 1st stage 
succesful
Greater than 90 Greater than 50 Satisfied
13 11 PNE succesful Greater than 50 Greater than 50 Unsatisfied
14 11
PNE unsuccesful, 
TLP 1st stage 
succesful
Greater than 90 Greater than 50 Satisfied
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TABLE 2 (CONTINUED)
Results of screening
Patient  
ID
Mos BoN-
TA-SNM
Test stimula-
tion result
Leakage im-
provement (%)
Frequency im-
provement (%)
1-yr  
satisfaction
Unsuccessful test stimulation with definitive implant not performed:
15 29
PNE unsuccesful, 
TLP 1st stage 
unsuccesful
Less than 50 Less than 50
16 18
PNE unsuccesful, 
TLP 1st stage 
unsuccesful
Less than 50 Less than 50
17 53
PNE unsuccesful, 
TLP 1st stage 
unsuccesful
Less than 50 Less than 50
18 18
PNE unsuccesful, 
TLP 1st stage 
unsuccesful
Less than 50 Less than 50
19 31
PNE unsuccesful, 
TLP 1st stage 
unsuccesful
Less than 50 Less than 50
20 27 PNE unsuccesful Less than 50 Less than 50
6
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DISCUSSION
This study is the first to describe the success of SNM (test stimulation) in OAB 
patients, after discontinuation of BoNTA treatment. The success rate of the 
SNM test stimulation in our preliminary observational study was 70% (14 of 
20). This finding is comparable to the published SNM test stimulation results in 
patients with OAB that were not previously treated with BoNTA injections.6,7 
The superiority of the TLP over the PNE has been studied before, up to 22% gain 
in test success has been shown.8 The 1-year satisfaction rate in this study was 
79%. This is comparable to the 85% satisfaction rate in patients who were treat-
ed with SNM after failure of conservative treatment.9 
BoNTA and SNM are both implemented in the urological guidelines for uri-
nary incontinence.10 Nevertheless, their place in the treatment algorithm is still 
unclear and no advice is given on what treatment to choose. Predictive factors 
for success and efficacy of these 2 treatments have been studied extensively. Pre-
vious treatment with BoNTA has never been identified as a predictive factor for 
SNM success. The fact that the success rate of SNM in this study is comparable 
to studies indicates that in patients with idiopathic OAB and who have been 
previously treated with BoNTA, SNM can be equally successful. This finding 
gives clinical support to the described results in histological studies, evaluating 
the structural (long-term) effects of BoNTA on the urinary bladder. These stud-
ies have shown that BoNTA does not produce changes in the human urotheli-
um or suburothelium after single or repeated injections.11 Another argument for 
the success of SNM after BoNTA is the difference of the working mechanism. 
Injection of BoNTA causes chemical denervation and reduction of cell activity, 
which leads to temporary inhibition of neuromuscular nerve signaling. SNM is 
supposed to have a modulating effect on the afferent signaling important for 
the coordination of storage and voiding, thereby having a central effect, where 
the working mechanism of BoNTA is local. 
Although the lack of structural changes of the bladder after BoNTA injec-
tions, functional changes (the occurrence of chronic PVR) do occur after the in-
127
jections. One of the major reasons for patients to stop BoNTA treatment is PVR, 
for which CISC is needed. In our study population we have included 3 patients 
who were still performing CISC at the time of test stimulation, with a minimum 
of 17 months after the last BoNTA injections. Studies have been conducted to 
evaluate the dose-effect ratio in relation to risk of PVR, even the use low doses 
(100 to 150 U) does not prevent the risk of PVR.1,2 Studies comparing urodynamic 
results before and after BoNTA treatment have showed a PVR incidence of 3% 
to 25% after BoNTA treatment, depending on the dose.12 In our study 2 of the 3 
patients with complaints of OAB who were performing CISC since BoNTA treat-
ment were treated successfully with SNM for their voiding and OAB complaints. 
This finding might indicate that SNM can have a positive effect on PVR as a 
consequence of BoNTA treatment. 
The duration of the effect of BoNTA is not well-defined, different studies 
have indicated the effect to last for 6 to 12 months.1,13 The duration is suggested 
to be dose dependent. In our results the duration of follow-up varied between 
7 and 53 months with a mean of 23 months. Remarkably all patients in whom 
the interval had been shorter than 12 months (5 of 20) experienced a successful 
SNM test stimulation. All these patients were dissatisfied with BoNTA, because 
of the lack of effect. This finding might suggest that there is no need to wait 
for up to 12 months before starting SNM screening, after unsatisfactory BoNTA 
injections. 
One advantage of SNM over BoNTA injections is the long and permanent 
treatment effect, where BoNTA needs repeat sessions more or less annually. 
Long-term studies on SNM show an efficacy of 60 to 70% at a mean followup of 
26 to 64 months.14-16
One year after the definitive implant 79% (11 of 14) of the patients indicated 
to be satisfied with the effect of SNM treatment. Unfortunately we have only 
evaluated the subjective patient satisfaction, because no validated question-
naires had been filled out. The recurrence of incontinence, which could not be 
controlled with changes in programming settings, was the reason for dissatis-
faction of 3 patients. There were no signs of lead migration or other technical 
failure of the system. Of these 3 patients 1 in whom SNM failed had a history of 
psychiatric disease, which is known to be a predictive factor for encountering 
adverse events (i.e. loss of efficacy) in permanent SNM treatment.17 
The small sample size is a limitation of this study. Although the BoNTA 
treatment has emerged to a widely performed treatment and has a 37% discon-
tinuation rate, the sample size of our recruitment shows little patients are re-
ferred to a tertiary referral center. 
6
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Despite the small sample size this first observational study demonstrates 
the possible role of SNM after BoNTA treatment. However, it does not give final 
guidance on the place of both interventions in the treatment algorithm. SNM 
and BoNTA are both regarded as minimally invasive, well accepted and safe. 
The success rates of the treatments (both up to 70%) are difficult to compare, 
because both treatments are evaluated differently.1,14,18,19
Studies on BoNTA are analyzed by intent to treat, were SNM is analyzed on 
the per protocol principle. Besides comparable clinical effectiveness, a recent 
study indicates that SNM compared to BoNTA for patients with idiopathic 
OAB is cost-effective during a period of 5 years.20 In our opinion, for the time 
being, it is up to the physician in consultation with the patient to decide which 
treatment to start with after failure of conservative treatments, considering 
all pros and cons. 
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CONCLUSIONS
Patients who are dissatisfied with or in whom BoNTA fails can respond success-
fully to sacral neuromodulation. The response rate of the test stimulation and 
the satisfaction at 1-year follow up is comparable to the response rate of patients 
who have received SNM immediately after conservative treatment. The place 
of both treatments in the treatment algorithm of OAB needs to be defined by 
future studies.
6
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ABSTRACT
Introduction
Functional disorders of the lower urinary tract often coexist with defecation 
disorders and sexual disorders. Although evacuation and storage disorders are 
often seen as separate entities, combined symptoms of urinary storage and 
bowel evacuation (or vice versa) also occur.
Materials and Methods
In this single center observational study, we included all patients with com-
bined micturition and defecation disorders who were treated with SNM in our 
institute between 2008 and 2013. The primary outcome measure was improve-
ment in leakage, defined as a greater than 50% improvement in episodes of urine 
leakage and severity of leakage or an improvement in the fecal incontinence or 
constipation episodes. At the routine annual outpatient check-up, the patients 
who received the definitive SNM implant were asked about their satisfaction.
Results 
In total 105 patients were included and were tested for SNM treatment in the 
period between 1997 and 2014. Of all the patients tested, 59 (56.2%) were im-
planted with a definitive system.  In 39 patients there was a successful result 
for only urinary symptoms. In 15 patients there was a successful result for both 
symptoms, and in 2 patients only for their fecal symptoms.
Conclusions
SNM is a feasible treatment option for patients with combined micturition and 
defecation disorders
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INTRODUCTION
Functional disorders of the lower urinary tract often coexist with defecation 
disorders and sexual disorders. Anatomically, the bladder, anorectum and re-
productive organs are closely related and all depend on the integrity and coor-
dination of the common innervation of the pelvic floor muscles. The etiology of 
pelvic floor disorders is complex and multifactorial. Different factors can be in-
volved, such as neural (e.g. pudendal nerve injury), mechanical (e.g. pelvic organ 
prolapse) or systemic (e.g. MS or Parkinson’s disease). Depending on the exact 
changes in these factors, both evacuation disorders (urinary retention, obsti-
pation) as well as storage disorders (urinary and fecal incontinence) can occur. 
Although evacuation and storage disorders are often seen as separate entities, 
combined symptoms of urinary storage and bowel evacuation (or vice versa) 
also occur. 
In our institution, an academic teaching hospital, patients with pelvic floor 
disorders are treated in a multidisciplinary team, including a urologist, sur-
geon, gynecologist and physiotherapist. Almost 74% of our patients report void-
ing dysfunctions and more than 23% of our patients report bowel dysfunction.1 
When conservative treatment fails, patients with combined problems can be 
treated with Sacral Neuromodulation (SNM). Sacral neuromodulation works by 
direct stimulation of the nerve roots in the sacral S3 foramen via an implanted 
electrode. The effect can be attributed to the modulation of afferent nerve sig-
nals in the spinal cord. SNM was first applied in patients with urinary inconti-
nence. Later, this treatment proved to be useful in treating other pelvic floor dis-
orders, including urinary retention, fecal incontinence and obstipation.2 Since 
the innervation of the pelvic floor organs is mediated by the same pathways, it 
has been postulated that SNM restores normal neural activity in the affected 
organ (e.g. overactive bladder, sphincter hypertonicity, or hypocontractility). 
In this study, we evaluated the clinical results of sacral neuromodulation in 
patients with combined urinary and fecal symptoms. Furthermore, a review of 
the literature on the treatment of combined problems with SNM was performed.
7
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MATERIAL AND METHODS
In this single center observational study, we included all patients with combined 
micturition and defecation disorders who were treated with SNM in our insti-
tute between 2008 and 2013. All patients were primarily treated for their mic-
turition symptoms. The symptoms consisted of overactive bladder syndrome 
(with or without urgency incontinence) or non-obstructive urinary retention. 
The concurrent defecation disorder symptoms included fecal incontinence or 
constipation. Fecal incontinence was defined as involuntary loss of stool at least 
once a week, which was documented by means of a 3-week bowel diary. 
History taking and a 3-day voiding diary assessed the urological complaints. 
The voiding diary as well as a defecation diary were used as a baseline. Physical 
examination and urinalysis were used to rule out other conditions. Urodynam-
ics were performed in all patients to confirm the diagnosis of detrusor overac-
tivity and to exclude other diagnoses. 
Physiological assessment included anal manometry using a Konigsberg 
catheter (Konigsberg Instrument Inc., Pasadena, California, USA) connected 
to a computer-assisted polygraph (Synectics Medical, Stockholm, Sweden). A 
history of anorectal malformation, rectal surgery within the past 12 months, 
presence of a rectal prolapse, rectocele or intussusception, inflammatory bow-
el disease and chronic diarrhea were exclusion criteria. All patients underwent 
SNM test stimulation with use of the PNE test or a tined lead test stimulation. 
During the test stimulation period, a 3-day voiding diary and a 2-week bowel 
diary were again filled out to evaluate the effect of SNM. The test stimulation 
was evaluated by comparing the data of the diaries filled out during the test 
stimulation and the baseline voiding diary.
The primary outcome measure was improvement in leakage, defined as a 
greater than 50% improvement in episodes of urine leakage and severity of leak-
age or an improvement in the fecal incontinence or constipation episodes. 
In the event of successful PNE, this was followed by a 1-stage TLP with defin-
itive placement of an implantable neurostimulator (InterStim® I or InterStim II, 
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Medtronic Inc). In the event of unsuccessful PNE test stimulation, a first stage 
TLP was performed. When the first stage was successful, the second stage of the 
TLP consisted of a definitive placement of an implantable pulse generator. Sev-
eral pulse generator settings were used, preferably unipolar electrode selection 
with a frequency of 10 Hz, a pulse width of 210 us and an amplitude just above 
sensation threshold (preferably lower than 2.0 V). The technical procedure for 
sacral neuromodulation has been described previously.3 
At the routine annual outpatient check-up, the patients who received the de-
finitive SNM implant were asked about their satisfaction. The data processing 
of this study was performed with IBM SPSS® statistics, version 18.
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RESULTS
In total 105 patients were included and were tested for SNM treatment in the pe-
riod between 1997 and 2014. Out of all the patients, 81 were female and 24 male. 
The primary (urinary) symptom was OAB (wet or dry) in 68 patients and non-ob-
structive urinary retention in 37 patients. The secondary (fecal) symptom was 
FI in 37 patients and constipation in 59 patients. Six patients reported both FI 
and constipation, 3 had other (urgency, anorectal pain) fecal problems. Table 1 
summarizes the combination of micturition and fecal symptoms at baseline.
TABLE 1
Combinations of urinary and fecal symptoms at baseline
Fecal symptoms
Urinary symptoms: 
Retention
Urinary symptoms: 
OAB
Total
Fecal incontinence 5 32 37
Constipation 30 29 59
Both 2 4 6
Other 0 3 3
Total 37 68 105
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Forty-three patients were first tested with a PNE procedure, and the test stim-
ulation was successful in 28 (65.2%) patients. Ninety-one TLP procedures were 
performed, 77 were 2-stage procedures and 14 single-stage procedures. Of all the 
patients tested, 59 (56.2%) were implanted with a definitive system. In 39 pa-
tients there was a successful result for only urinary symptoms. In 15 patients 
there was a successful result for both symptoms, and in 2 patients only for their 
fecal symptoms. Table 2 shows the results of all patients tested with TLP, strat-
ified by the combination of symptoms.
TABLE 2
Success rate of TLP test stimulation, stratified by combination of urinary and fecal symptoms
Combination of 
symptoms
TLP succes:
Yes
TLP succes:
No
% Succes
UR + FI 1 2 33%
UR + constipation 11 13 46%
UR + both 1 1 50%
OAB + FI 20 9 68%
OAB + constipation 19 7 73%
OAB + both 4 0 100%
OAB + other 3 0 100%
Total 59 32
7
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7·5
DISCUSSION
The lower urinary tract, anorectal channel and pelvic floor are closely related, 
both anatomically and functionally. Dysfunction of the lower urinary tract and 
dysfunction of the bowel are problems that can have a major impact on the 
quality of life. Patients may complain about multiple symptoms: urgency and 
frequency, urgency urinary incontinence, urinary retention, genito-urinary 
pain syndromes and also fecal incontinence and constipation. Fecal inconti-
nence (FI) is a common symptom that has a devastating impact on the quality 
of life. Reported prevalence ranges from 7-15% in community dwelling men and 
women.4 Because healthcare providers do not often screen for these symptoms 
and patients do not voluntarily report them, the real prevalence is probably un-
derreported. Constipation presumably has less impact on the quality of daily 
life, however it represents a significant burden and is often associated with FI 
or urinary problems. SNM is a well-established therapy for both urinary and 
fecal complaints.5,6 For both indications, the working mechanism of SNM is not 
completely known.7 SNM probably involves different modes of action and acts 
on various levels of the nervous system, including sacral, spinal, supraspinal 
and cortical areas. 
The various urinary and fecal disorders all demand a specific treatment ap-
proach, and sometimes therapies can have bothersome interactions. For exam-
ple, OAB can be treated with anticholinergic drugs, however, these drugs can 
have a negative impact on constipation. Surgery of the anorectum or pelvic or-
gan prolapse can increase urinary urgency. Hence, treatment of patients with 
combined symptoms can be a challenge. SNM has the advantage that both mic-
turition and defecation can improve with the same therapy. SNM has several 
advantages compared to other available techniques. 
Compared to percutaneous tibial nerve stimulation (PTNS), SNM has the 
advantage of the duration of its effect. Furthermore PTNS has to be repeated 
weekly. The efficacy for PTNS in patients with fecal complaints could not be 
proven with the CONFIDeNT trial, a double-blind, multi centre, pragmatic, par-
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allel-group, randomized controlled trial. The authors concluded that PTNS giv-
en for a period of 12 weeks did not confer significant clinical benefit over sham 
electrical stimulation in the treatment of adults with fecal incontinence.8 
Long-term results with SNM therapy differ between the indications. After 
five years of follow-up, positive results were seen in 56% of patients with OAB 
symptoms compared to 71% in patients with urinary retention. No life-threat-
ening or irreversible adverse events occurred during this long-term follow-up.5 
Long-term results with SNM for fecal incontinence and constipation range 
from 54 to 63%.9 Although the course of treatment for patients with combined 
symptoms was mentioned in earlier studies10, to our knowledge only one study 
reported long-term results for these patients.11 El-Gazzaz et al reported on SNM 
in 24 patients with combined symptoms, of whom 10 showed a significant im-
provement at a mean follow-up of 24 months. Four patients in this study had 
their system explanted; in 2 patients this was due to a lack of clinical result for 
one of the symptoms, and in 2 other patients due to infection. 
We describe a population of 105 patients, both men and women. In our study, 
25% of implanted patients showed >50% improvement in both urinary and fecal 
symptoms.  Although this rate might seem low, these patients have a clinically 
significant reduction in both symptoms, most probably leading to a high overall 
satisfaction and increase in quality of life. As far as we know, there is no oth-
er single-modality treatment that can have this impact on patients with com-
bined urinary and fecal symptoms. We found the highest response to SNM in 
patients with OAB as the primary complaint (see table 2). Both the combination 
of FI and constipation showed a success rate of approximately 70%. The reason 
for patients with urinary retention responding less to SNM could be that pa-
tients with both UR and constipation represent a specific patient group with a 
specific pathophysiology (e.g. bladder/bowel underactivity) that is less suitable 
for neuromodulation. 
Although long-term results are lacking, the effect of SNM in patients with 
isolated urinary or fecal symptoms appears to be durable, with reported effica-
cy rates of 70% after 5 years. Caremel et al conducted a survey among patients 
with double incontinence. They interviewed 37 patients who were implanted 
with a neurostimulator (on average 30 months since implantation) about their 
urinary and fecal complaints. In total, 49% reported an improvement in both 
complaints.12 Predictors for SNM success have been studied previously but no 
clear factor is repeatedly reported.13-15
SNM has been proven to be a safe therapy. All patients tested in this study 
who experienced negative results were explanted without complications. 
7
142
In the group of implanted patients, 13 re-operations were performed  due to 
complications; in total 5 revisions of the lead, 5 revisions of the pocket where the 
IPG was implanted and 3 re-operations due to infections. 
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CONCLUSIONS
With this study we have shown that SNM is a feasible treatment option for pa-
tients with combined micturition and defecation disorders. In 25% of all pa-
tients, more than a 50% improvement in both urinary and fecal symptoms can 
be accomplished. As there may be  a common etiology, SNM may work for both 
urinary and fecal problems. Unfortunately, in the majority of patients the etiol-
ogy is unknown. Patients with combined symptoms who experience symptoms 
of OAB might be the better candidates for SNM than those with a combination 
with urinary retention. 
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CHAPTER 8
General Discussion
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8·1
INTRODUCTION
Sacral Neuromodulation (SNM) is an established treatment for patients with 
refractory lower urinary tract dysfunction. Since the FDA approval in 1997 there 
have been many advancements in technical and surgical aspects which have 
improved treatment safety and efficacy. These include the percutaneous tined 
lead, use of local anesthesia and fluoroscopy, and a smaller implantable stimu-
lator. This thesis gives an overview of the clinical experience with SNM treat-
ment. Also, clinical experience and continuous research resulted in a better un-
derstanding of the application of SNM. This has improved patient selection, 
the application of this technique and the management of complications during 
follow-up. Besides SNM, other neuromodulatory techniques have been devel-
oped over the last decades, including transcutaneous electrical nerve stimula-
tion, percutaneous tibial nerve stimulation and pudendal nerve stimulation. 
Together with the use of intravesical botulinum toxin type-A injections, these 
treatments have completely changed the specialized management of the over-
active bladder syndrome. In this section we will discuss the evolution of SNM 
treatment. We will present an overview of the most important improvements 
in the past, the role of SNM compared to other third-line treatments at present, 
and the role of SNM and opportunities for improvement in the future.
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PAST
In the 1980’s Tanagho et al. developed a clinically applicable method for SNM by 
using an implantable stimulator.1 At first, the implantation of the electrode was 
regarded as a complex and time-consuming procedure. The stimulation lead 
was positioned in the sacral foramen under direct vision using a large midline 
incision. After correct placement, the lead was secured to the sacral periosteum. 
Although treatment results of this early technique were good, complications 
such as wound infection and post-operative pain were relatively frequent. More-
over, there was uncertainty whether the positive effects of SNM were durable. 
As outlined in Chapter 3, we analysed the long-term results of SNM in a large 
group of patients that were treated in our center using the initial technique. 
We showed that SNM is a safe and durable therapy for patients with refracto-
ry symptoms of OAB and non-obstructive urinary retention. In addition, the 
number of revision rates due to complications steadily decreased with the grow-
ing experience in our center. Patients implanted before 1995 had a considerably 
higher rate of adverse events compared to patients implanted after 1995. An im-
portant reason for this difference is the improvement of patient selection and 
technical aspects of the implantation procedure. In 1994 a new pulse generator 
(Itrell-II) and electrode became available. The same phenomenon was seen in 
1999 when an updated pulse generator, the Interstim I device and buttock place-
ment of the pulse generator were introduced. We can conclude that technical 
developments markedly improved SNM therapy over the years. 
In 2002, a percutaneous technique for implantation of the stimulation lead 
was introduced, also called the tined lead procedure (TLP), this replaced the 
open procedure. Spinelli et al were the first to publish on the use of this less 
invasive self-anchoring lead.2 The tined lead can be placed under local anesthe-
sia and sensory information during intra-operative stimulation can be used to 
search for the perfect location for stimulation. The quadripolar tined lead con-
sists of four sets of tines proximal to the electrodes, which engage the subcuta-
neous tissue and muscle around the lead to prevent migration2. The tined lead 
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made it possible to perform a longer test phase (2-3 weeks) with the definitive 
lead implanted. If this test period showed positive results the pulse generator 
could be implanted during a second stage of the surgical procedure. Another 
major advantage of the TLP procedure is that patients can experience in real 
life how it feels to have constant stimulation. Our results with the tined lead 
technique are described in chapter 4. We concluded that this new minimally 
invasive approach for SNM is easier to perform than the classic open method. 
It gives positive results in both the short- and medium-term. Two-stage testing 
with the tined lead appears to be a more reliable method than the classic PNE 
because of a prolonged testing period and perhaps because of the lower risk of 
electrode migration. Therefore testing with a tined lead is a useful alternative 
for patients with an inconclusive PNE result. Stimulation is given by a perma-
nent lead with four contact points and can be unipolar as well as bipolar. As 
there was only one lead migration during the medium-term follow-up of up to 
3 years, it is obvious that the lead anchoring method is sufficient for fixing the 
electrode. A follow-up study of the patients in the study mentioned above shows 
that the tined lead is also effective and safe in the long-term, with a success rate 
of approximately 70%.3 The incidence of lead migration was rather low (1.6%), 
indicating that the self-anchoring technique is reliable. Due to these convinc-
ing results, the TLP has replaced the classic open technique. The minimally 
invasive nature of the TLP also makes it ideal for test stimulation. Compared 
with PNE, a longer trial stimulation can be conducted with superior lead fixa-
tion, making the test stimulation more reliable.4-6 Although TLP is a better tool 
for selecting eligible candidates for SNM than PNE, the long-term outcome for 
patients screened with either of these tools is comparable.7 Hence, both these 
tools can still be used in daily practice, depending on the specific indication and 
physician or patient preference. 
The original IPG (Interstim I) has an average battery life of 7-10 years. It is 
preferred in patients who require high voltage for stimulation in order to max-
imize the time until IPG replacement. The InterStim II device, introduced in 
2006, is 50% lighter and smaller. The smaller generator allows for a smaller in-
cision and pocket to be created leading to less discomfort and higher patient 
acceptance.4 It is ideal in lean patients, pediatric patients and those with lower 
stimulation intensity requirements determined at the time of test stimulation. 
However due to the smaller size, the average battery life is only three to five 
years. 
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Predictive Factors
Many papers reported on predictive factors for a successful result with SNM. 
Scheepens et al. already tested 212 patients with a PNE test in 2002. They found 
that intervertebral disk prolapse, duration of complaints, neurogenic bladder 
dysfunction, and urgency incontinence were found to be significant predictive 
factors.8 
Presumably, the incidence and degree of psychological problems might have 
an effect on the treatment outcome of SNM, and psychiatric comorbidity has 
previously been proposed as a negative predictor by some authors. However, 
those results were based on small patient groups, with retrospective data. The 
role of a broad spectrum of psychological factors was prospectively evaluated 
in relation to SNM treatment by using validated psychological screening ques-
tionnaires. The relationship between psychiatric history and the outcome of 
chronic SNM treatment was also assessed. The conclusion was that there was 
no evidence that psychological screening with the ABQ or SCL-90-R can predict 
the outcome of SNM treatment. Patients with a medical history of psychiatric 
disease appear to be more likely to encounter adverse events with permanent 
SNM treatment.9 These results were confirmed in a more recent paper which 
concluded that although it is known that psychological factors play a role in the 
severity of LUTS, they do not predict SNM outcome.10 
With the introduction of the tined lead placement, the possibility to implant 
a definitive system under local anesthesia was created. An advantage could be 
that the sensory response could give direct feedback during lead placement. 
It was hypothesized that this could give better results. Peters et al tested 141 
subjects (82% female), of which 86 (61%) had sensory testing and 55 (39%) did 
not. They had to conclude that intraoperative sensory testing during sacral lead 
placement does not necessarily improve IPG implantation rates or clinical out-
comes of SNM.11 Although sensory testing in this large group seemed not to 
improve the results, in individual cases the sensory feedback can be very use-
ful. Further research will hopefully give more direction in selecting good can-
didates for SNM. 
 
Urodynamics
Different groups found a correlation between SNM results and changes in uro-
dynamic studies. In 1997 Everaert et al. published their results of urodynamic 
evaluation of SNM in patients with voiding dysfunction.12 They concluded that 
ideal candidates for SNM are those patients with a spastic pelvic floor syndrome 
or with a hypo-contractile detrusor, in combination with sphincter instabili-
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ty, and impaired sphincter relaxation. An increase of bladder contractility, en-
hancement of sphincter relaxation and decrease in bladder capacity and resid-
ual urine were the most important features of the response in the patients they 
studied. 
An analysis of ambulatory urodynamic data in patients with an overactive 
bladder was presented in 2003. Thirtyfour patients were studied, for 22 patients 
a detrusor activity index (DAI) could be calculated. A significant correlation (p 
0.03) was found in DAI reduction of the ambulant urodynamic studies before 
and during SNM as compared to clinical improvement in overactive bladder 
symptoms.13 
Other groups found a significant correlation between treatment efficacy and 
urodynamic changes in OAB patients and in patients with urinary retention 
treated with SNM.14-17 
Very recently the value of urodynamic tools to guide patient selection in 
SNM were studied.18 With this study the authors explored whether urodynam-
ic testing with the addition of ambulatory urodynamic study (UDS), is able 
to better predict and assess SNM treatment outcome. 98 patients with lower 
urinary tract symptoms (storage and/or voiding dysfunction) were included in 
an ambulatory urodynamic measurement database. The success rate of SNM 
in patients with storage dysfunction was around 70%, according to either con-
ventional-UDS or ambulatory-UDS diagnosis. Based on conventional-UDS, the 
success rate of SNM in patients with hypocontractility was 67% and in acontrac-
tile patients 35%. According to ambulatory-UDS diagnosis, success rates were 32 
and 17%, respectively. This study showed that conventional-UDS overestimates 
the amount of patients diagnosed with a hypocontractile or acontractile blad-
der. Patients with reduced contractility on ambulatory-UDS were shown to have 
a lower chance of SNM success. Hence, ambulatory-UDS facilitated the selec-
tion of patients with a real a-contractile bladder and predicted SNM failure. In 
patients with storage dysfunction, additional ambulatory-UDS did not seem to 
contribute in predicting SNM outcome.
Bilateral Stimulation
Bilateral SNM has been proposed as a more effective treatment for chronic void-
ing dysfunction; a prospective randomized study with a relatively small group 
of 33 patients tested with a PNE test showed that bilateral is generally not supe-
rior to unilateral SNM.19 However, in some individuals bilateral stimulation has 
been shown to be more effective in relieving symptoms. Therefore the authors 
concluded that if unilateral stimulation fails, a bilateral test should be consid-
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ered. Even more interesting was a study with patients who had all failed unilat-
eral stimulation. In this small group 4 out of 12 analyzed patients had a positive 
response to bilateral stimulation after they had failed unilateral stimulation20. 
Further investigation will be necessary to determine the real value of bilateral 
stimulation.
Stimulation Parameters
In most individuals treated with SNM for LUTD standard stimulation param-
eters can be used. Some patients however did have a loss or reduction of effect 
over time in which case the stimulation parameters could be changed to restore 
adequate stimulation. 
Some studies were performed to search for optimal stimulation parameters. 
In a study with 50 patients looking for optimal parameters four different sets of 
parameters were tested; 41 of the patients included (82%) had overactive bladder 
symptoms and 9 (18%) had chronic non-obstructive urinary retention. No sig-
nificant difference was found in the clinical outcome of the voiding diary and 
questionnaire between the pulse rates and none of the 4 rates was significantly 
related to SNM associated pain. However, individuals appeared to benefit from 
changing the pulse rate in terms of treatment efficacy and stimulation related 
pain.21 
Another study searching for the ideal stimulation rates used a 3×3 orthog-
onal Latin squares crossover design to assess variability in overactive bladder 
symptoms and adverse events when subjects were exposed to three rate settings 
of SNM. Twelve subjects completed the study. Upon enrollment, each subject 
was randomized to one of three rate-setting sequences: 5.2, 14, and 25 Hz. Each 
subject tested each rate setting for 1 week. The rate significantly affected the 
number of incontinence episodes and pad changes per day. The number of ad-
verse events was similar across the three rate settings with programming-relat-
ed adverse events lowest in the 14 Hz group.22 
In the treatment of fecal constipation, a small double-blind randomized 
multicenter study was performed.23 This study aimed to see if alteration of the 
pulse width or frequency improved the outcome for those with constipation. 
Eleven patients with constipation being treated by SNM were recruited from 
three centers. They were randomized to five different stimulation protocols 
each of which was applied for 5 weeks. Group 1 used standard settings (pulse 
width 210 μs, frequency 14 Hz); in the other four groups (Groups 2-5) the pulse 
width and/or frequency were halved or doubled. Patients and investigators were 
unaware of the group allocation. The Cleveland Clinic constipation score varied 
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significantly between the five groups. Group 1 achieved the lowest mean score (± 
SD) 13.4 (± 4.4) (P=0.03). The number of digitations per defecation was the low-
est in Group 4, 90 μs and 14 Hz (P<0.01). No other variable changed significantly. 
The recruited patients generally preferred the standard settings. 
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PRESENT
The position of SNM as a third-line treatment in the treatment algorithm for 
OAB has not been proven yet. Various guidelines recommend the use of SNM, 
PTNS or BoNT-A, without mentioning a preferred sequence. Also, with the 
introduction of mirabegron, a new pharmacological option has arisen for the 
treatment of refractory OAB patients. The choice for a third-line therapy is de-
pendent on multiple factors including patient preference, surgical expertise, 
available resources and finances. Hence the current treatment evidence and 
possible considerations in the third-line management of OAB remains an im-
portant point of discussion.
Pharmacologic Therapy
Various medications with antimuscarinic effects are available for the treat-
ment of OAB symptoms. The most commonly used are oxybutinin, tolterodine, 
solifenacin, darifenacin, fesosterodine and trospium. Several studies have re-
viewed the efficacy and adverse events of these drugs. Although all drugs have 
similar efficacy, oxybutynin was associated with more side effects compared to 
the others.24-26 Antimuscarinics provide a health-related quality of life benefit 
to patients with OAB, with no significant difference between various agents.27
Mirabegron is a selective b3-adrenoreceptor agonist and has a different phar-
macological profile and mechanism of action than antimuscarinics. Bladder 
relaxation is obtained by the activation of the b3-adrenoceceptor and the sub-
sequent activation of adenylyl cyclase, which catalyses the conversion of adenos-
ine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Six large 
randomized trials have evaluated the efficacy and adverse events of mirabegron 
compared to placebo (or an active control group) and showed that mirabegron is 
efficacious and safe in treating patients with OAB.28-30 The clinical results were 
in line with those observed with well-established antimuscarinic treatments. 
However, there is a lack of evidence for long-term efficacy yet. While mirabe-
gron is effective and well tolerated in the short-term, its place in the treatment 
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algorithm of OAB remains debatable. Some guidelines have already adapted 
the use of mirabegron as a possible first-line treatment (AUA) whereas others 
recommend its use in patients who do not respond to antimuscarinics (NICE). 
The number of pharmacological agents that should be tried before commencing 
more invasive treatment is also arguable. 
Combination therapy with antimuscarinics and mirabegron might be a 
promising option for refractory OAB patients. In the SYMPHONY trial, a to-
tal of 1306 patients were randomised to 12 week combination of solifenacin/
mirabegron or monotherapy with solifenacin or mirabegron, or placebo.31 Com-
bination therapy with solifen-acin/mirabegron was well tolerated and signifi-
cantly improved OAB symptoms compared with solifenacin 5 mg monotherapy. 
Yamaguchi et al. evaluated the effect of additional therapy with mirabegron in 
patients treated with solifenacine.32 Patients who were being treated with so-
lifenacin at a stable dose for at least 4 weeks were included. Patients continued 
to receive solifenacin (2.5 or 5 mg once daily) and additional mirabegron (25 
mg once daily) for 16 weeks. After 8 weeks of treatment, the mirabegron dose 
could be increased to 50 mg if symptom improvement was not sufficient. There 
were significant improvements in OAB symptoms while using the combination 
therapy with mirabegron and solifenacin. The combination therapy was well 
tolerated, with the most common adverse effect being constipation. 
Currently, the potential of combination treatment with mirabegron and so-
lifenacin is being explored further by the SYNERGY trial (ClinicalTrials.gov id: 
NCT01340027) and the BESIDE trial (ClinicalTrials.gov id: NCT01908829). 
SNM
The U.S. Food and Drug Administration (FDA) has approved SNM in 1997 for 
both urgency incontinence and urgency–frequency syndrome in refractory 
OAB. There is convincing evidence for the success of SNM with positive long-
term results regarding efficacy and safety.33,34 Eight randomized studies and 
many long-term observational studies have been published, with a reported 
clinical response rate between 64 and 88% of all patients.14,35-38 All parameters 
reported showed significant improvement compared to the placebo group: a 
23–46% decrease in the number of voids per day, 44–77% increase in the aver-
age voided volume, 56–90% decrease in incontinence episodes per day, 64–100% 
decrease in pads and 39% increase in maximum cystometric capacity. After 5 
years, 121 patients with refractory OAB showed persistence of treatment effect: 
84% of the patients with urgency incontinence and 71% of the patients with 
urgency/frequency.14
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In a recent randomized controlled trial, Siegel et al. compared the results of 
SNM with standard medical therapy (SMT).39 Subjects were randomized to SNM 
(n=70) and to SMT (n=77). Patients were included in the SMT group if they failed 
at least one anticholinergic medication, and had at least one medication that 
they had not yet attempted. Of all patients, 93% were female and the mean age 
was 58. The intention to treat analysis showed that the success rate at 6 months 
was significantly greater in the SNM group (61%) than the SMT group (42%, 
p=0.02). The device-related adverse event rate was 30.5% and the medication-re-
lated adverse event rate was 27.3%. 
A randomized crossover trial comparing sacral with pudendal nerve simula-
tion studied 30 patients that all had an electrode implanted at both the sacral 
nerve S3 and the pudendal nerve. In a blinded, randomized fashion, each lead 
was tested for 7 days. In total, 24 patients (80%) showed a successful response 
to either sacral or pudendal stimulation. The overall reduction in symptoms 
was 63% for pudendal and 46% for SNM. Subjectively, the majority of patients 
(79%) preferred pudendal over sacral stimulation. Long-term data have not been 
published yet.40
PTNS
Percutaneous tibial nerve stimulation (PTNS) is a peripheral neuromodulation 
technique, in which the posterior tibial nerve is stimulated above the medial 
ankle. The possible working mechanism is neuromodulation at the spinal lev-
el.41 PTNS requires repeated sessions of stimulation, varying from 6 to 12-week-
ly episodes. There is evidence of significant improvement in OAB symptoms 
using PTNS, which is comparable to the effect of antimuscarinics but with a 
better side effect profile. The SUmiT trial; a multicenter, double-blind, random-
ized, controlled trial compared the efficacy of PTNS to sham through 12 weeks 
of therapy.42 A total of 220 adults with overactive bladder symptoms were ran-
domized to 12 weeks of treatment with weekly PTNS or sham therapy. The PTNS 
group had statistically significant improvement in frequency, nighttime voids, 
and urinary urge incontinence episodes compared to sham. No serious device 
related adverse events were reported. In the OrBIT-trial, 100 adults were ran-
domized to treatment with PTNS to extended-release tolterodine.43 The global 
response assessment demonstrated that subject assessment of overactive blad-
der symptoms compared to baseline was statistically significant in the PTNS 
group (79.5%) compared to the tolterodine group (54.8%, p=0.01).
A review reported improvement in 60-80% of OAB patients in incontinence 
episodes, frequency and urgency44. Others showed that PTNS has a sustained 
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safety and efficacy over 36 months with initial success after 12 weekly treat-
ments45. The average number of treatments was 1.1 treatments per month. Al-
though PTNS is considered a safe and effective treatment, long-term results are 
still lacking. The current NICE guidelines do not recommend PTNS as first-line 
therapy for the treatment of refractory OAB because of the lack of clinical evi-
dence. 
BoNT-A 
More than a decade ago, onabotulinum toxin A became a valid option in the 
treatment of OAB, whether neurogenic or non-neurogenic. It is a valid and ef-
fective option in refractory non-neurogenic OAB. As recently reviewed, many 
trials have evaluated the efficacy and safety of BoNT-A in refractory OAB.46 
A systematic review and meta-analysis found a total of 1,020 subjects studied 
in 12 randomized controlled trials. Botulinum toxin-A was associated with less 
urinary frequency, less incontinence episodes and improvement in quality of 
life. The most common adverse events were high post-void residual (necessitat-
ing CIC) and higher urinary tract infection. Doses of 100-300 U were not consis-
tently differentiated from each other in voiding diaries, quality of life and urge 
urinary incontinence. No statistically significant difference was seen between 
bladder body and bladder base, bladder body and bladder body plus trigone in 
urinary retention and urinary tract infection.47
Evaluating a group of 85 patients with refractory OAB who received BoNT-A 
it was found that patients with intolerance to side effects of antimuscarinic 
therapy were more likely to respond to BoNT-A than patients who experienced 
insufficient effect. Patients with intolerance had an 86 % success rate as opposed 
to 60% of patients with inefficacy. This finding might indicate that patients who 
respond to antimuscarinics are more suitable candidates for BoNT-A.48 Yet, the 
small sample size and retrospective nature of this study demands further inves-
tigation in a larger cohort. It would be interesting to evaluate if this response 
is a consistent finding in all patients with OAB refractory to antimuscarinics.
Comparative trials
Few studies have directly compared third-line treatment strategies for OAB. 
In chapter 6 we described the results of SNM in 20 patients who were initially 
treated with BoNT-A.49 Most of these patients had discontinued BoNT-A due to 
a lack of efficacy (n=17) and some patients requested a more permanent solution 
despite good results (n=3). The mean interval between the botulinum toxin-A 
and the SNM test stimulation was 23 months. In 14 patients (70%) the test stim-
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ulation was successful and they were implanted with a device. 
In 2012, the ROSETTA trial was started. In this randomized, open-label tri-
al, the results of 200 units BoNT-A are compared with SNM in patients with 
refractory urgency incontinence.50 Recently the first result were presented. A 
total of 386 women were randomly assigned; 369 were treated, and 364 were 
available for the primary outcome analyses. The onabotulinumtoxinA group re-
ported significantly greater mean reduction in incontinence episodes per day 
compared to the neuromodulation group. The onabotulinumtoxinA group was 
significantly more likely to experience complete resolution of urgency incon-
tinence, report greater improvements in overactive bladder symptom bother. 
Urinary tract infections were higher in the onabotulinumtoxinA group (35% 
vs.11%, p<0.001). Self-catheterization was required in 8% and 2% of the onabot-
ulinumtoxinA group at one and six months, respectively and neuromodulation 
device revisions/removals occurred in 3%.51
Concomitant Fecal and Urinary Symptoms
Functional disorders of the lower urinary tract often coexist with defecation dis-
orders, pelvic pain or sexual dysfunction. Anatomically, the bladder, anorectum 
and reproductive organs are closely related. Different factors can be involved, 
such as neurogenic, mechanical or systemic disease. In this thesis we evaluated 
the use of SNM in patients with combined urinary and defecation symptoms. 
In total, 105 patients underwent a test stimulation, of which 59 (56%) were im-
planted with a definitive system. Of the implanted patients, 39 had a successful 
result for only urinary symptoms, 15 had a successful result for both symptoms 
and 2 only for their fecal symptoms. Compared to botulinum-toxin, SNM has 
the advantage that both micturition and defecation can improve with the same 
therapy. Long term results with SNM for fecal incontinence and constipation 
range from 54 to 63%.52 Also, SNM has proven to be effective in certain patients 
with chronic pelvic pain.53 Some studies evaluated the results of SNM in pa-
tients with combined urinary and fecal symptoms.54,55 El-Gazzaz et al. reported 
that 40% of all patients treated had a significant improvement at a mean follow 
up of 24 months. Caremel et al. conducted a survey among patients with double 
incontinence. They interviewed 37 patients who were treated with SNM (aver-
age 30 months since implantation) about their urinary and fecal complaints. In 
total, 49% reported improvement in both complaints.56 Although the working 
mechanism of PTNS is essentially the same as in SNM, the evidence of PTNS in 
the treatment of functional bowel disorders is less convincing. Recently a large 
randomized controlled trial showed no significant clinical benefit of PTNS over 
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sham electrical stimulation in the treatment of adults with fecal incontinence.57 
Thin et al. conducted a randomized clinical trial of SNM vs PTNS for fecal in-
continence. Although both treatments showed clinical effect, the patients in 
the SNM group experienced fewer incontinence episodes to the PTNS group. 
Therefore, in patients with combined symptoms, SNM might be the pre-
ferred treatment. Yet, the degree of bother from each symptom must be taken 
into consideration, and the focus of treatment should initially be on the most 
debilitating symptom.
Patient Reference
Although patient satisfaction with refractory OAB treatments has been studied, 
little research has been done to discover what patients prefer when considering 
a refractory treatment for OAB, and which factors influence their decision-mak-
ing. In studies focusing on SNM, temporary loss of efficacy, discomfort at the 
implant site, the battery replacement procedure, medical need for magnetic res-
onance imaging (MRI), and concerns about passing through metal detectors 
were found to be associated with patient satisfaction.58 With respect to Botox, 
the need for repeated injections, potential need for self-catheterization, and 
side effects were found to be associated with patient satisfaction.59 Hashim et al 
conducted a survey among patients with refractory OAB, and asked about their 
preference for third-line treatment, scaling via best-worst, focusing on treat-
ment characteristics.60 Among these patients, 57% chose PTNS, 34% chose SNM, 
and 9.4% chose Botox as their most preferred option. Nevertheless, over 80 % of 
the patients reported that they would be willing to try each of the options. In 
contrast, Balchandra et al.61 who compared preferences for Botox versus SNM 
among 50 women in the UK, found that 74% preferred Botox and 26% preferred 
SNM. From these conflicting results it seems that the way physicians counsel 
their patients has an impact on the treatment preference. Since PTNS is the 
least invasive procedure of the three, most patients probably choose this treat-
ment as a first option. Nevertheless, patient preference is an important factor in 
the decision making process and this should always be taken into account when 
commencing a third-line treatment for OAB.
Cost-Effectiveness
The main goal in dealing with refractory OAB is to give the best quality of life to 
each patient at the lowest possible cost for a National Health Care System. The 
preferred methodology for an economic evaluation is costutility analysis, and 
the calculation of the incremental cost per additional quality adjusted life year 
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(QALY) gained. Various studies have previously evaluated the cost-effectiveness 
of third-line treatments in both Europe62,63 and North America.64,65 Most studies 
suggested that SNM is cost-effective in the medium and long-term compared to 
BoNT-A. Two recent studies also evaluated the cost-effectiveness of SNM com-
pared to other therapies. Bertapelle et al. conducted a cost-utility analysis of the 
Italian healthcare system.66 They showed that initiating treatment with SNM 
appears to be cost effective from year three onwards and becomes dominant 
(i.e. more effective and less costly) at year ten: cumulative costs were €32,975 
for early SNM and €33,309 for early BoNT-A, while cumulative QALYs were 7.52 
and 6.93, respectively. Autiero et al. compared SNM with percutaneous nerve 
evaluation (PNE) or tined-lead evaluation (TLP) with optimal medical therapy, 
BoNT-A and PTNS in the UK.67 At 5 years, SNM (PNE or TLP) was more effec-
tive and less costly than PTNS. Compared with ongoing medical therapy at 10 
years, SNM (PNE or TLP) was more costly and more effective, and compared 
with BoNT-A, SNM with PNE was less costly and more effective, and SNM with 
TLE was more costly and more effective. 
SNM seems to be both cost saving and more effective, or acceptably cost-ef-
fective compared to ongoing medical therapy, PTNS or BoNT-A. The costs for 
SNM mainly involve device acquisition and implantation. All other treatments 
involve on-going drug costs and physician visits for maintenance treatment. 
However, it has to be notified that most study groups received financial support 
by Medtronic, which possibly introduces a bias. Furthermore, all studies used a 
simulation model (Markov) which does not fully represent clinical practice. Per-
haps the awaited ROSETTA trial, the first randomized, open-label 2-year study 
designed to compare the effectiveness and cost-effectiveness of BoNT-A and 
SNM, will provide a direct comparison of these competing treatment options.50 
As mentioned the first results show that the onabotulinumtoxinA group was 
significantly more likely to experience complete resolution of urgency inconti-
nence and report greater improvements in overactive bladder symptom bother, 
but as these are only short term results it is too early for any hard conclusions.51 
To summarize, multiple minimally invasive treatments are available for the 
treatment of refractory OAB, with none showing a strong superiority over an-
other at this time. If the results of one therapy are not satisfactory, switching 
to another third-line treatment can be attempted. The treatment algorithm is 
dependent on several factors, including age, comorbidity, patient preference, 
surgical expertise and financial concerns. All these factors should be taken into 
consideration before initiation of treatment.
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FUTURE PERSPECTIVES
Although SNM is an established treatment with a good long-term efficacy, 
there are still various aspects that can be improved. After implantation, some 
patients lose the therapeutic benefit of SNM. In patients with technical failure 
(e.g. lead migration or device malfunctioning), treatment effect can often be re-
stored. Yet, approximately 30% of patients experience treatment failure despite 
interventions or re-programming of the device.36 Furthermore, the number of 
adverse events, such as device or stimulation related pain symptoms is relatively 
high, with a reported rate of 27%.3 In the future, procedural and technical mod-
ifications for SNM should be anticipated. In our view, the improvement of SNM 
should be targeted at:
• Increase in treatment efficacy
• Improvement of patient selection
• Increase of patient comfort
• Reduction of adverse events and re-interventions
Patient Selection
Electrodiagnostic monitoring techniques seem to be promising, since they 
may allow better patient selection and increase the success rate of test stimu-
lation.68,69 Pudendal nerve stimulation and laparoscopic implantation of neu-
roprotheses can be considered as a conceptual extension of SNM.70,71 CT or 3D 
fluoroscopy guidance has been suggested for complex cases, such as spina bifi-
da, other morphological anomalies of the sacral foramina, revision surgery or 
obese patients.72,73 However, for the vast majority of patients no additional bene-
fit is expected. The use is further limited by the lack of sensitivity. Edlund et al. 
demonstrated that ‘adequate sensations’, indicating an electrode position in the 
S3 or S4 foramen, were obtained with a surprisingly wide variety of electrode 
locations, as shown by x-ray and computed tomography.74
In a randomized study it has been shown that the tined lead can be bent 
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along the nerve with a curved stylet, thereby achieving activation of more nerve 
fibers and motor response at significantly lower voltages in the deepest poles 
than with the conventional technique.75 The authors suggested that battery life 
could be maximized and programming facilitated. However it has to be proven 
in further trials, whether these findings will translate into a significantly im-
proved clinical outcome. 
Electrodiagnostic techniques during intraoperative lead placement may fur-
ther improve patient selection and success rates, especially for urological indi-
cations, where a more specific urological marker has been discussed. Benson 
could improve his test success rates significantly up to 80% in a small series of 
patients by monitoring urethral response with compound muscle action poten-
tials (CMAP), measured by ring electrodes located on a Foley catheter which had 
been inserted into the urethra.68 In 7 out of 15 patients the position of the elec-
trode relative to the nerve was changed based on the amplitude of the CMAP 
rather than on the usual biological motor or sensory response. Six of these 7 
patients had similar motor/sensory responses, so this alone would not lead to 
change in nerve site selection. Sensory responses were unreliable; a positive re-
sponse to testing was obtained in 5 patients who did not have a rectal or vaginal 
localization of the sensory response. 
The LION Procedure (Laparoscopic Implantation of Neuroprothesis) allows 
direct access to pelvic nerves, thereby having a broad treatment potential. How-
ever, the procedure which requires advanced surgical skills, could result in acci-
dental nerve damage due to the nerve diameter in micrometer range and is still 
at an experimental stage. 
The method of two-dimensional pelvic intraoperative neuromonitoring of 
urinary bladder and internal anal sphincter innervation was found to accurate-
ly predict functional results following low anterior resection for rectal cancer.76 
This novel approach was recently combined with SNM in order to improve lead 
placement under additional observation of the autonomic innervation.69 There-
by, it may further elucidate the mechanism of action and possibly reveal the 
underlying neuro-physiological phenomena involved during SNM. Matzel et al. 
already assumed over 20 years ago that the autonomic nervous system to be 
affected reflexively by SNM.77 Moreover SNM may give further insight into the 
truths and myths of nerve sparing pelvic surgery. 
Ambulatory-UDS could be a helpful instrument In selecting good candidates 
for the treatment of a hypocontractile or a-contractile bladder with SNM. Dros-
searts et al showed that in this group an ambulatory-UDS proves to be better to 
identify patients with a real acontractile bladder and predicting SNM failure.18
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Patient Comfort
Patient comfort has improved considerably over the years by a change from 
open surgery to a minimal invasive procedure and the change from abdominal 
pacemaker placement to the buttock region. A smaller device, the Interstim II, 
was also a positive improvement in this respect. We suggest as a potential next 
step an even smaller, rechargeable device, which makes the need for an IPG re-
placement, once the battery is empty, obsolete.
Conditional Stimulation
Intermittent or ‘on-demand’ stimulation may be an effective alternative to con-
tinuous stimulation to reduce stimulation time while preserving efficacy of 
continence control. In chapter 5 we studied the on-demand use of SNM. We con-
cluded that on-demand neuromodulation is a feasible therapy regimen in the 
majority of patients with urgency incontinence successfully treated with SNM 
therapy. Patients can experience more autonomy with on-demand stimulation 
because they gain full control over the device and are able to tailor the amount 
of stimulation to their needs. In addition, on-demand stimulation can prolong 
battery life, postponing replacement of the implantable stimulator. However, 
inhibitory stimulation must ideally be delivered soon after an overactive con-
traction begins in order to be effective. Conditional stimulation applied only 
during bladder contractions, may be more effective than continuous or on-de-
mand stimulation by minimizing habituation of spinal reflexes.78 Horvath et 
al. used EMG of the external urethral sphincter to detect overactive bladder 
contractions and trigger conditional stimulation of the dorsal genital nerve in 
patients with spinal cord injury.79 Using this closed-loop system, a stimulator 
was turned on automatically for 20 s after detection of an overactive detrusor 
contraction. The EMG measurement reliably detected overactive contractions 
(threshold > 10cm H2O) and could be successfully used as a real-time feedback 
signal. Although conditional stimulation in this study did not show a signifi-
cant difference in maximum cystometric capacity increase compared to contin-
uous stimulation, it significantly reduced stimulation time. These results may 
support future efforts in developing a neural prosthesis for closed-loop electri-
cal control of urinary continence.
Expanding Indications
Interstitial cystitis (IC) is a condition characterized by symptoms of urinary 
frequency, urgency and pelvic pain. Pharmacotherapy is the current mainstay 
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of treatment, but is inadequate for many. However, the urinary symptoms are 
FDA approved indications for SNM, and chronic pelvic pain is not. In a study of 
21 refractory IC patients treated with SNM, subjective pain was reported to be 
improved and additionally, it decreased narcotic usage at a mean of 15.4 months 
follow-up.80 Chronic pelvic pain in the absence of urinary symptoms shows to 
be a difficult problem to treat. Often it presents with a variety of symptoms 
and affects multiple systems and for that reason no standard treatment can be 
applied.81
SNM was evaluated in one series of ten patients with chronic, refractory pel-
vic pain without significant voiding symptoms. Improvement of at least 40% 
after PNE qualified patients for a permanent implant. Median follow-up was 
19 months (6-74 months) after implantation. Six out of 10 patients experienced 
a substantial benefit. SNM decreased subjective pain severity and the number 
of hours with pain.82 In a review of 10 studies evaluating SNM in patients with 
chronic pelvic pain, the success rate was reported to be between 60 and 77%.53 
The mean reduction in pain symptoms ranged between 27 and 50%. However, 
there is currently insufficient data to determine the role of SNM in the treat-
ment of chronic pelvic pain. Because the results seem to be promising, larger 
prospective trials with long-term evaluation are recommended. 
SNM has also been widely used for functional bowel disorders. Fecal incon-
tinence is currently treated with medications, pelvic floor biofeedback and sur-
gery. The role of SNM has been explored by Altomare et al. in a multicenter 
study of 94 fecal incontinence patients. 63% of these patients went on to have 
permanent lead placement and 87% had long term follow-up (mean 74 months). 
Three-quarters of the patient population maintained at least 50% improvement 
after more than five years. They showed significant improvements in physical, 
social and emotional functioning on QOL domains. Manometric data for rest-
ing and squeeze anal pressure significantly improved. Urgency sensation and 
maximal volume tolerated showed a trend towards reduction.83 Two recent 
reviews confirmed the efficacy and safety, with positive results in the long-
term.84,85 SNM has also been successfully used in the treatment of constipa-
tion. Ten studies evaluated the results of SNM in patients with constipation.86 
A total of 225 temporary neuromodulation tests and 125 permanent implants 
were performed. Bowel diaries showed improvement in the assessment criteria 
in more than 50% of patients on temporary neuromodulation and the results 
were maintained in approximately 90% of patients who underwent a permanent 
implantation over medium to long-term follow-up (median follow up ranged 
from 11 to 42 months). SNM might also be a promising treatment for irritable 
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bowel syndrome. In a randomized cross-over trial of 20 patients Fassov et al. 
showed that SNM changes rectal sensitivity. SNM reduced wall stiffness and 
increased sensitivity to stretch, which are associated with an improved irritable 
bowel symptom score87. In the same group of patients, IBS-specific symptom 
and quality of life scores were significantly reduced during stimulation.88 At 
1-year follow-up, the median IBS-specific symptom score (25; range, 13-65) was 
significantly lower than that at baseline (62; range, 45-80) (p=0.0001).
Dysfunctional elimination syndrome in children includes disturbances of 
the GI and urinary tract. Dwyer et al. studied 105 patients with symptoms re-
fractory to medical therapy.89 The mean follow-up was 2.7 years. SNM showed 
improvement in urinary incontinence (88%), constipation (79%), frequency 
and/or urgency (67%), and nocturnal enuresis (66%) of all patients. Groen et al. 
showed success of SNM in 18 children with OAB and voiding dysfunction due to 
Fowler syndrome.90 An initial full response was achieved in 9 out of 18 patients 
(50%) and partial response in 5 (28%). After a mean follow-up of 28 months, 6 
out of 15 patients (40%) had a full response and 5 (33%) had a partial response. 
Although the results of SNM in the pediatric population seem promising, both 
the efficacy 
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CONCLUSION
SNM is a safe and effective third-line treatment option for patients with re-
fractory OAB and non-obstructive urinary retention. Advances in implantation 
technique and improvement of materials have made SNM a minimally-invasive 
and upfront treatment. The current role of SNM in the management of refrac-
tory OAB is debatable and the choice of treatment is dependent on multiple 
factors including age, comorbidity, patient preference, surgical expertise and 
resources. Future studies will hopefully elucidate the exact position in the algo-
rithm of different treatment strategies and cost-effectiveness. Moreover, future 
research should focus on further improvement of existing and development of 
new neuromodulation techniques , improvements in the selection of optimal 
candidates or development of customized approaches and a further increase in 
patient comfort.
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SUMMARY
Sacral Neuromodulation (SNM) is an established treatment for patients with 
refractory lower urinary tract dysfunction. Since the FDA approval in 1997 there 
have been many advancements in technical and surgical aspects, which have 
improved treatment safety and efficacy. These developments include the per-
cutaneous tined lead, use of local anesthesia and fluoroscopy, and a smaller im-
plantable stimulator. This thesis gives an overview of the clinical experience 
with SNM treatment. Clinical experience and continuous research resulted in a 
better understanding of the application of SNM. This has improved patient se-
lection, the application of this technique and the management of complications 
during follow-up.  
Chapter 1 discusses the different types of lower urinary tract dysfunction. The 
principle of neuromodulation is discussed and the historical developments and 
different forms of neurostimulation are described. The technique of sacral neu-
romodulation and its indications are also explained. Finally the outline of this 
thesis is presented. 
Chapter 2 gives an overview of the current knowledge on neuromodulation. 
We describe the developments in electrostimulation and neuromodulation, and 
discuss the evolution of neuromodulation techniques, starting with the periph-
eral nerve evaluation test. Initially a positive test result was followed by an open 
implantation, and this evolved into a 2-phase procedure. Later the minimally 
invasive tined lead was introduced and the open procedure was abandoned. In 
most patients, the 3rd sacral root is stimulated during SNM. Success rates are 
presented and vary between 60 to 80%. Most seen complications are lead mi-
gration, pain at implant side and infection. Finally the expanding indications 
as the treatment of neurogenic lower urinary tract dysfunction, the treatment 
of chronic bladder and pelvic pain and the treatment of bowel dysfunctions are 
discussed. 
Chapter 3 reviews the results of our analysis studying the influence of tech-
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nical improvements in SNM and the long-term results in our clinic. We con-
cluded that SNM provides lasting benefit in patients with refractory symptoms 
of overactive bladder and non-obstructive urinary retention. The improvement 
in outcome and reduction of reoperation rate can be attributed to the learning 
curve and technical improvements. 
Chapter 4 describes our medium term results with the tined lead in 49 pa-
tients.  The tined lead made it possible to perform the procedure under local 
anesthesia and it can be used as a test stimulation. We concluded that test stim-
ulation with the tined lead is more reliable than the open procedure and that 
the clinical efficacy is high and durable.
Chapter 5 presents the results of a study on the feasibility to use SNM in an on 
demand setting. Intermittent stimulation may enable an increase in battery life 
and may postpone loss of efficacy in the long term. We observed that intermit-
tent stimulation gave no worsening in symptoms in the majority of patients. 
An additional benefit was that several patients felt more in control over their 
voiding symptoms with on demand stimulation. 
Chapter 6 evaluates whether patients with overactive bladder and inconti-
nence who discontinued intravesical botulinum toxin A therapy can be success-
fully treated with SNM. We concluded that the success rate after botulinum A 
therapy was comparable with the group of patients without a history of botuli-
num toxin-A treatment. 
Chapter 7 presents our experiences with SNM in patients with combined mic-
turition and defecation disorders.  We included all patients from our Pelvic Care 
Center Maastricht with combined disorders that were treated with SNM be-
tween 2008 and 2013. We concluded that 25% of the implanted patients showed 
>50% improved for both urinary and fecal symptoms. 
Chapter 8 is the general discussion. We present an overview of the most im-
portant improvements in the past, the role of SNM compared to other third-line 
treatments at present, and the role of SNM and opportunities for improvement 
in the future. After the introduction of SNM by Tanagho, the procedure was 
complex and time consuming, but during the 1990’s technical improvements 
were made resulting in better clinical results. In 2002 the tined lead was intro-
duced and made a percutaneous technique possible. Predictive factors for se-
lecting good candidates were studied in different settings. Psychological prob-
lems might have an effect on the outcome. 
Urodynamic studies revealed that with SNM an increase in bladder contrac-
tion, an enhancement of sphincter relaxation and a decrease in bladder capacity 
can be achieved. Recently a study on ambulatory urodynamics showed that the 
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presence of bladder contractility is of importance for the success of SNM treat-
ment. 
We conclude that in the future, procedural and technical modifications in 
SNM should be anticipated. In our view, the improvement of SNM should be 
targeted at increase in treatment efficacy, improvement of patient selection, in-
crease of patient comfort and reduction of adverse events. Ambulatory urody-
namics could be a helpful instrument in selecting good candidates. Electro-di-
agnostic techniques during intraoperative lead placement may further improve 
patient selection and success rates. Intermittent therapy should be considered 
to increase battery life and can give patients an increased bodily control. A re-
chargeable device can further improve patient comfort. 
In summary, SNM is a safe and effective third-line treatment option for pa-
tients with refractory OAB and non-obstructive urinary retention. Many im-
provements made SNM a minimally invasive and successful treatment. Future 
research should focus on further improvement of existing, and development 
of new techniques, comprehensive selection of optimal candidates and further 
increase in patient comfort. 
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NEDERLANDSE SAMENVATTING
Dit proefschrift beschrijft de resultaten van de behandeling van chronische 
blaasklachten met behulp van sacrale neuromodulatie. Chronische blaasklach-
ten zoals een overactieve blaas of niet-obstructieve blaasledigingsklachten vor-
men vaak een lastig probleem en zijn een uitdaging voor de uroloog. De meeste 
patiënten worden behandeld met fysiotherapie, medicatie of een combinatie 
van beide. Als het probleem blijft bestaan, vinden er soms ingrijpende behan-
delingen plaats zoals operaties om de blaas te vergroten of geheel te vervangen. 
Dit zijn grote operaties met mogelijk belangrijke complicaties. Dit was een re-
den om te gaan zoeken naar een minder ingrijpende therapie. De Amerikaanse 
uroloog Tanagho ontwikkelde eind jaren ‘80 een methode om de sacrale zenu-
wen te stimuleren bij patiënten met blaasklachten. Er werd aangenomen dat 
de blaascontrole hersteld kon worden door stimulatie van de zenuwprikkels die 
richting de hersenen gaan en door modulatie van de blaasreflexen in het centra-
le zenuwstelsel. De behandeling die hieruit ontstaan is, werd sacrale neuromo-
dulatie (SNM) genoemd. 
De techniek van SNM bestaat uit een electrode die gekoppeld is aan een ge-
implanteerde neurostimulator. In de beginperiode werd deze electrode via een 
open operatie geplaatst waarbij het heiligbeen werd vrij gelegd. Later is er een 
methode ontwikkeld om een zelf-verankerende electrode te plaatsen zonder dat 
het nodig is een incisie te maken, de zogenaamde ‘tined lead procedure’ (TLP). 
In dit proefschrift worden de resultaten beschreven van zowel de eerste tech-
niek (hoofdstuk 3) als ook de meer moderne methode (hoofdstuk 4). 
Omdat de oorzaak van blaasklachten bij patiënten niet altijd duidelijk is, is 
het erg lastig geschikte kandidaten voor de behandeling met SNM te selecteren. 
Om de beste kandidaten te kiezen wordt er voor de definitieve implantatie altijd 
eerst een proefstimulatie uitgevoerd. In de begin jaren bestond deze proeffase 
uit een ‘Percutaneous Nerve Evaluation’ test (PNE), waarbij via een naald de ze-
nuwreactie getest wordt en waarna bij een goede reactie een dunne electrode 
geplaatst kon worden. Omdat deze electrode zeer fragiel was en zich makkelijk 
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verplaatste, wordt deze tegenwoordig tijdens de testfase vaak vervangen door 
een zelf-verankerende electrode. Dit noemen we de eerste fase van een TLP. 
Het doel van dit proefschrift is het beschrijven van de resultaten met sacrale 
neuromodulatie. De lange termijnresultaten van zowel de oude als de nieuwe 
techniek zijn geëvalueerd, waarbij gelet is op de effectiviteit, complicaties en 
patiënt tevredenheid. De behaalde resultaten zijn telkens gerelateerd aan de op 
dat moment bekende behandelingsmogelijkheden. Omdat er in de loop van de 
jaren nieuwe indicaties maar ook nieuwe behandelingen bijgekomen zijn, wordt 
ook hier op ingegaan en werpen we tevens een blik op de toekomst. 
Hoofdstuk 1 is een inleidend hoofdstuk en geeft een overzicht van de chronische 
blaasklachten zoals overactieve blaas en urine incontinentie. Tevens worden de 
verschillende behandelopties besproken. Ook wordt er een overzicht gegeven 
van de verschillende vormen van zenuwstimulatie en de tot dusver  bekende 
resultaten. Tenslotte wordt in dit hoofdstuk de opbouw van dit proefschrift ge-
presenteerd.
Hoofdstuk 2 geeft een overzicht van het ontstaan en de resultaten van SNM. 
Er wordt beschreven hoe neuromodulatie een ontwikkeling is die voortvloeit uit 
allerlei andere vormen van neurostimulatie die in de loop van de geschiedenis 
in de geneeskunde toegepast zijn. Ook wordt beschreven welke ontwikkelingen 
de implantatietechniek heeft doorgemaakt. Er worden verschillende studies ge-
citeerd die allemaal concluderen dat SNM een veilige en effectieve therapie is. 
Vervolgens worden enkele nieuwere indicaties beschreven zoals de behandeling 
van mictieklachten bij patiënten met een neurogene blaas, de behandeling van 
interstitiële cystitis en de behandeling van darmklachten. 
Hoofdstuk 3 beschrijft de lange termijn resultaten van 149 patiënten die van-
af 1990 in het MUMC+ behandeld zijn. Hierbij zit dus de beginperiode van de 
behandeling met ook de bijbehorende leercurve. Geconcludeerd wordt dat SNM 
een blijvend effect heeft bij de behandeling van hardnekkige symptomen van 
overactieve blaas en niet-obstructieve urine retentie. De verbetering van het ef-
fect en het verminderen van het aantal complicaties kan toegeschreven worden 
aan de leercurve en de technische verbeteringen. 
In hoofdstuk 4 geeft de resultaten op middellange termijn weer van 49 pati-
enten die middels de ‘tined lead’ methode behandeld zijn.  Geconcludeerd wordt 
dat er op middellange termijn positieve resultaten te zien zijn, waarbij blijkt dat 
het testen in 2 fasen meer betrouwbaar is dan de PNE test. De zelf verankerende 
electrode lijkt bovendien op middellange termijn goed gefixeerd te blijven. 
Hoofdstuk 5 bespreekt een pilot-intervention studie waarin onderzocht is of 
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het mogelijk is om patiënten die met SNM behandeld worden ook intermitte-
rend (on-demand) te stimuleren. De aanleiding voor deze studie was het ver-
lies van effect dat bij sommige patiënten na een aantal jaren gezien werd en 
geduid werd als gewenning van het zenuwstelsel. De resultaten tonen aan dat 
na 2 weken on-demand gebruik er bij de meerderheid van de patiënten een ver-
gelijkbaar effect gezien werd als bij continu stimulatie. Intermittente stimulatie 
levert meer autonomie op, leidt tot een langere levensduur van de batterij en 
veroorzaakt minder kans op gewenning van de stimulatie. 
In hoofdstuk 6 wordt een studie gepresenteerd met de resultaten van een groep 
patiënten die behandeld werden met neuromodulatie nadat ze één of meerdere 
behandelingen met botuline toxine (botox) injecties hebben gehad. 
De conclusie van deze studie is dat een behandeling met neuromodulatie met 
goed resultaat mogelijk is na een behandeling met botox. De resultaten na 1 jaar 
zijn vergelijkbaar met patiënten die geen behandeling met botox van tevoren 
hebben gehad. 
In hoofdstuk 7 worden de resultaten van een groep patiënten die zowel mic-
tie- als defecatieklachten hebben geëvalueerd. Binnen ons Pelvic Care Centrum 
Maastricht rapporteert 74% van de patiënten mictieproblemen en 23% klaagt 
over darmklachten. Patiënten die een gecombineerd probleem hadden, werden 
getest en bij goed resultaat behandeld met sacrale neuromodulatie therapie. 
Met deze studie is aangetoond dat neuromodulatie een mogelijke therapie is 
voor mensen met een dubbel probleem. Afhankelijk van de klachten en de etio-
logie is er een hogere kans op succes mogelijk. 
Hoofdstuk 8 is het discussie hoofdstuk waarin we een overzicht geven van 
belangrijke verbeteringen die in het verleden met sacrale neuromodulatie gere-
aliseerd zijn. Vervolgens worden de huidige mogelijkheden voor de behandeling 
van overactieve blaas met deze techniek besproken en met elkaar vergeleken. 
Tenslotte is aangegeven welke verdere verbeteringen in de toekomst verwacht 
mogen worden. 
Conclusie: SNM is een veilige en effectieve therapie voor patiënten die niet rea-
geren op de standaard therapie voor overactieve blaas en niet-obstructieve urine 
retentie. In de loop van de jaren zijn er vele verbeteringen doorgevoerd, waar-
door SNM een minimaal invasieve behandeling is geworden die goede resultat-
en oplevert. 
Toekomstig onderzoek moet zich richten op de ontwikkeling van nieuwe 
technieken, op verbetering van patiëntenselectie en op optimalisatie van het 
patiëntencomfort. 
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VALORISATION ADDENDUM
Introduction
Chronic lower urinary tract dysfunction (LUTD) is a common disorder that has 
a significant impact on quality of life. As described in the introduction of this 
thesis, the term ‘dysfunction’ refers to an abnormality in the physiology of the 
lower urinary tract, including the detrusor muscle, urinary sphincter, bladder 
neck and the associated peripheral and central nervous system. According to 
the type of dysfunction, different clinical symptoms can arise. The Overactive 
Bladder Syndrome (OAB) is the most common disorder, and is defined as the 
presence of urinary urgency, usually accompanied by frequency and can occur 
with or without urinary incontinence. In contrast, lower urinary tract dysfunc-
tion (LUTD) can also result in the inability to evacuate urine. Insufficient con-
traction of the detrusor can lead to difficult elimination or urinary retention: 
the underactive bladder. Suffering from LUTD can be very bothersome and has 
significant effects on many aspects of an individuals’ life, representing a partic-
ularly impactful health burden to quality of life and productivity.
Epidemiology of lower urinary tract dysfunctions
According to the EpiLUTS study, a large population-based, cross-sectional in-
ternet survey, conducted in the UK, Sweden, and the USA, OAB and other low-
er urinary tract symptoms are problems many people suffer from. In the USA, 
31,588 respondents completed the survey, making EpiLUTS one of the largest 
population-based epidemiological studies specifically focusing on OAB.1,2 De-
fined by the presence of urinary urgency of at least ‘sometimes’ and/or urge-uri-
nary incontinence, 43% of female and 27% of male respondents reported OAB. 
With a more restrictive definition of at least ‘often’, the prevalence of OAB was 
33% for women and 16% for men.
For the OAB Physical and Occupational Limitations (OAB-POLL) study 
10,000 US adults were recruited to complete an internet survey regarding their 
OAB symptoms, demographic and clinical characteristics, and physical activity 
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data, in order to estimate the prevalence of OAB and LUTS and the effects of 
OAB on work productivity and physical functioning.3 The authors defined OAB 
similarly to the EpiLUTS study, as urgency at least ‘sometimes’ and/or the pres-
ence of urge urinary incontinence. Based on this definition, the overall preva-
lence of OAB in the total US population was 23.3%, with women reporting OAB 
almost twice as frequently as men (30.0 vs. 16.4%, respectively).
Socio-economic relevance
Individuals with OAB report significant impairment to overall quality of life: 
OAB interfered with daily activities, including symptoms that caused them 
to stay at home, decreased physical activity because of OAB and even gaining 
weight because of an inability to exercise. Women with OAB were also signifi-
cantly more likely than those without OAB to report disturbed sleep, decreased 
self-esteem, decreased sexuality, and feelings of overall declining health. Find-
ings from the NOBLE study also demonstrated significant effects of OAB on 
health-related quality of life as measured by validate surveys.4 
From a patient’s perspective, the costs associated with OAB tends to be for 
routine care, such as incontinence pads, diapers, and laundry, generally reflect-
ing the burden of urinary incontinence.
Estimates of the individual and societal costs for the management of OAB 
continue to rise. In 2007, average annual per capita costs of OAB in the United 
States were $1925 ($1433 in direct medical, $66 in direct nonmedical, and $426 
in indirect costs). Applying these costs to the 34 million people in the United 
States with OAB results in total national costs of $65.9 billion. Average annual 
costs in 2015 and 2020 would be $76.2 billion and $82.6 billion, respectively.5
People with symptoms of OAB often delay seeking treatment until increased 
symptom severity or bother appear. An important aspect of OAB is that it re-
mains difficult to treat effectively. Pharmacotherapy is generally effective based 
on individual clinical trials but often only modestly superior to placebo. 
In chapter 8 (general discussion) we describe that SNM has been shown to 
be both more effective and cost saving, or at least acceptably cost-effective com-
pared to other therapies (PTNS or BoNT-A).
Autiero et al. compared SNM with optimal medical therapy, BoNT-A and 
PTNS in the UK. At 5 years, SNM was more effective and less costly than PTNS. 
Compared with ongoing medical therapy at 10 years, SNM was more costly and 
more effective, and compared with BoNT-A, SNM with PNE was less costly and 
more effective, and SNM with TLP was more costly and more effective.6 The 
costs for SNM mainly involve device acquisition and implantation. All other 
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treatments involve on-going drug costs and physician visits for maintenance 
treatment. 
Recently the results of the ROSETTA trail were presented. In this multi-
center open-label randomized trial to assess whether BoNT-A is superior to 
SNM 369 women with refractory urgency urinary incontinence were treated, 
and 364 were available for the primary outcome analyses. The BoNT-A group 
reported significantly greater mean reduction in incontinence episodes per day 
compared to the SNM group. The BoNT-A group was significantly more like-
ly to experience complete resolution of urgency incontinence, report greater 
improvements in overactive bladder symptom bother. Urinary tract infections 
were higher in the BoNT-A group (35% vs.11%, p<0.001). Self-catheterization was 
required in 8% and 2% of the BoNT-A  group at one and six months, respectively 
and neuromodulation device revisions/removals occurred in 3%.7 
It has to be notified that most studies regarding cost effectiveness for SNM 
received financial support by the manufacturer of SNM devices, which possibly 
introduces a bias. 
Target population
The results of this manuscript are relevant to patients with symptoms of lower 
urinary tract dysfunction such as frequency, urgency-incontinence or urinary 
retention. Some of our results are also important for patients who suffer from 
the combination of urinary tract dysfunctions as well as fecal problems (incon-
tinence and/or constipation). For example patients can be better informed on 
what results and possible complications to expect and patients can benefit from 
longer battery life. 
Furthermore our study data can be relevant for medical device corporations 
who want to develop less costly devices then the ones that are used today. These 
devices should be small, rechargeable and MRI compatible.
Products 
Although no new products have been developed with the results of this thesis 
directly, we showed that changes made in the way of implantation are safe and 
effective (chapter 4). We also found that patients prefer to have control over 
the devices used in SNM (chapter 5), the possibilities for self control can be ex-
panded in future designs. The size of the implantable pulse generator is already 
reduced for better patient comfort, and another company introduced a smaller 
and rechargeable device for more patient comfort and efficacy. 
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Innovation and future
In our view, the improvement of SNM should be targeted at:
• Increase in treatment efficacy
• Increase of patient comfort
• Reduction of adverse events and re-interventions
We estimate this can be reached by better patient selection and therefore a good 
test phase is most important. The test phase is preferably performed by a tined 
lead test phase while this gives more reliable results than testing with a PNE. 
We showed that patients who are dissatisfied with BoNTA or when BoNTA 
treatment fails can be treated successfully with SNM. 
Further improvement of patient comfort can be reached by using on-demand 
stimulation, with the positive side effect of more patient controlled therapy, or 
by conditional stimulation as we explained in chapter 8. 
For patients with urinary as well as fecal problems we advise a combined 
work-up in a center were treatment options such as SNM, PTNS and BoNTA can 
be used and treatments for functional problems of the lower urinary tract and 
of the bowel tract can be combined for more (cost) effectiveness. 
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DANKWOORD
Eindelijk! Dat is iets wat velen zullen denken nu mijn proefschrift een feit is. 
Het heeft even geduurd en dat is natuurlijk voornamelijk aan mijzelf te wij-
ten. Toch zijn er heel wat mensen in mijn omgeving die het gelukt is mij van 
mijn werk af te houden. Vakanties, vriendenweekendjes, autobeurzen, kroegbe-
zoek, noem maar op. Ik heb er erg van genoten, maar helaas is dit proefschrift er 
niet sneller door afgerond. Diegenen die zich hieraan schuldig hebben gemaakt: 
bedankt voor deze momenten van ontspanning! 
Een aantal mensen die me wel continu achtervolgd en geholpen hebben wil 
ik graag noemen. 
Prof. dr. Ph.E.V.A. Van Kerrebroeck, promotor, beste Philip, je hebt me ooit aan-
genomen als onderzoeker waarmee mijn urologische carrière is begonnen. In-
middels ben ik uroloog en ervan overtuigd dat dit promotietraject een goede 
investering is geweest. Dank voor je betrokken begeleiding, de introductie in de 
wetenschap, je aanwijzingen en je inzichten. Je bent in de loop van de jaren een 
van de mensen geweest die mij continu gestimuleerd heeft dit promotietraject 
af te ronden. Ik waardeer je vertrouwen.
Prof. dr. G.A. van Koeveringe, promotor, beste Gommert, ik ben blij dat jij me 
ook hebt willen helpen dit proefschrift af te ronden. Het is prettig om met je 
samen te werken en je ontwikkeling mee te hebben kunnen maken van uroloog 
tot hoofd van de afdeling. Jouw inzichten en kennis van de functionele urologie 
zijn van grote waarde. 
Dr. E.H.J. Weil, copromotor, beste Ernest(o), vooral in de beginjaren was jij 
voor mij mijn meest directe begeleider. Van jou heb ik veel klinische zaken ge-
leerd zoals de implantatie van neuromodulatie onder lokale anesthesie. Daar-
naast heb je ontelbaar veel tips gegeven over het reilen en zeilen van het leven 
binnen maar zeker ook buiten het ziekenhuis! Bedankt voor deze prettige en 
leerzame samenwerking. 
Dr. T.A.T. Marcelissen, copromotor, beste Tom, jij bent als aanstormend ta-
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lent precies op het goede moment op mijn pad gekomen. Jij had je proeve van be-
kwaamheid al doorstaan en je zocht een nieuwe wetenschappelijke uitdaging en 
ik kon jouw hulp goed gebruiken. Tom, bedankt voor je bijdragen en jou wacht 
een mooie toekomst als uroloog en wetenschapper! 
De leden van de manuscriptcommissie, prof. dr. H.W.M. Steinbusch (voorzit-
ter), prof. dr. K. Everaert, prof. dr. M. Van Kleef, prof. dr. A.A.B. Lycklama à Nije-
holt en prof. dr. A.A.M. Masclee dank voor het beoordelen van mijn proefschrift. 
Dr. R. de Jongh, beste Rick, toen ik als onderzoeker begon zat jij al in het 
hok. We hebben samen leuke en leerzame jaren doorgebracht op deze 5 vierkante 
meters waarbij ik in ieder geval veel van je heb opgestoken. Ik ben blij dat jij als 
paranimf en vriend aanwezig bent!
Prof. dr. M.A.T.M. van Vugt, beste Marcel, zonder twijfel was jij altijd al de 
echte wetenschapper van ons beiden. Met genoegen denk ik terug aan onze 
reizen die alle perfecte ingrediënten hadden. Dank dat je mij vanuit de cam-
pingstoel zo af en toe nog eens wat hebt bijgespijkerd over wetenschap, genees-
kunde en Unox hamburgers. Super dat je er als paranimf bij kunt zijn. 
Mijn collega onderzoekers Wout Scheepens en Anco van Voskuilen, het was 
prettig dat jullie al voorbereidend werk gedaan hadden waardoor ik niet het 
wiel opnieuw heb hoeven uitvinden. Wout, erg leuk dat je er bij kunt zijn als 
lid van de corona. En degenen die na mij gekomen zijn: Randall Leong, Tom 
Marcelissen, Martijn Smits en Jamie Drossaerts. Een deel van jullie heeft mij al 
ingehaald, Jamie jij bent er ook bijna! Bedankt voor de samenwerking. 
Jarno Melenhorst, als collega onderzoeker van de heelkunde zaten we lang 
in hetzelfde schuitje. Wat een geluk dat ik in het zuiden jou als wijze uit het 
oosten tegenkwam. We vormden een goed team in de kliniek maar ook deelden 
we vaak dezelfde fantasieën over opgevoerde Saabs en saaie Volvo’s. Een ideale 
combinatie!
Victor Zambon, jij hebt mij ooit als coassistent enthousiast gemaakt voor de 
urologie. Dankzij jou kon ik ook de volgende stappen zetten in de goede richting 
en kwam er contact met de urologen in Maastricht. Bedankt voor jouw enthou-
siasme en hulp. 
Na mijn eerste jaren als onderzoeker moest ik ook nog opgeleid worden tot uro-
loog. Van de onderzoeker moest eerst een dokter gemaakt worden. Hiervoor ben 
ik de meeste dank verschuldigd aan mijn collega’s uit het toenmalige Atrium 
MC: assistenten chirurgie en urologie, chirurgen en urologen bedankt.
Mijn speciale dank gaat uit naar dr. Rob Welten en dr. Karl Delaere: gelukkig 
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mocht ik nog profiteren van jullie opleiding oude stijl. 
Het laatste deel van mijn opleiding deed ik in het Maastricht UMC+ en hier 
kon ik mijn onderzoek weer oppakken. Dit was alleen maar mogelijk dankzij de 
leuke groep assistenten. Bedankt hiervoor. 
Naast mij klaar te stomen als uroloog ben ik door de stafleden ook vaak gesti-
muleerd dit proefschrift af te maken, waarvoor dank.  Speciale dank voor Kees 
van de Beek als opleider. 
Het afronden van een proefschrift en de transformatie naar een daadwerkelijk 
boekje is onmogelijk zonder goede ondersteuning. Hiervoor ben ik erg blij ge-
weest met de hulp van het secretariaat urologie van het MUMC+ en het LZR. 
Vooral Nancy dank voor al je hulp en tips. Katy dank voor je correcties. Zeer 
veel dank ook voor Patrick Ketelaars die de lay-out van dit proefschrift heeft 
verzorgd. 
Mijn schoonouders, Noud en Rita Ketelaars, bedankt voor jullie hulp, met name 
voor het vaak acuut inspringen als oppas zodat ik toch aan mijn proefschrift 
kon werken. 
Een woord van dank voor mijn familie: Karin en Janneke, jullie ondersteu-
ning in goede en slechte tijden is onmisbaar. Pap en Mam: bedankt voor alle 
steun en mogelijkheden die jullie mij altijd gegeven hebben. 
Moedertje, dat jij dit niet meer mee kan maken doet nog iedere dag pijn. Goe-
de herinneringen blijven en je nuchtere kijk op dit proefschrift is daar een van: 
‘Je bent er zelf aan begonnen, dus zorg maar dat ‘t af komt.’
Mijn laatste woord van dank is voor mijn meest kostbare verzameling: mijn 
vrouwen. Livia, Anna en Rosa, strikt genomen hebben jullie ook wat vertraging 
van dit hele verhaal veroorzaakt, maar dat is niet erg. Jullie inspireren, jullie 
laten me lachen, jullie zijn onmisbaar. Fabrizia: je bent een droomvrouw, jouw 
hulp is onmisbaar. Ti voglio bene!
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LIST OF ABBREVIATIONS
BoNT-A onabotulinum toxin-A
CISC  clean intermittent self catheterization
FI  fecal incontinence
INS  implantable neuro stimulator
IPG  internal pulse generator
LUTD   lower urinary tract dysfunction
OAB   overactive bladder (syndrome) 
PNE  percutaneous nerve evaluation
PS  pudendal (nerve) stimulation
PTNS  percutaneous tibial nerve stimulation
SNM  sacral neuromodulation
SNS   sacral nerve stimulation
S3  third sacral root
TENS   transcutaneous electrical nerve stimulation
TLP  tined lead procedure
UF   urgency frequency
UI  urinary incontinence
UR  (non obstructive) urinary retention
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pervisor: dr. R. Speyer, Townsville. 
- Janneke Hoeijmakers: Small fiber neuropathy and sodium channels; a paradigm shift. Supervisor: 
prof. dr. R.J. van Oostenbrugge; Co-Supervisors: dr. C.G. Faber/dr. I.S.J. Merkies. 
- Stephanie Vos: The Role of biomarkers in preclinical and prodromal Alzheimer’s disease. Supervisor: 
prof. dr. F.R. Verhey; Co-Supervisor: dr. P.J. Visser. 
- Muriël Doors: The Value of Optical Coherence Tomography in Anterior Segment Surgery. Supervi-
sors: prof. dr. R.M. Nuijts/prof. dr. C.A. Webers; Co-Supervisor: Dr. T.T.J.M. Berendschot.
- Anneke Maas: Sleep problems in individuals with genetic disorders associated with intellectual disabil-
ity. Supervisors: prof. dr. I. Curfs/prof.dr. R. Didden.
- Sebastiaan van Gorp: Translational research on spinal cord injury and cell-based therapies; a focus 
on pain and sensorimotor disturbances. Supervisors: Prof.dr. B. Joosten / Prof.dr. M. van Kleef; 
Co-Supervisors: Dr. J. Patijn /Dr. R. Deumens, KU Leuven.  
- Andrea Sannia: High risk newborns and brain biochemical monitoring. Supervisor: prof. dr. J.S.H. 
Vles; Co-Supervisors: dr. D. Gazzolo, Alessandria, Italy/dr. A.W.D. Gavilanes. 
 - Julie A.D.A. Dela Cruz: Dopamine mechanisms in learning and memory: Evidence from rodent studies. 
Supervisors: prof. dr. H.W.M. Steinbusch/prof. dr. R.J. Bodnar, New York; Co-Supervisor: dr. 
B.P.F. Rutten.
- René Besseling: Brain wiring and neuronal dynamics; advances in MR imaging of focal epilepsy. Su-
pervisors: prof. dr. A.P. Aldenkamp/prof. dr. ir. W.H. Backes; Co-Supervisor: dr. J.F.A. Jansen. 
- Maria Quint-Fens: Long-term care after stroke; development and evaluation of a long-term interven-
tion in primary care. Supervisors: prof. dr. J.F.M. Metsemakers/prof. dr. C.M. van Heugten/prof. 
dr. M. Limburg, Almere; Co-Supervisor: dr. G.H.M.I. Beusmans. 
- Veronique Moulaert: Life after survival of a cardiac arrest; the heart of the matter. Supervisors: prof. 
dr. J.A. Verbunt/prof. dr. C.M. van Heugten/prof. dr. D.T. Wade, Oxford, UK. 
- Feikje Smeets: The hallucinatory-delusional state: a crucial connection in the psychosis symptom 
network. Supervisor: prof. dr. J. van Os; Co-Supervisor: dr. T. Lataster.
- Lies Clerx: Alzheimer’s disease through the MR-eye; novel diagnostic markers and the road to clinical 
implementation. Supervisor: prof. dr. F. Verhey; Co-Supervisors: dr. P.J. Visser/P. Aalten. 
- Sonny Tan: The subthalamic nucleus in Parkinson’s disease. Supervisors: prof. dr. Y. Temel/prof. dr. 
H.W.M. Steinbusch/prof. dr. T. Sharp, Oxford, UK/prof. dr. V. Visser-Vandewalle, Koln.  
- Koen van Boxem: The use of pulsed radiofrequency in the management of chronic lumbosacral radicu-
lar pain. Supervisors: prof. dr. M. van Kleef/prof. dr. E.A.J. Joosten; Co-Supervisor: assoc. prof. 
dr. J. van Zundert. 
- Jérôme Waterval: Hyperostosis cranialis interna. Supervisors: prof. dr. J.J. Manni/prof. dr. R.J. 
Stokroos. 
- Sylvie Kolfschoten-van der Kruijs: Psychogenic non-epileptic seizures; the identification of neuro-
physiological correlates. Supervisors: prof. dr. A.P. Aldenkamp/prof. dr. K.E.J. Vonck, Universite-
it Gent; Co-Supervisors: dr. J.F.A. Jansen/dr. R.H.C. Lazeron, Kempenhaeghe.
- Wouter Pluijms: Spinal cord stimulation and pain relief in painful diabetic: polyneuropathy, a trans-
lational approach. Supervisors: prof. dr. M. van Kleef/prof. dr. E.A. Joosten; Co-supervisor: dr. 
C.G. Faber.
- Ron Handels: Health technology assessment of diagnostic strategies for Alzheimer’s disease. Super-
visors: prof. dr. F.R.J. Verhey/prof. dr. J.L. Severens (EUR); Co-Supervisor: dr. M.A. Joore/dr. 
C.A.G. Wolfs. 
- Evelyn Peelen: Regulatory T cells in the pathogenesis of Multiple Sclerosis: potential targets for vita-
min D therapy. Supervisors: prof. dr. R.M.M. Hupperts/prof. dr. J.W. Cohen Tervaert; Co-Super-
visor: dr. J.G.M.C. Damoiseaux/dr. M.M.G.L.Thewissen, Diepenbeek. 
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- Reint Jellema: Cell-based therapy for hypoxic-ischemic injury in the preterm brain. Supervisors: prof. 
dr. B.W.W. Kramer/prof. dr. H.W.M. Steinbusch; Co-Supervisor: dr. W.T.V. Germeraad/dr. P. 
Andriessen, Veldhoven.
- Maria Wertli: Prognosis of Chronic Clinical Pain Conditions: The Example of Complex Regional Pain 
Syndrome 1 and Low Back Pain. Supervisors: prof. dr. M. van Kleef; Co-Supervisor: dr. F. Brunner, 
Zürich/dr. R. Perez, VUmc. 
- Dagmar Zeef: An experimental model of Huntington’s disease: Validation & Stimulation. Supervisors: 
prof. dr. Y. Temel/prof. dr. H.W.M. Steinbusch; Co-supervisor: dr. A. Jahanshahi.
- Jeroen Decoster: Breaking Down Schizophrenia into phenes, genes and environment. Supervisors: 
prof. dr. I. Myin-Germeys/prof. dr. M. De Hert, KU Leuven; Co-Supervisor: dr. R. van Winkel.
- Eaja Anindya Sekhar Mukherjee: Fetal Alcohol Spectrum Disorders: exploring prevention and 
management. Supervisor: prof. dr. L.M.G. Curfs; Co-Supervisor: prof. S. Hollins, St. George’s 
University of London, UK. 
-  Catherine van Zelst: Inside out; On stereotype awareness, childhood trauma and stigma in psychosis. 
Supervisors: prof. dr. Ph. Delespaul/prof. dr. J. van Os.
- Ibrahim Tolga Binbay: Extended Psychosis Phenotype  in the Wider Social Environment. Supervisor: 
prof. dr. J. van Os; Co-Supervisor: dr. M. Drukker. 
- Frank Van Dael: OCD matters in psychosis. Supervisors: prof. dr. J. van Os/prof. dr. I. Myin-Ger-
meys. 
- Pamela Kleikers: NOXious oxidative stress: from head toe too and back. Supervisors: prof. dr. 
H.H.H.W. Schmidt/prof. dr. H.W.M. Steinbusch; Co-Supervisor: dr. B. Janssen.
- José Luis Gerardo Nava: In vitro assay systems in the development of therapeutic interventions strate-
gies for neuroprotection and repair. Supervisors: prof. dr. med. J. Weis/prof. dr. H.W.M. Steinbus-
ch; Co-Supervisor: dr. G.A. Brook, RWTH Aachen.
- Eva Bollen: Cyclic nucleotide signaling and plasticity. Supervisors: prof. dr. H.W.M. Steinbusch/
prof. dr. R. D’Hooge, KU Leuven; Co-Supervisor: dr. J. Prickaerts. 
2015
- Jessica A. Hartmann: A good laugh and a long sleep; Insights from prospective and ambulatory assess-
ments about the importance of positive affect and sleep in mental health. Supervisor: prof. dr. J. van 
Os; Co-Supervisors: C.J.P. Simons/dr. M. Wichers. 
- Bart Ament: Frailty in old age; conceptualization and care innovations. Supervisors: prof. dr. 
G.I.J.M. Kempen/prof. dr. F.R.J. Verhey; Co-Supervisor: dr. M.E. de Vugt. 
- Mayke Janssens: Exploring course and outcome across the psychosis-continuum. Supervisor: prof. dr. 
I. Myin-Germeys; Co-Supervisor: dr. T. Lataster.
- Dennis M.J. Hernau: Dopayours is not dopamine: genetic, environmental and pathological variations 
in dopaminergic stress processing. Supervisor: prof. dr. I. Myin-Germeys; Co-Supervisors: prof. dr. 
F.M. Mottaghy/sr. D. Collip. 
- Ingrid M.H. Brands: The adaptation process after acquired brain injury Pieces of the puzzle. Super-
visors: prof. dr. C.M. van Heugten/prof. dr. D.T. Wade, Oxford UK; Co-Supervisors: dr. S.Z. 
Stapert/dr. S. Köhler.
- Francesco Risso: Urinary and salivary S100B monitoring in high risk infants. Supervisor: prof. dr. 
J.S.H. Vles; Co-Supervisors: dr. D. Gazzolo, Genoa,Italy/dr. A.W.D. Gavilanes.
- Alessandro Borghesi: Stem and Progenitor Cells in Preterm Infants: Role in the Pathogenesis and 
Potential for Therapy. Supervisor: prof. dr. L. Zimmermann; prof. dr. B. Kramer; Co-Supervisors: 
dr. D. Gazzolo, Genoa,Italy/dr. A.W.D. Gavilanes.
- Claudia Menne-Lothmann: Affect dynamics; A focus on genes, stress, and an opportunity for change. 
Supervisor: prof. dr. J. van Os; Co-Supervisors: dr. M. Wichers/dr. N. Jacobs. 
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- Martine van Nierop: Surviving childhood new perspectives on the link between childhood trauma and 
psychosis. Supervisors: prof. dr. I. Myin-Germeys/prof. dr. J. van Os; Co-Supervisor: dr. R. van 
Winkel.
- Sylvia Klinkenberg: VNS in children; more than just seizure reduction. Supervisors: prof. dr. J. 
Vles/prof. dr. A. Aldenkamp; Co-Supervisor: dr. H. Majoie.
- Anouk Linssen: Considerations in designing an adult hearing screening programme. Supervisor: 
prof. dr. B. Kremer; Co-Supervisors: dr. L. Anteunis/dr. M. Joore. 
- Janny Hof: Hearing loss in young children; challenges in assessment and intervention. Supervisors: 
Prof.dr. B. Kremer / Prof.dr. R. Stokroos / Prof.dr. P. van Dijk, RUG; Co-Supervisor: dr. L. An-
theunis. 
- Kimberly Cox-Limpens: Mechanisms of endogenous brain protection; Clues from the transcriptome. 
Supervisors: prof. dr. J. Vles/prof. dr. L. Zimmermann; Co-Supervisor: dr. A. Gavilanes.
- Els Vanhoutte: Peripheral Neuropathy outcome measures; Standardisation (PeriNomS) study part 2: 
Getting consensus. Supervisors: prof. dr. C. Faber/prof. dr. P. van Doorn; Co-Supervisor: dr. I. 
Merkies, Spaarne ziekenhuis Hoofddorp.
- Mayienne Bakkers: Small fibers, big troubles; diagnosis and implications of small fiber neuropathy. 
Supervisors: prof. dr. C. Faber/prof.dr. M. de Baets; Co-Supervisor: dr. I. Merkies, Spaarne 
ziekenhuis Hoofddorp.
- Ingrid Kramer: Zooming into the micro-level of experience: An approach for understanding and 
treating psychopathology. Supervisor: prof. dr. J. van Os; Co-Supervisors: dr. M. Wichers, UMC 
Groningen/dr. C. Simons.
-  Esther Bouman: Risks and Benefits of Regional Anesthesia in the Perioperative Setting. Supervisors: 
prof. dr. M. van Kleef/prof. dr. M. Marcus, HMC, Qatar/prof. dr. E. Joosten; Co-Supervisor: dr. 
H. Gramke.
- Mark Janssen: Selective stimulation of the subthalamic nucleus in Parkinson’s disease; dream or near 
future. Supervisors: prof. dr. Y. Temel/prof. dr. V. Visser-Vandewalle, Keulen/prof. dr. A. Benaz-
zouz, Bordeax, France.
- Reina de Kinderen: Health Technology Assessment in Epilepsy; economic evaluations and preference 
studies. Supervisors: prof. dr. S. Evers/prof. dr. A. Aldenkamp; Co-Supervisor: dr. H. Majoie/dr. 
D. Postulart, GGZ O-Brabant. 
- Saskia Ebus: Interictal epileptiform activity as a marker for clinical outcome. Supervisors: prof. dr. A. 
Aldenkamp/prof. dr. J. Arends, TUE/prof. dr. P. Boon, Universiteit Gent, België.
- Inge Knuts: Experimental and clinical studies into determinants of panic severity. Supervisor: prof. 
dr. I. Myin-Germeys; Co-Supervisor: dr. K. Schruers; Influencing panic. 
- Nienke Tielemans: Proactive coping post stroke: The Restored4Stroke Self-Management study. Su-
pervisors: prof. dr. C. van Heugten/prof. dr. J. Visser-Meily, UMC Utrecht; Co-Supervisor: dr. 
V. Schepers, UMC Utrecht.
- Tom van Zundert: Improvements Towards Safer Extraglottic Airway Devices. Supervisors: prof. dr. 
A.E.M. Marcus/prof. dr. W. Buhre/prof. dr. J.R. Brimacombe, Queensland, Australia/prof. dr. 
C.A. Hagberg.
- Tijmen van Assen: Anterior Cutaneous Nerve Entrapment Syndrome Epidemiology and surgical 
management. Supervisors: prof. dr. G.L. Beets/prof. dr. M. van Kleef/dr. R.M.H. Roumen/dr. 
M.R.M. Scheltinga, MMC Veldhoven.
- Rohit Shetty: Understanding the Clinical, Immunological and Genetic Molecular Mechanisms of Kera-
toconus. Supervisors: prof. dr. R.M.M.A. Nuijts/prof. dr. C.A.B. Webers.
- Christine van der Leeuw: Blood, bones and brains; peripheral biological endophenotypes and their 
structural cerebral correlates in psychotic disorder. Supervisor: prof. dr. J. van Os; Co-supervisor: 
dr. M. Marcelis.
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- Sanne Peeters: The Idle Mind Never Rests; functional brain connectivity across the psychosis continu-
um. Supervisor: prof. dr. J. van Os; Co-supervisor: dr. M. Marcelis.
- Nick van Goethem: 7 nicotinic acetylcholine receptors and memory processes: mechanistic and behav-
ioral studies. Supervisor: prof. dr. H.W.M. Steinbusch; Co-supervisor: dr. J. Prickaerts.
- Nicole Leibold: A Breath of fear; a translational approach into the mechanisms of panic. Supervisor: 
prof. dr. H.W.M. Steinbusch; Co-supervisors: dr. K.R.J. Schruers/dr. D.L.A. van den Hove.
- Renske Hamel: The course of mild cognitive impairment and the role of comorbidity. Supervisor: prof. 
dr. F.R.J. Verhey; Co-supervisors: dr. I.H.G.B. Ramakers/dr. P.J. Visser.
- Lucia Speth: Effects of botulinum toxin A injections and bimanual task-oriented therapy on hand 
functions and bimanual activities in unilateral Cerebral Palsy. Supervisors: prof. dr. J. Vles; prof. dr. 
R. Smeets; Co-supervisor: dr. Y. Janssen-Potten, Adelante Hoensbroek.
- Yuan Tian: The effects of Lutein on the inflammatory pathways in age-related macular degeneration 
(AMD). Supervisors: prof. dr. C. Webers; prof. dr. A. Kijlstra, WUR; Co-supervisor: dr. M. 
Spreeuwenberg; dr. H. Tange.
- Peggy Spauwen: Cognition and Type 2 diabetes; the interplay of risk factors. Supervisors: prof. dr. F. 
Verhey; prof. dr. C. Stehouwer; Co-supervisor: dr. M. van Boxtel. 
- Marc Hilhorst: Crescentic glomerulonephritis in ANCA associated vasculitis. Supervisors: prof. dr. 
J. Cohen-Tervaert; Co-supervisor: dr. P. van Paassen. 
- Martin Gevonden: The odd one out: exploring the nature of the association between minority status 
and psychosis. Supervisors: prof. dr. J-P. Selten; prof. dr. J. Booij, Uva; prof. dr. I. Myin-Germeys.
- Bart Biallosterski: Structural and functional aspects of sensory-motor Interaction in the urinary 
bladder. Supervisors: prof. dr. Ph. Van Kerrebroeck; prof. dr. S. De Wachter, UvAntwerpen; 
Co-supervisors: dr. G. van Koeveringe; dr. M. Rahnama’i.
-  Alexandra König: The use of information and communication technologies (ICT) for the assessment of 
patients with Alzheimer’s Disease and related disorders. Supervisors: prof. dr. F. Verhey; prof. dr. Ph. 
Robert, Nice, Fr; Co-supervisors: dr. P. Aalten; dr. R. David, Nice. France. 
- Michelene Chenault: Assessing Readiness for Hearing Rehabilitation. Supervisors: prof. dr. M.P.F. 
Berger; prof. dr. B. Kremer; Co-supervisor: dr. L.J.C. Anteunis.
- Anand Vinekar: Retinopathy of Prematurity. Recent advances in tele-medicine screening, risk factors 
and spectral domain optical coherence tomography imaging. Supervisor: prof. dr. C.A.B. Webers; 
Co-supervisor: dr. N.J. Bauer. 
- Fleur van Dooren: Diabetes and Depression: exploring the Interface between Pathophysiological and 
Psychological factors. Supervisors: prof. dr. F.R.J. Verhey; prof. dr. J.K.L. Denollet, UvT; prof. dr. 
F. Pouwer, UvT; Co-supervisor: dr. M.T. Schram.
- Gabriëlla Pons van Dijk: Taekwondo and physical fitness components in middle-aged healthy volun-
teers; the Sekwondo study. Supervisors: prof. dr. J. Lodder; prof. dr. H. Kingma; Co-supervisor: dr. 
A.F. Lenssen. 
- Yara Pujol López: Development and psychoneuroimmunological mechanisms in depression. Supervi-
sor: prof. dr. H.W.M. Steinbusch; Co-supervisors: dr. G. Kenis; dr. D. van den Hove; dr. Aye Mu 
Myint, München. 
- Romina Gentier: UBB+1; an important switch in the onset of Alzheimer’s disease. Supervisors: prof.  
H. Steinbusch; prof. D. Hopkins; Co-supervisor: dr. F. van Leeuwen.
- Sanne Smeets: Insights into insight: studies on awareness of deficits after acquired brain injury. Su-
pervisor: prof. C. van Heugten; prof. R. Ponds; Co-supervisor: dr. I. Winkens
- Kim Beerhorst: Bone disease in chronic epilepsy: fit for a fracture. Supervisor: prof. A. Aldenkamp; 
prof. R. van Oostenbrugge; Co-supervisor: dr. P. Verschuure.
- Alex Zwanenburg: Cerebral and cardiac signal monitoring in fetal sheep with hypoxic-ischemic 
encephalopathy. Supervisor: prof. T. Delhaas; prof. B. Kramer; Co-supervisors: dr. T. Wolfs; dr. P. 
Andriessen, MMC. 
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- Ismail Sinan Guloksuz: Biological mechanisms of environmental stressors in psychiatry. Supervisor: 
prof. J. van Os; Co-supervisors: dr. B. Rutten; dr. M. Drukker.
- Seyed Ehsan Pishva MD: Environmental Epigenetics in mental health and illness. Supervisor: prof. 
dr. J. van Os; Co-supervisors: dr. B.P.F. Rutten; dr. G. Kenis.
- Ankie Hamaekers: Rescue ventilation using expiratory ventilation assistance; innovating while clutch-
ing at straws. Supervisors: prof. dr. W.F. Buhre; prof. dr. M. van Kleef.
- Rens Evers: 22q11.2 deletion syndrome: intelligence, psychopathology and neurochemistry at adult age. 
Supervisors: prof. dr. L.M.G. Curfs; prof. dr. T. v. Amelsvoort.
- Sarah-Anna Hescham: Novel insights towards memory restoration. Supervisor: prof. dr. Y. Temel; 
Co-supervisor: dr. A. Blokland; dr. A. Jahanshahi.
- João P. da Costa Alvares Viegas Nunes: Insulin receptor sensitization improves affective pathology 
in various mouse models. Supervisor: prof. dr. H.W.M. Steinbusch; Co-supervisors: dr. K-P. Lesch; 
dr. T. Strekalova; dr.B.H. Cline, Oxford.
- Yanny Ying-Yee Cheng: Clinical Outcomes After Innovative Lamellar Corneal Transplantation Sur-
gery. Supervisor: prof. dr. R.M.M.A. Nuijts; Co-supervisor: dr. J.S.A.G. Schouten.
2016
- Oliver Gerlach: Parkinson’s disease, deterioration during hospitalization. Supervisor: prof. dr. R. 
van Oostenbrugge; Co-supervisor: dr. W. Weber.
- Remo Arts: Intracochlear electrical stimulation to suppress tinnitus. Supervisor: prof. dr. R.J. 
Stokroos; Co-supervisor: dr. E.L.J. Georg. 
- Mitchel van Eeden: The €- Restore4stroke study: Economic evaluation of stroke care in the Nether-
lands. Supervisors: prof. dr.mr. S.M.A.A. Evers; prof. dr. C.M. v. Heugten; Co-supervisor: dr. 
G.A.P. van Mastrigt. 
- Pim Klarenbeek: Blood pressure and cerebral small vessel disease. Supervisor: prof. dr. R.J. van 
Oostenbrugge; Co-supervisor: dr. J. Staals. 
- Ramona Hohnen: Peripheral pharmacological targets to modify bladder contractility. Supervisor: 
prof. dr. Ph.E.V. van Kerrebroeck; Co-supervisors: dr. G.A. van Koeveringe; dr. M.A. Sahnama’i; 
Dr. C. Meriaux. 
- Ersoy Kocabicak: Deep brain stimulation of the subthalamic nucleus: Clinical and scientific aspects. 
Supervisors: prof. dr. Y. Temel; prof. dr. K. van Overbeeke; Co-supervisor: dr. A. Jahanshahi. 
- Sven Akkerman: Temporal aspects of cyclic messenger signaling in object recognition memory; a phar-
malogical approach. Supervisor: prof. dr. H.W.M. Steinbusch; Co-supervisors: dr. J. Prickaerts; 
dr. A. Blokland.
- Anja Moonen: Emotion and Cognition in Parkinson’s disease; etiology and neurobiological mecha-
nisms. Supervisor: prof. dr. F.R.J. Verhey; Co-supervisor: dr. A.F.G. Leentjens. 
-  Anna Schüth: Three-dimensional bladder tissue morphology. Supervisors: prof. dr. G.A. van Koev-
eringe; prof. dr. M. v. Zandvoort, Aachen; prof. dr. Ph. V. Kerrebroeck.
- Elisabeth van der Ven: Ethnic minority position as risk indicator for autism-spectrum and psychotic 
disorders. Supervisors: prof. dr. J.P. Selten; prof. dr. J. van Os.
- Zuzana Kasanova: Environmental reactivity for better or worse; The impact of stress and reward 
on neurochemistry, affect and behavior across the psychosis continuum. Supervisor: prof. dr. I. 
Myin-Germeys, KU Leuven/UM; Co-supervisor: dr. D. Collip.
- Danielle Lambrechts: Ketogenic diet therapies; treatment for children and adults with refractory 
epilepsy. Supervisors: Prof.dr. H.J.M. Majoie; Prof.dr. J.S.H. Vles; prof. dr. A.P. Aldenkamp; 
Co-supervisor: dr. A.J.A. de Louw, Kempenhaghe, Heeze.
- Frank van Bussel: Advanced MRI in diabetes; cerebral biomarkers of cognitive decrements. Supervi-
sors: Prof.dr.ir. W.H. Backes; Prof.dr. P.A.M. Hofman; Co-supervisor: dr. J.F.A. Jansen.
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- Lisa Schönfeldt: Neurostimulation to treat brain injury? Supervisors: prof. dr. Y. Temel; prof. dr. S. 
Hendrikx, Hasselt; Co-supervisor: dr. A. Jahanshahi.
- Rianne Geerlings: Transition in patients with childhood-onset epilepsy; a long way to adulthood. 
Supervisor: prof. dr. A.P. Aldenkamp; Co-supervisors: dr. A.J.A. de Louw, dr. L.M.C. Gottmer, 
Kempenhaeghe.
- Nele Claes: B cells as multifactorial players in multiple sclerosis pathogenesis: insights from therapeu-
tics. Supervisors: prof. dr. V. Somers, Hasselt; prof. dr. R. Hupperts; Co-supervisors: prof. dr. P. 
Stinissen, dr. J. Fraussen, Hasselt.
-  Olaf Schijns: Epilepsy surgery and biomarkers from history to molecular imaging. Supervisors: prof. 
dr. J.J. van Overbeeke; prof. dr. H. Clustermann, Aachen; Co-supervisors: dr. G. Hoogland; dr. 
M.J.P. v. Kroonenburgh.
-  Lizzy Boots: Balanced and Prepared; development and evaluation of a supportive e-health interven-
tion for caregivers of people with early-stage dementia. Supervisors: prof. dr. F.R.J. Verhey; prof. dr. 
G.I.J.M. Kempen; Co-supervisor: dr. M.E. de Vugt.
- Wouter Donders: Towards patient-specific (cerebro-) vascular model applications. Supervisors: prof. 
dr. T. Delhaas; prof. dr. ir. F.N. van de Vosse, TUE; Co-supervisor: dr. ir. W. Huberts.
- Sizzle Vanterpool: The implications of intrauterine invasion by microbes for placental Pathology and 
the occurrence of adverse pregnancy outcomes. Supervisor: prof. dr. B.W. Kramer. Co-supervisors: 
dr. J.V. Been, Erasmus MC Rotterdam, dr. U von Rango.
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